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ABSTRACT 
 
 
 Since its first introduction in 1990s, the Edmonton Protocol for human islet 
transplantation has helped more than 500 patients with type 1 diabetes worldwide and 
met great success from bench to bedside. The Edmonton Protocol involves isolating islets 
from a cadaveric donor pancreas by enzymatic digestion and infusing into the patient's 
portal vein. Each recipient usually receives islets from two or three donors for an optimal 
outcome and is dosed with two immunosuppressive drugs, sirolimus and tacrolimus and a 
monoclonal antibody drug daclizumab to prevent the graft rejection. However, despite 
the administration of immunosuppressive drugs and the recent improvement in islet 
isolation, preparation and transplantation, insulin independence is rarely sustained for 
long term after islet transplantation. It was reported that by a year after transplant, 
50-68% of patients do not need to receive additional insulin, but by five years after the 
procedure, few than 10% of total patients are free of daily insulin injection. 
 
The wide application of human islet transplantation is hindered by two major 
barriers, the immune rejection from the organ recipients and the PNF of islet grafts. 
Immune rejection describes a process where transplanted islets are attached, recognized 
and attacked by the host immune system while the PNF is characterized as the loss of 
islet viability and function caused by non-immune reasons, such as the disruption of islet 
microvasculature during islet isolation and purification process, hypoxia in the core of 
islet grafts and production of inflammatory cytokines at the transplantation sites. 
 
Several strategies have been proposed to address the immune rejection and the 
PNF. Gene therapy, which relies on “vectors” to deliver therapeutic genes into human 
islets, was successful in immunodeficient animal models because the potent expressions 
of therapeutic proteins usually lead to an advantage in the post-transplantation survival of 
human islets. However, gene therapy provided limited success to overcome the immune 
rejection. Also gene therapy faced inherited problems such as the low transfection 
efficiency of non-viral vectors and the increasing safety concerns of the viral vectors.  
 
Cell therapy especially stem cell therapy, on the other hand, has recently met 
great success as a novel regenerative medicine to support solid organ transplantation 
including human islet transplantation. Among all types of stem cells, mesenchymal stem 
cells (MSCs) are given special interest for their self-renewal potential, multi-lineage 
capacities, paracrine effects (trophic mediator) and immune modulatory effects, making it 
a great candidate for improving human islet transplantation. MSCs are mostly found in 
bone marrow, adipose and umbilical cord blood, are one of the most extensively studies 
adult stem cells used in treating degenerative diseases as well as solid organ 
transplantation. Unlike embryonic stem cells (ESCs) or induced pluripotent stem cells 
(iPSCs), adult stem cells show restricted proliferation and lineage differentiation, and 
consequently have less risk of inducing tumor. MSC-based therapy has been used to 
improve human islet transplantation from three major aspects. First, MSC was used as an 
immune modulator to prevent the immune rejection of human islets. Second, MSC was 
used as a trophic mediator to improve the revascularization of human islets. Third, MSC 
 v 
was induced in vitro to form insulin producing cell as an alternative sources of human 
islets. The third aspect seems to be quite promising theoretically, but no group has 
successfully generated enough “artificial” islets for human transplantation. Our focus is 
mainly on the immunomodulatory effects and the trophic effects of MSCs to improve the 
human islet transplantation. 
 
We also introduce humanized mouse model into the studies of islet 
transplantation. Humanized mouse model contains mature human immunity and is a good 
model to determine the immune rejection to human islet after transplantation. Our study 
is innovative because this is the first time humanized animal is used test the efficacy of 
MSC based regenerative medicine on solid organ transplantation. We plan to answer the 
following questions in this study. 1) Can humanized mouse model pose an immune 
rejection to human islets after transplantation? 2) What is the duration and limitation of 
the adoptively transferred human immunity? 3) What is the efficacy and mechanism of 
stem cell therapy in improving human islet transplantation in humanized mouse model?  
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CHAPTER 1.    INTRODUCTION 
 
 
Human Islet Transplantation 
 
Diabetes is affecting 25.8 million people in United States. Among them, 5% are 
type 1 diabetes or insulin dependent diabetes. Edmonton Protocol for human islet 
transplantation, first introduced by Dr. Shapiro and his group from University of Alberta 
in late 1990s [1], has the potential to be a permanent treatment for patients with type 1 
diabetes.  
 
Edmonton Protocol described a manner to isolate islets using a mixture of highly 
purified enzymes from the pancreas of a deceased donor (Figure 1-1) [2]. Collagenase 
solution is injected into the pancreatic duct, runs through the whole pancreas and causes 
distension of the pancreas. Pancreas is subsequently cut into small chunks and subjected 
to further digestion until the islets are liberated and removed from the solution. Isolated 
islets are then separated from the exocrine tissue and debris in a process called 
purification. During the transplant, transplant surgeons are guided by ultrasound and 
radiography to place a catheter through the upper abdomen and into the portal vein of the 
liver. The islets are then infused through the catheter into the liver. Each recipient 
receives islets from one to as many as three donors. The islets are infused into the 
patient's portal vein, and are then kept from being destroyed by the recipient's immune 
system through the use of two immunosuppressants, sirolimus and tacrolimus as well as a 
monoclonal antibody drug used in transplant patients called daclizumab. The blood 
glucose of the patient will be closely monitored and insulin may be needed until control 
is achieved. If the transplantation outcome is not good, a second infusion of islets may be 
needed.  
 
 
Challenges of Human Islet Transplantation 
 
In the last two decades, human islet transplantation has marched a long trip from 
bench to bedside as a potential treatment for type 1 diabetes. According to the 2010 
annual report conducted by Collaborative Islet Transplant Registry which is funded by 
the National Institute of Diabetes and Digestive and Kidney Diseases, 571 patients with 
type 1 diabetes have received human islet transplantation worldwide and nearly two-
thirds of recipients achieved "insulin independence", a status defined as being able to stop 
insulin injections for at least 14 days, during the year following transplantation. However,
                                                 
 
 Portions modified with permission from American Chemical Society. Narang AS and 
Mahato RI (2006) Biological and biomaterial approaches for improved islet 
transplantation. Pharmacol Rev 58: 194-243. 
Other portions modified with permission from Springer. Wu H, Ye Z and Mahato RI 
(2011) Genetically Modified Mesenchymal Stem Cells for Improved Islet 
Transplantation. Mol. Pharmaceutics 8: 1458-1470. 
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Figure 1-1. The process of clinical islet transplantation for the treatment of type 1 
diabetes  
  
 3 
insulin independence is difficult to maintain over time. At 2-year follow-up, the 
proportion dropped to about one-third of recipients and at 5-year follow-up, the 
proportion dropped to below 20%. This fact explained why less North American centers 
performed islet transplantation and Edmonton Protocol is still an experimental treatment 
for type 1 diabetes. Two of the most important limitations to the widespread of human 
islet transplantation are the limited supply of islets for transplantation and the inadequate 
means for preventing islet loss after transplantation [2]. Moreover, because of the 
extensive posttransplantation challenges, a patient needs at least 10,000 islet equivalents 
(IEs) per kilogram of body weight (extracted from two or more donor pancreases) for an 
optimal transplantation outcome, making the current shortage in islet supply even worse 
[3, 6]. The major reasons for islet graft failure and useful interventions are listed in Table 
1-1. 
 
To address the issue of limited supply of human islets, researchers are seeking 
alternative sources of human islets by either using islets from alternative species or 
generating human islets and insulin-producing cells from stem cells. Porcine islets are 
widely reported as a competent alternative for xenogeneic islet transplantation with the 
assistance of biological and biomaterial approaches to prevent enhanced immune 
destruction of the xenografts [7, 8]. For in vitro transdifferentiation strategy, several 
groups have reported successful generation of insulin-producing β-cells and islet-like 
structures from both ES cells. Lumelsky, et al. demonstrated that ES cells could 
differentiate in to insulin-producing cells which self-assemble into islet-like clusters.[9] 
Blyszczuk et al. reported the differentiation of ES cells into insulin-producing cells 
through transduction of plasmid vectors encoding paired box gene 4 (Pax-4) and 
pancreatic duodenal homeobox 1 (Pdx-1).[10] However, caution should be exercised as 
the differentiation from pluripotent ES cells can not 100% and the remaining 
undifferentiated ES cells may still hold tumorigenicity. Several groups used MSCs as a 
relatively safer source and succeed in generation islet-like cluster or insulin-producing 
cells [11-13]. However, most of them relied on genetic manipulation of MSCs and the 
ability of producing large numbers of functional tissues by this means was not proven. 
 
Islet loss happens because of two major reasons, the immune rejection from the 
recipients and the primary nonfunction (PNF) of islet grafts [2]. Immune rejection 
describes a process where transplanted islets are attached, recognized and attacked by the 
host immune system. Immunosuppressive regimens are capable of preventing immune 
rejection from months to years, but the agents used in these treatments may induce 
significant side effects, resulting in progressive decline in graft function. Some of the 
most commonly used immunosuppressive agents such as tacrolimus (also known as FK-
506 or Fujimycin), mycophenolic acid (MPA), and sirolimus (also known as rapamycin) 
are also deleterious to islet function and insulin secretion [4, 5]. PNF is characterized as 
the loss of islet viability and function caused by non-immune reactions, such as the 
disruption of islet microvasculature during islet isolation and purification process, 
hypoxia in the core of islet grafts and production of inflammatory cytokines at the 
transplantation sites. Once PNF happens, islets are still alive but in an apoptosis process 
and ceasing to actively produce insulin in response to the fluctuation of the blood glucose 
level. Failure to revascularization and subsequent apoptosis are the most frequent reasons 
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Table 1-1. Reasons for islet graft failure and useful interventions  
 
Obstacles to islet 
transplantation 
Strategies 
Loss of viability during 
isolation 
Improved enzymatic blends for islet isolation, 
culture media composition and conditions 
  
Failure to revascularize Encapsulation with vascular growth promoting 
proteins; ex vivo growth factor gene 
delivery for revascularization 
  
Inflammatory response/immune 
rejection 
Immunoisolation membranes; generalized 
immunosuppression; immune tolerance induction; 
antiapoptotic and immune modulating gene 
delivery 
  
Inadequate islet mass Optimization of islet mass and transplantation site 
  
Inadequate islet supply Xenotransplantation 
Stem cell-based approaches 
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leading to PNF. Human islet, in its native status, is a cluster of heterogeneous cell types 
with extensive intra-islet vasculature formed of fenestrated capillary endothelial lining, 
which gets disrupted during islet isolation, leading to collapse of vasculature, 
accumulation of endothelial fragments and compromised perfusion in the core of the 
islets.[14] Therefore, unlike whole pancreas and other solid organ transplantations, islet 
transplantation is ectopic and requires extensive and functional revascularization to 
promote the posttransplantation survival of islet grafts.[15, 16] Less or abnormal 
revascularization usually lead to hypoxia, apoptotic islet death and thus compromised 
transplantation outcome. 
 
To summarize, the long term outcome of human islet transplantation was impeded 
by several obstacles, the limited supplies of donor islets, the inadequate means of 
immune suppression, the loss of islets in the isolation, transportation and transplantation 
process and the poor post-transplantation revascularization. All these obstacles can be 
approached from two directions, to increase the resistance of islets or to reduce the 
immune rejection from the recipients. Gene therapy has been proven to be an effective 
strategy for achieve the formal goal while stem cell therapy can be used for the latter. 
 
 
Gene Therapy 
 
Almost all human diseases are the results of dysfunction or malproduction of 
proteins. Traditional small molecule drugs usually interact with proteins such as 
enzymes, hormones and transcriptional factors to exert their therapeutic potential. 
However, many severe and deliberating diseases (e.g., diabetes, hemophilia, cystic 
fibrosis) and several chronic diseases (e.g., hypertension, ischemic heart disease, asthma, 
Parkinson’s disease, motor neuron disease, multiple sclerosis) remain inadequately 
treated by the conventional pharmaceutical approaches. 
 
Gene therapy is the use of nucleic acids as a pharmaceutical agent to treat disease. 
It derives its name from the idea that DNA can be used to supplement or alter genes 
within an individual's cells as a therapy to treat disease. Unlike small molecule drugs or 
protein drugs which are usually formulated in capsule or tablet forms, therapeutic nucleic 
acids are packaged within a specialized vector to get inside cells within the body.  
 
 
Viral vectors 
 
All viruses hold the inherited advantage to bind to their hosts and introduce their 
genetic material into the host cell with high efficiency. Native viruses must be modified 
to transfer genetic materials. To construct a viral vector, the genes responsible for the 
viral replication and pathogenicity are first removed and replaced with a transgene 
cassette. Then the recombinant viral genome is inserted into a shuttle plasmid and 
transduced into a packaging cell line which contains the genes responsible for the viral 
replication to generate the recombinant viral vectors. Viral vectors typically hold high 
transduction efficiency and do not need additional carriers for effective gene delivery. To 
 6 
date approximately 70% of all gene therapy clinical trials employ viral vectors. 
Retrovirus, lentivirus, adenovirus and adeno-associated virus (AAV) are the most 
extensively studied and used viral vectors for human gene therapy. Their characteristics 
have been listed and compared in Table 1-2. 
 
 
Non-viral vectors  
 
The inherited problems with recombinant viruses such as immunogenicity, 
neutralizing antibodies and insertional mutagenesis have called for the design of efficient 
non-viral vectors for human gene therapy. Non-viral vectors are significantly less 
immunogenic and are not likely to induce insertional mutagenesis and unwanted 
homologous recombination after uptake by the cells. They are also relatively easy to be 
manipulated, produced and purified in large scale compared with their viral counterparts. 
Non-viral gene therapy includes local administration of naked plasmid or using 
specialized carriers such as cationic liposomes and polymer-based systems to deliver 
plasmids to targeted area (Table 1-3). However, their clinical utility is still hampered by 
the low transfection efficiency, which stems from non-specific uptake of the vector by the 
epithelial barriers and extracellular matrix and poor delivery into the therapeutic target. 
The intracellular gene silencing machinery also prevents the long term transgene 
expression. New emerging delivery systems and vector-constructing technologies try to 
address these issues. 
 
Gene therapy usually targets one or more defected genes without affecting the 
normal gene at the site of diseases. Gene therapy target can be an abnormal oncogene 
whose product has the potential to cause a tumor or a defect gene whose product is 
critical to maintain normal physiological functions. Compared with small molecule drugs, 
gene therapy will not induce drug resistance even after repeated treatments since the 
targets of gene medicine are not certain receptors but the genes encoding them. 
Moreover, this technique could be a permanent treatment to give someone that is born 
with a genetic disease a chance to live a normal life once and for all. However, there are 
certain limitations of gene therapy as well. The major disadvantage of gene therapy is 
that gene medicines are not easy to be formulated into conventional dosage forms and 
delivered for a routine use. Therefore, the clinical applications of gene therapy can so far 
only be conducted in hospitals with well-trained specialists. The cost of gene therapy is 
so far also much higher compared with traditional medicines. 
 
 
Progress in Gene Therapy 
 
The ultimate goal of gene therapy is to improve the resistance and function of 
human islets under the challenges after transplantation. Four important questions should 
be asked for the success of gene therapy on human islet transplantation. Which gene 
should be expressed? How to improve the gene transfer efficiency? How to improve the 
gene expression potency? How to prevent the side effects of gene therapy? 
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Table 1-2.  Characteristics of viral vectors for gene transfer 
 
Characteristics Retrovirus Lentivirus Adenovirus Adeno-associated virus
Genetic material RNA RNA dsDNA ssDNA 
Genome size 7-11 kb 8 kb 26-45 kb 4.7 kb 
Cloning capacity 8 kb 8 kb 7-35  kb < 5 kb 
Genome forms Integrated Integrated Episomal Stable/Episomal 
Diameter 100-145 nm 80-120 nm 80-100 nm 20-22 nm 
Tropism Dividing cells only Broad, Dividing & Non-
dividing cells 
Broad, Dividing & Non-
dividing cells 
Broad, not suitable for 
hematopoietic cells 
Virus protein expression No Yes/No Yes/No No 
Transgene expression Slow, constitutive Slow, constitutive Rapid, 
Transient 
Moderate, constitutive, 
transient 
Delivery method Ex vivo Ex vivo Ex/In vivo Ex/In vivo 
Typical yield 
(viral particle/ml) 
< 108 < 107 < 1014 < 1013 
Pre-existing immunity Unlikely Perhaps, 
Post-entry 
Yes Yes 
Immunogenicity Low Low High Moderate 
Potential pathogenicity Low High Low None 
Safety Insertional Mutagenesis Insertional Mutagenesis Potent Inflammatory 
Response 
None to date but long-
term not clear. 
Physical stability Poor Poor Fair High 
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Table 1-3. Summary of non-viral methods used for gene transfer 
 
Methods Advantages Disadvantages 
Naked DNA No special skills needed, easy to produce. Low transduction efficiency, transient gene 
expression. 
Microinjection Up to 100% transduction efficiency (nuclear 
injection) 
Requires highly specialized skills for delivery, 
limited to ex vivo delivery. 
Gene gun Easy to perform, effective immunization with low 
amount of DNA. 
Poor tissue penetration. 
 
Electroporation High transduction efficiency. Transient gene expression, toxicity, tissue damage, 
highly invasive. 
Sonoporation Method well tolerated for other applications. Transient gene expression, toxicity not yet 
established. 
Laser irradiation Can achieve 100% transduction efficiency. Special skills and expensive equipment necessary. 
Magentofection Safety of method established in the clinic. Poor efficiency with naked DNA. 
Liposomes Easy to produce. Protein and tissue binding, transient gene 
expression. 
Micelles Easy to produce and manipulate. Unstable, protein and tissue binding.  
Cationic polymers High DNA loading, easy to produce and 
manipulate.  
Transient gene expression, toxicity. 
Dendrimers High DNA loading, high transduction efficiency. Extremely toxic. 
Solid lipid nanoparticles Low Toxicity, controlled release and targeting. NA 
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Which gene should be expressed? 
 
Numerous genes have been introduced into human islets to prevent the loss of 
function and viability of islets after transplantation. Most of these genes can be attributed 
into two categories, the genes preventing the apoptosis of islets and the genes promoting 
the revascularization of islets. In some rare cases, genes regulating insulin production are 
also introduced into human islets.  
 
The production of inflammatory cytokines especially interleukin-1β (IL-1β) has 
been shown to inhibit islet beta cell function as well as to activate islet apoptosis in a 
nitric oxide-caspase-dependent manner. Gene therapy strategies have been studied to 
inhibit this pathway. For example, Giannoukakis et al. first reported that adenoviral gene 
transfer of interleukin 1 receptor antagonist (IL-1Ra) prevented IL-1β-mediated nitric 
oxide production from human islets in vitro as well as the suppression of insulin-
producing β cell function as determined by glucose-stimulated insulin production [3]. In 
our lab, Narang et al. and Panakanti et al. combined the gene expression of vascular 
endothelia growth factor (VEGF) and IL-1Ra to improve the therapeutic effects of single 
gene therapy while Li et al. and Cheng et al. targeted downstream pro-apoptotic factors of 
IL-1β pathway and used small heparin RNA to inhibit the expression of iNOS and 
caspase 3, respectively [4-7]. During the time we worked on the apoptosis of human 
islets, we identified a potent anti-apoptotic factor X-linked inhibitor of apoptosis (XIAP), 
which binds to and inhibits caspase 3, 7 and 9 at the same time. We hypothesized that 
overexpression of XIAP can be a more effective strategy to improve the resistance of 
human islets because XIAP showed ubiquitous silencing effects to almost all caspases 
while previous strategies only targeted one gene at a time. The detailed results are 
presented in Chapter 3. 
 
Timely and functional revascularization is required for the survival of human 
islets after transplantation. Gene transfer of angiogenesis factors such as VEGF and 
hepatocyte growth factor (HGF) can be an effective strategy to fulfill this purpose and 
has been widely reported by us and other groups [7-9]. VEGF is a popular angiogenic 
factor, but its effect is so potent that caution should be exercised to avoid aberrant 
angiogenesis [10]. Recently, HGF has been seen as a more favorable factor because it can 
prevent apoptotic islet death and can promote the proliferation of pancreatic β-cells [11]. 
 
 
How to improve the gene transfer efficiency? 
 
Islet is a compact cluster of about 1000 non-dividing cells. It is difficult to 
transfect intact islets using non-viral approaches due to low transfection efficiency. 
Cationic liposomes and polymer-based systems were employed to assist the transfection 
process but are toxic at high doses [12, 13]. On the other hand, viral vectors have 
demonstrated to be effective gene carriers to human islets. For example, replication 
deficient adenoviral vectors, from which the viral genome E1 and E3 are deleted, are 
known to efficiently transduce islets and promote transgene expression up to two weeks 
[14]. In addition, adenovirus vectors can be produced in high titers and there is no risk of 
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insertional mutagenesis as they do not integrate into host genome. We and others have 
demonstrated adenoviral vector-based gene therapy to be effective in promoting the 
revascularization and engraftment of human islets posttransplantation [12, 15]. For 
example, growth factor gene expression can significantly improve the islet 
revascularization after transplantation [4, 8, 12], while anti-apoptotic protein expression 
can increase the resistance of islet grafts to multiple posttransplantation challenges in 
human islets [5, 6, 15]. The recent success in constructing bipartite viral vectors which 
can simultaneously promote revascularization and increase the resistance of transplanted 
islets may highlight the promising future of gene therapy [4, 8]. However, because of the 
cluster-like property of islet, multiplicity of infection (MOI) of higher than 500 is usually 
required to achieve optimal transduction efficiency as suggested from many reports [4, 6, 
8, 16]. Therefore, despite its effectiveness, the clinical application of gene therapy is still 
hindered by the high risk of immunogenicity of viral vectors.  
 
 
How to improve the gene expression potency? 
 
Gene expression potency involves two aspects, gene expression duration and gene 
expression level. Gene expression duration is usually determined by the choices of 
vectors while gene expression level is usually determined by the structure of vectors.  
 
Previous studies suggested that the first two weeks is of critical important to the 
success of the whole islet transplantation because most of the islet death or loss of 
function happen in that time. Therefore, gene therapy must be able to generate 
therapeutic proteins in human islets for no shorter than two weeks after gene transfer. 
Plasmid has been demonstrated to be incapable to express therapeutic proteins for more 
than 1 week, therefore unsuitable to promise the long term survival of human islets [13, 
17]. Adenoviral vectors are the most frequently used gene transfer carriers for human 
islet transplantation because 1) adenoviruses lead to a potent gene expression to ~ 2 
weeks which is exactly what islet transplantation requires; 2) adenoviruses can be 
generated in a higher titer and is easy to be manipulated and modified and 3) 
adenoviruses causes less risk of insertional mutagenesis and subsequent tumorigenicity. 
Lentiviral vectors or retroviral vectors have recently attracted some attentions because 
these vectors promoted transgene expression up to months. But since these vectors will 
insert genetic materials into host genome, precautions must be taken to avoid the risk of 
insertional mutagenesis and consequent tumorigenicity. 
 
Structure of vectors, especially the choice of promoters and enhancers, is critical 
to the expression of therapeutic proteins. Although cytomegalovirus (CMV) promoter 
drives considerable transgene expression in human islets, the discoveries of new islet-
specific promotes and enhancers boost the expression of therapeutic proteins 
significantly. For example, we previously reported that U6 promoter is transcriptionally 
more effective than H1 promoter in human islets [6]. Sharma et al. demonstrated that 
transgene expression can be drastically increased by incorporating an islets-specific 
enhance into the construct [18]. Other factors such as the spacing within the construct 
may also play a role. For example, we found out that insertion of a VEGF expression 
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cassette between the CMV promoter and iNOS-shRNA significantly enhanced iNOS 
gene silencing [19]. Since a majority of my work was done using adenovirus vectors 
containing CMV promoter which drives optimal transgene expression in both human 
islets and stem cells. The screening for new islet-specific promotes and enhancers is the 
not the main scope of my work. 
 
 
How to prevent the side effects of gene therapy? 
 
The conflict between the potency and side effects of adenovirus mediated gene 
therapy is in fact the conflicts between the transduction efficiency and the safety profile, 
which is further exaggerated by the cluster-like nature of human islets. MOIs higher than 
500 are usually required to achieve optimal transduction efficiency but even at this MOI, 
the cells in the core of islet are hardly transduced. Further increase of MOI will cause 
toxicity to the cells on the surface of human islets. Another problem with adenovirus 
mediated gene therapy is that some proteins in the viral genome will be co-expressed 
with therapeutic proteins though in a lesser extent. This phenomenon may lead to an 
unwanted outcome; human islets transduced with adenovirus will be recognized and 
cleared by the host immune system in a significantly faster manner. 
 
To solve the side effects of adenovirus without significantly impaired its 
transduction efficiency, modified adenovirus was proposed. Adenovirus is usually 
modified in two manners, which are to reduce the immunogenicity or to increase the 
transduction efficiency. For the formal purpose, more viral genome was deleted or 
replaced with transgene to reduce the immunogenicity of adenovirus. The first generation 
of adenovirus contained only E1 deletion. Recently adenoviruses with both E1 and E3 
inserts to simultaneously express two therapeutic genes have been reported [8]. 
Moreover, adenoviruses with E1, E3 and E4 deletion and even “gutless” adenovirus have 
been constructed to drive transgene expression [20, 21]. For the latter purpose, 
researchers have been modifying the genome of adenovirus in such a way that some 
transduction-assisting ligands can be expressed on the surface of the viral particles. 
Arginine-Glycine-Aspartic acid (RGD) peptide is the most frequently used ligand for this 
purpose because it binds with high affinity to several types of integrins present on the 
surface of mammalian cells. Part of our work involved the construction of RGD modified 
adenovirus. Detailed results are described in Chapter 4. 
 
 
Stem Cell Therapy 
  
Stem cells exist in all multicellular organisms and share two characteristic 
properties. They have prolonged or unlimited self-renewal capacity and the potential to 
differentiate into a variety of specialized cell types. The earliest stem cells in human life 
are ESC cells, derived from the inner cell mass of the blastocyst and capable to 
differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, 
and mesoderm. Besides the ES cells which can only be isolated from early embryos, there 
are other types of stem cells in the mature tissues of all aged mammals, the adult stem 
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cells.  Adult stem cells have unlimited self-renewal capacity and more restricted 
differentiation potential. They multiply by cell division to replenish dying cells and 
regenerate damaged tissues. The most famous adult stem cells are hematopoietic stem 
cells (HSCs) which give rise to all the blood cell types and lymphoid lineages. Bone 
marrow also contains a population of adult stem cells named MSCs.  
 
Although bone marrow is considered as the primary source of MSCs, they can be 
isolated from other tissues, including adipose tissue, trabecular bone, synovium, skeletal 
muscle, deciduous teeth, and human umbilical cord blood [22-27], suggesting the diverse 
distribution of MSCs in a body. However, MSCs derived from organs other than bone 
marrow exhibit limited differentiation potential [28, 29]. Among all types of stem cells, 
MSCs have attracted special attentions because of its wide application as regenerative 
medicine. ES cells were first studied as regenerative medicine because of their self-
renewal capacity and differentiation potential. However, direct injection of highly-
pluripotent ES cells into ectopic organ often give rise to teratoma, a benign tumor 
containing derivatives of all three germ layers [30]. MSCs are less potent to induce 
teratoma or other malignant transformation as they only have restricted differentiation 
potential [31]. Compared with other adult stem cells such as HSCs, mammary stem cells 
or neural stem cells, MSCs have a well-characterized trophic effect and 
immunomodulatory property, making them good candidates in treating degenerative 
diseases. For example, intravenous transplantation of MSCs was reported to be successful 
in treating systemic diseases such as graft versus host disease (GvHD) and osteogenesis 
imperfecta in human [32, 33]. Wakitani et al. also reported several successful clinical 
cases treating cartilage defects with MSCs [34]. Nevertheless, primary MSCs have also 
been employed in regenerating hematocytes, tendon, bone marrow, muscle, and other 
connective tissues [35-39].  
 
Bone marrow derived mesenchymal stem cells (BMSC) are morphologically 
defined as plastic, adherent, pluripotent fibroblast-like cells. BMSCs are stem cells 
because of their stem cell-like properties such as unlimited self-renewal capacity and 
potential for multilineage differentiation. Primary BMSCs can be expanded for 34~50 
population doublings (PD) without losing their native characteristics. BMSCs can 
differentiate into a variety of cell types including osteoblasts, chondrocytes, and 
adipocytes under in vitro and in vivo conditions [40].  
 
  
Progress in Stem Cell Therapy 
 
There are two major directions of applying BMSCs to human islet transplantation, 
as trophic mediators to support islet function or as immune modulators to prevent graft 
rejection. 
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BMSCs support islet function 
 
In vivo studies using BMSCs to treat diabetes used to support a hypothesis that 
BMSCs might differentiate into insulin-producing β cells or they might induce 
endogenous progenitor proliferation/differentiation. Ezquer et al. demonstrated that 
systemic administration of BMSCs increased β cell mass and reverted hyperglycemia in 
streptozotocin (STZ) induced type 1 diabetic mice [41]. However, whether BMSCs can 
directly replenish the loss of β cells is still under debate. The native β cells are derived 
from neural crest cells during the process of neurulation, while BMSCs are derived from 
mesoderm. Although the number of islets does not increase throughout human life, 
insulin-producing β cells do proliferate according to several reports [41-43].  Hess et al. 
first raised doubt that MSCs did not directly rescue the pancreatic injuries by in vivo 
differentiation and migration but instead induced endogenous pancreatic tissue repair in 
an unknown manner [44]. Lately, both Choi et al. [45] and Dor et al. [46] confirmed that 
new pancreatic β-cells are derived from the expansion of pre-existing β cells rather than 
exogenous stem cells through the convincing lineage tracing studies. Since then, 
emerging evidence suggested that BMSCs supported islet function through a predominant 
paracrine model, or in other words served as a “trophic mediator.”  
 
BMSCs actively produced HGF, which is a potent mitogen to many cells 
including pancreatic β-cells [47]. For example, in a study using human BMSCs to treat 
STZ induced diabetic mice, Lee et al. demonstrated that the major effect of human 
BMSCs treatment was to increase the number of mouse islets and mouse insulin-
producing cells, which were most likely to arise from the proliferation, migration, and 
neural differentiation of the nearby endogenous mouse neural stem cells [42].  
 
Most studies suggested that BMSCs actively participate in angiogenesis of human 
islets by secreting VEGF and HGF which are potent angiogenic factors [48]. Izumida et 
al. reported that proliferative activity and differentiative response in the pancreatic ductal 
cells were significantly raised once rats were treated with HGF positive BMSCs [49]. 
Sordi et al. found that BMSCs of bone marrow origin facilitated the restoration of 
normoglycemia and the neovascularization of the islet graft [50]. which was confirmed 
by a recently study by Rackham et al. that islets co-transplanted with BMSCs maintained 
a morphology that more closely resembled that of islets in the endogenous pancreas both 
in terms of size, endocrine and endothelial cell distribution [51]. We also demonstrated 
that islet/BMSC co-transplantation under the kidney capsule of diabetic mice formed a 
more intense and function vasculature [52]. Other studies suggested that BMSCs may 
also differentiate into endothelial cells and directly assist the neo-vessel formation [53]. 
Silva et al. reported the transdifferentiation of BMSCs into an endothelial phenotype in a 
canine ischemia model, which is supported by the report from Ito et al. that BMSCs 
directly differentiate into a van-willebrand-factor-positive vascular endothelial cell type 
to improve the islet graft morphology and function [54]. However, these results should be 
explained cautiously because the new-formed vessels may arise from native BMSCs 
instead of infused BMSCs.  
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BMSCs prevent graft rejection 
 
The allograft rejection from the host innate immune system is another major issue 
for islet transplantation. The most potent antigen-presenting cells, dendritic cells (DCs) 
play a key role in allograft recognition and rejection. Briefly, the precursor monocytes 
migrated through the capillaries into tissue and differentiate into immature DCs. Once 
encountering foreign cells, DCs process and present the allogeneic antigen through major 
histocompatibility complex class II (MHC II) to the T cell receptor (TCR) of native T 
cells (T0) and promote T cell activation into cytotoxic T cells (Tc), helper T cells (Th) 
and memory T cells (Tm), while immature DCs themselves undergo maturation 
simultaneously. Tc cells then mediate the acute immune attack to the allograft. Th cells 
recruit and activate more immunocytes including Tc, macrophages and B cells and lead 
to an enlarged immune response. Tm cells circulate in the host body and mediate the 
long-term rejection. 
 
BMSCs are hypoimmunogenic cells, expressing MHC1 but not MHC II. They 
also lack co-stimulatory molecules including CD14, CD86, CD40L and CD95L (FasL) 
[55]. Therefore, BMSCs can evade the alloreactive T cells and natural killer (NK) cells in 
a similar manner like cancer cells [56, 57]. Most researchers believe that MSCs induced 
immune tolerance by inhibiting T cell activation and proliferation. Two models have 
been proposed: 1) BMSCs inhibited T cell activation through physical contact (the 
direction inhibition model) and 2) BMSC produced immunosuppressive soluble factors to 
reverse the maturation of antigen-presenting DCs and subsequently led to T cell 
inactivation (the indirect inhibition model) (Figure 1-2).  
 
The direct inhibition model proposed that the rate of T cell inhibition was 
increased when cell contact between BMSCs and T cells was allowed [58]. Krampera et 
al. showed that the inhibitory activity of BMSCs was abrogated when BMSCs were co-
cultured with T cells in a transwell system or when BMSCs were replaced by BMSC 
culture supernatant [59]. Ding et al. supported the direct inhibition model by reporting 
that the extracellular matrix proteins such as matrix metalloproteinase (MMP)-2 and 
MMP-9 of BMSCs cleaved the IL-2 receptor from the surface of T cells and suppress T 
cell responses [60]. However, overwhelming studies supported the indirect model, 
showing BMSCs actively secreted multiple soluble immunosuppressive factors such as 
indoleamine-pyrrole 2, 3-dioxygenase (IDO), HGF, transforming growth factor-β (TGF-
β), prostaglandin E2 (PGE2) and inhibited the alloreactivity of T cells in recipients and 
prolonged the allograft survival [58, 61-64]. 
 
However, it is worth noting that multiple discrepancies exist among these soluble 
factors secreted by MSCs. For example, evidences from Beyth et al. showed that adding 
neutralizing antibody to human TGF-β had no effect on the inhibitory activity of 
MSCs[65], in contrast to the report by Di Nicola et al.[58]. Ryan et al. reported 
constitutive expression of IL-10 by MSCs while Beyth et al. only detected IL-10 in 
MLR/MSCs co-culture [55, 65]. Moreover, studies by Tse et al. showed that none of IL-
10, TGF-β or PGE2 produced by MSCs was responsible for the T-cell inhibitory effect 
[66]. Although such discrepancies could be explained by the multiple sources and  
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Figure 1-2. MSCs inhibit T cell activation  
A. The allograft rejection mediated by T cells. Briefly, antigen-presenting Dendrite Cells 
(DCs) present allogeneic antigen through MHC II to the TCR of T0 cells. With assist 
from co-stimulatory molecules DCs become activated into mature DCs and 
simultaneously promote T cell activation into Tc, Th and Tm. Then the activated T cells 
lead to a cascade of immune responses to mediate acute graft rejection and long term 
graft rejection. B. MSCs inhibit T cell activation through two mechanisms. (1) Direct T 
inhibition, which is achieved by a so-far unknown cell-cell contract mechanism or 
MMP2/MMP9 mediated CD25 cleavage on the surface of activated T cells. (2) Indirect T 
cell inhibition, which is achieved by releasing soluble factors to inhibit and reverse DCs 
maturation. The antigen presenting process through immature DCs which in lack of co-
stimulatory molecules leads to inactivation of activated T cells, proliferation of 
immunosuppressive Treg and allogeneic tolerance. 
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lineages of MSCs and variation in culture conditions among the research groups, the 
underlying signal transduction pathway between soluble factors released by BMSCs and 
the antigen-presenting DC require further exploration. Moreover, most of these studies 
are conducted using an in vitro cell culture instead of animal model. One goal of our 
work is to resolve the mysteries of the immunomodulatory effect of BMSCs. 
 
The immunomodulatory effect of BMSC makes them good candidate in organ 
transplantation. Ding et al. reported that BMSCs co-transplanted under the kidney 
capsule of immune competent mice protected islet grafts by inhibiting the alloreactivity 
of infiltrating T cells [60]. Longoni et al. reported that BMSCs induced a reduction of 
inflammatory cytokines and improved the viability of islets infused into the portal vein of 
diabetic rats [67]. Li et al. reported reduced Th1/Th2 ratio, Tc cells and Tm cells number 
and suppressed DCs maturation once BMSCs were co-transplanted with allograft islets 
under the kidney capsules of diabetic C57LB/6 mouse [68]. Kim et al. reported the 
combined use of autologous BMSCs and low-dose cyclosporine A to further prolong 
graft survival after allogeneic rat islet transplantation [69]. BMSCs were also used to 
prevent the allograft rejection in the transplantation studies of other organs including 
kidney,[61, 70] skin[71] and heart [62, 72, 73] (Table 1-4).  
 
 
Stem Cell Based Gene Therapy 
 
In the last decade, gene therapy and stem cell therapy are frequently combined 
together to enhance the therapeutic effect, unusually referred as stem cell based gene 
therapy. Stem cell based gene therapy can be applied on human islet transplantation from 
two directions: 1) Stem cells were used as gene delivery vehicles to express therapeutic 
gene in the target sites and 2) stem cells were reprogrammed or transdifferentiated by 
genetic modification to replenish the defect cells or tissues (regenerative medicine).   
 
Traditional gene therapy requires direct transduction on targeted tissue so that 
transgene can be introduced and expressed afterward. The gene transfer process normally 
takes 16~24 hours and has several drawbacks in human islet transplantation. The first is 
the loss of islet viability and function during the transduction process. One extra day of in 
vitro culture can make a big difference in the function, viability and quantity of islets 
needed for optimal transplantation outcome. The second issue is the toxicity and 
immunogenicity of adenoviral vectors. Adenoviral at high MOI will kill islets. Even at a 
moderate MOI which is not toxic to human islets, adenovirus will increase the 
immunogenicity of human islets and consequently induce strong immune rejection. 
Therefore for some soluble factors whose effect can be exerted from outside of the 
cytoplasm, use stem cells as nursing cells to deliver therapeutic genes can be a smart 
strategy to overcome the issues with direction transduction (Figure 1-3). Part of our work 
focused on the feasibility of using BMSC as a gene delivery vehicle to support the 
survival of human islets after transplantation and the detailed results are presented in 
Chapter 5.  
 
BMSCs not only regenerate mesenchymal tissues such as chondrocytes,
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Table 1-4. BMSCs improve solid organ transplantation 
 
Organs Experimental design Therapeutic effects of BMSCs 
Kidney Human of 14 subjects. In vitro MLR study of donor 
BMSCs against recipients lymphocytes. 
BMSCs inhibit the proliferation of Th and Tc from the 
recipients by cell-cell contact and IL-10 and IDO. No effect 
on B or NK cells [61]. 
Human of 2 subjects. Autologous BMSCs were injected 
IV into recipients at day 7 posttransplantation. 
BMSCs inhibit the proliferation of Tm and Tc. Increase 
Treg percentage [70]. 
   
Skin Baboons study. Donor BMSCs from MHC mismatched 
donor were injected IV into recipients on the day of 
transplantation. 
BMSCs inhibit lymphocyte reactivity and prolong the graft 
survival and suppress the proliferation. IL-2 partially 
reverse the effects of BMSCs [71]. 
   
Heart Rat. In vitro expanded BMSCs were injected IV 1 week 
before and on the day of transplantation. 
BMSCs reduce the alloreactivity of recipient’s T cells and 
shift the Th1/Th2 balance to immunosuppressive Th2 [72]. 
Mice. In vitro expanded BMSCs were injected IV before 
transplantation. 
BMSCs induce donor-specific Treg proliferation and 
impaired Th1 alloreactivity. Donor-specific Treg do not 
lead to immune tolerance of allograft from third-party [73]. 
Rat. BMSCs were injected IV with a short course of low-
dose mycophenolate. 
BMSCs induce tolerance by secretion IDO and interaction 
with DCs [62]. 
   
Islet Rat. In vitro expanded BMSCs co-infused into liver. Reduce islet number needed for reversal of diabetes 
promote revascularization [54]. 
Rat. In vitro expanded BMSCs were co-transplanted into 
omental pouch. 
Inhibit Th1 cell activation promote IL-10 producing CD4+ 
T cells [74]. 
Mice. In vitro expanded BMSCs were co-transplanted 
beneath the kidney capsule 
BMSCs secreted MMP2 and MMP9 to cleave CD25 from 
IL-1R and thus lead to interleukin-2 hyporesponsiveness in 
T-cells [60]. 
Monkey. BMSCs from donor and third party were co-
infused into portal vein and injected IV thrice at day 4, 5 
11 after transplantation. 
BMSCs prolong graft viability and function, probably by 
increasing Treg proliferation in peripheral blood [75]. 
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Figure 1-3. Gene therapy and stem cell based gene therapy 
In vivo gene transfer involves direct administration of the vector in the tissue of interest. 
Ex vivo gene transfer requires collection of cellular targets from the patient. The cells are 
treated in culture with the vector. Cells expressing the therapeutic transgene are harvested 
and given back to the patient. 
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osteoblasts, and adipocytes but also undergo transdifferentiation into cells from other  
lineages upon proper induction, indicating plasticity of these adult stem cells. Gene 
transfer into primary BMSCs may greatly promote their transdifferentiation into insulin-
producing cells even islet-like cluster, which may replenish the current shortage in the 
supply of donor islets. Chen et al. first reported in vitro transdifferentiation of rat MSCs 
into functional insulin-producing islet-like cells that actively controlled blood glucose 
level in diabetic rats [76]. Then Karnieli et al. and Li et al. independently reported the 
generation of insulin-producing cells from human MSCs which were genetically 
manipulated to overexpress Pdx-1 with retrovirus and adenovirus, respectively [77, 78]. 
The research in this area provided new insights and has bright future in human islet 
transplantation. However, we just initiate our work in this area and it is out of the scope 
of this thesis. 
 
 
Diabetic Humanized Animal Model 
  
Immune deficient animal models are most frequently used for the research in 
human islet transplantation. These models provide optimal environment for the 
engraftment of islets from multiple sources because of the absence of immune rejection. 
However, these models can only be used to study the function of islets against the non-
immune challenges such as hypoxia, inflammatory cytokines and early graft apoptosis, 
which is the PNF of islets. 
 
To understand the physiology of islet grafts under the immune rejection of the 
recipient, a humanized mouse model was introduced. Lenny Schultz first introduced the 
idea of humanized mouse in which human immune system was rebuilt in mouse by 
injecting and settling human peripheral blood mononuclear cells (PBMCs) [79, 80]. The 
success in building human immunity in mice relies on the species and strain of mouse. 
For example, human immunity can be readily built by injecting PBMCs into NOD.Cg-
PrkdcscidIL2rgtm1Wjl/SzJ (NSG) mice but not Nonobese diabetic severe combined immune 
deficient (NOD-SCID) mice. This may be a result of the knock-out of IL-2rgamma, 
which has great impact on the settlement of PBMCs, in the NSG mice. Another mouse 
model was NOD.Cg-Rag1tm1MomIns2AkitaIl2rgtm1Wjl/SzJ (NRG-Akita) mice, which 
spontaneously develop diabetes from 5-7 weeks. However, the difficulty of using NRG 
mice is that not all mice develop similar extent of diabetes at a same pace. To control the 
extent of diabetes, we choose STZ induced NSG mice for islet transplantation studies.  
 
The risk of GvHD is another factor need to be taken into consideration. The 
mature PBMCs has the potential to recognize and attack the xenogeneic organs after 
infusion. GvHD is usually characterized by the weight loss, hunched posture, ruffled fur, 
reduced mobility, extremely low blood glucose and tachypnea and will lead to animal 
death in one day or two. To avoid GvHD, Dose of PBMCs used for infusion is important. 
The most frequently reported dose is 5x106 PBMCs/mouse, which is enough to build 
human immunity but less potent to induce GvHD. However, even at such a low dose, 
GvHD is only pended but not avoided. GvHD will occur at 5~10 weeks after infusion in 
most cases, therefore we only buy ourselves a limited window to evaluate the immune 
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rejection of human islets even at the safety dose of PBMCs. Recently, a lot of efforts 
have been put onto the maturation of human immunity in mice using hematopoietic stem 
cells. It was recently demonstrated that the immunocytes matured inside the body of 
mouse has less potential to attack organs of mouse and therefore less likely to induce 
GvHD like symptoms.    
 
Induce diabetes in humanized mice or vice versa (humanize diabetic mice) are 
both tricky task. We chose the latter strategies because of two reasons: 1) it provides 
direct contrast of the responses of animals to transplanted human islets in the absence and 
presence of human islets and 2) the chemical used to induce diabetes, STZ is strong 
immune activation drug and the injection of STZ into humanized mouse will elicit a fast 
and strong GvHD and cause animal death in less than 2 weeks. NRG-Akita mouse was 
not used in this study purely due to cost considerations. Because mice develop diabetes at 
different pace but islets always come together and vary from preparation to preparation. 
We need a strategy which is capable of develop suitable extent of diabetes in most mice 
in the same day so all of them are suitable for human islet transplantation.  
 
To generate diabetic humanized mouse, we first induce diabetic in NSG mice by 
intraperitoneally injection of STZ. We wait 3~4 week until all mice showed similar 
extent of diabetes (blood glucose 300~500mg/dL). Then islets were transplanted with or 
without BMSCs. After additional 4 weeks, PBMCs were injected to introduce human 
immunity.  Detail experiments are described in Chapter 6.  
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CHAPTER 2.    SPECIFIC AIMS 
 
 
Aim I. Adenovirus Mediated XIAP Expression to Prevent the Early Graft Apoptosis 
in Human Islet Transplantation 
 
The main objective of this part of research is to find the best anti-apoptotic gene 
to prevent the early apoptosis in human islet transplantation. Our formal lab members 
identified several target genes in the apoptotic pathway of human islet. For example, 
Feng Li silenced iNOS gene while Guofeng Cheng silenced caspase 3 using RNA 
interference for in vitro protection of human islets from inflammatory cytokines [5, 6]. 
Ravikiran Panakanti blocked IL-1 pathway by overexpressing IL-1 receptor antagonist 
(IL-1Ra) to prevent the early graft loss after islet transplantation into NOD-SCID mice 
[4, 8]. All these previous work inspired our research and hereby we hypothesized that 
XIAP over expression can be a more effective strategy to prevent the early graft 
apoptosis in human islet transplantation. We propose several objectives in this part of 
research and discuss in detail in Chapter 3. 
 
1) Learn the techniques in the culture of rat insulinoma cells (INS-1E) and 
human islets. 
2) Learn the techniques in the generation, amplification, tittering and storage of 
adenovirus. 
3) Test the transgene expression of XIAP in genetically modified human islets. 
4) Test whether XIAP expression improves the outcome of human islet 
transplantation in immunodeficient NOD-SCID mice. 
 
 
Aim II. RGD Peptide Modified Adenovirus Encoding XIAP and HGF to 
Simultaneously Prevent Early Graft Apoptosis and Promote Revascularization to 
Improve the Outcome of Human Islet Transplantation 
 
 The main objective of this research is to improve the transduction efficiency of 
traditional adenoviral vectors. In 2004, when we first initiated gene therapy project, we 
used plasmid and lipid-mediated transfection to introduce gene of interest into human 
islets [12]. However, the gene transfer efficiency of this strategy was extremely low. In 
2006 we converted the plasmids to adenoviral vectors, which significantly improved the 
gene transfer efficiency [7]. However, the titer of adenovirus must be strictly controlled 
because high titer of virus is known to induce toxicity in human islets. After that we 
designed several bipartite adenoviral vectors so that two therapeutic genes can be co-
expressed simultaneously without increase the viral titer [4, 8]. But this strategy was 
incompetent to reduce the viral titer for optimal transgene expression. Hereby we were 
trying to modify the surface of adenovirus so that less viral particles can be used to 
transduce human islets without compromising the transduction efficiency. We propose 
several objectives in this part of research and discuss in detail in Chapter 4.  
 
1) Learn the techniques in the induction of moderate diabetes in mice. 
 22 
2) Compare the transduction efficiency of unmodified adenovirus and RGD 
modified adenovirus.  
3) Test the transgene expression of XIAP and HGF in genetically modified 
human islets. 
4) Test whether genetically modified human islets improve the outcome of 
human islet transplantation in immunodeficient NOD-SCID mice. 
 
 
Aim III. Use BMSCs as Gene Delivery Vehicles to Express HGF and IL-1Ra to 
Improve the Outcome of Human Islet Transplantation 
 
The main objective of this study is to determine whether gene therapy can be 
achieved without the direct gene transfer into human islet. We successfully decreased the 
viral titer for optimal transgene expression in the previous study. However, the use of 
virus, at whatever titer, will raise safety concerns such as immunogenicity and 
tumorigenicity. Moreover, before islet transplantation can be performed, gene transfer 
into human islets will cost one extra day, which makes great difference in the viability 
and function of islets and thus the outcome of islet transplantation. We hypothesized that 
BMSC can be genetically modified by adenovirus before the arrival of islet preparations 
and co-transplanted with fresh human islets to treat type 1 diabetes. We propose several 
objectives in this part of research and discuss in detail in Chapter 5. 
 
1) Test the transduction efficiency of adenovirus on BMSCs. 
i. Test whether the adenoviral transduction affects the gene expression prolife 
and stem cell like properties of BMSC. 
ii. Test the duration and level of transgene expression in genetically modified 
BMSCs. 
2) Test the protection of genetically modified BMSCs to human islets in islet 
perifusion study in vitro. 
3) Test whether islet/BMSCs cotransplantation improve the outcome of human 
islet transplantation in immunodeficient NOD-SCID mice.  
 
 
Aim IV. Use BMSCs to Prevent the Immune Rejection of Islet Allografts in 
Humanized NSG Mice 
 
Gene therapy is incompetent to prevent the immune rejection, while stem cells 
can be an effective strategy to overcome the immune rejection. In this study, we 
borrowed an up-to-date humanized animal model to determine immunomodulatory effect 
of BMSC to protect human islets in the presence of human immunity. We propose 
several objectives in this part of research and discuss in detail in Chapter 6.  
 
1) Build human immunity in STZ-induced diabetic NSG mice through 
intraperitoneal injection of human PBMCs. 
2) Determine the immunomodulatory effects of BMSCs in vitro.  
i. Characterize the surface markers of BMSCs. 
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ii. Test whether BMSCs can suppress the proliferation and activation of 
PBMCs in the mixed lymphocyte reaction (MLR). 
iii. Test whether BMSCs can promote the regulatory T cells in MLR. 
3) Determine the mechanism underlying the immunosuppressive effect of 
BMSCs. 
i. Determine whether BMSC alone can suppress the proliferation and 
activation of PBMCs. 
ii. Determine the role of IL-10 in the immune modulation mediated by 
BMSCs. 
iii. Determine the sources of IL-10 production in the MLR/BMSC mixture. 
4) Test the tropic effect of BMSCs in vitro. 
i. Test the gene expression profile of BMSC. 
ii. Test whether BMSC can improve the insulin production of islets under the 
challenges by inflammatory cytokines. 
5) Test whether BMSCs prevent the graft rejection in human islet transplantation 
in a humanized immune-competent mice model. 
i. Test whether BMSCs prevent T cell infiltration into the transplantation site. 
ii. Test whether BMSCs increase Tregs.  
iii. Test whether BMSCs improve early engraftment and revascularization of 
human islet transplantation. 
 
 
Aim V. Use Small Molecular Compound Drug to Prevent the Immune Rejection of 
Islet Allografts in Humanized NSG Mice 
 
 BMSCs were capable to prevent the immune rejection of human islets in 
humanized mouse model. However, BMSCs will be sequestered in the lung after 
intravenous injection, making them unsuitable for repeated dosing. Despite the 
hypoimmunogenic nature, BMSCs from a third party, if used in large quantity, will raise 
safety concerns about the immunogenicity and tumorigenicity. In this study, we 
synthesized a compound drug (E)-2,3,5-trihydroxy-5-(propylcarbamoyl)cyclohexyl 6-(4-
ethoxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-
enoate (JP-3-110) by conjugating anti-apoptotic compound 1,3,4,5-tetrahydroxy-N-
propylcyclohexanecarboxamide (KZ41) and immunosuppressive compound MPA. We 
hypothesized that this new compound can exert the immunosuppressive effect through 
intravenous injection while avoiding the toxicity associated with MPA. We propose 
several objectives in this part of research and discuss in detail in Chapter 7. 
 
1) Synthesis and characterization of a compound drug JP-3-110 which is 
composed of MPA, an immunosuppressive drug and KZ-41, a novel anti-
apoptotic compound for human islet transplantation. 
2) Compare the anti-apoptotic effect of JP-3-110 and KZ41 against the 
inflammatory cytokines. 
3) Compare the immunosuppressive effect of JP-3-110 and MPA on PBMCs. 
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CHAPTER 3.    XIAP OVEREXPRESSON MEDIATED BY ADENOVIRUS TO 
PREVENT APOPTOSIS OF ISLET TRANSPLANTATION 
 
 
Introduction 
 
The loss of function of transplanted human islets is usually accompanied with the 
apoptosis of insulin-producing β cells. The apoptosis of β cells can be caused by many 
reasons including lack of supplies of oxygen and nutrition, poor revascularization, 
inflammatory cytokines, and reactive oxidative species.  In most cases, islet loss occurs in 
the first two weeks after transplantation, and will decrease significantly due to successful 
revascularization thereafter [81, 82]. Therefore, expression of an antiapoptotic gene in β 
cells timely may be an effective strategy to improve islet viability post transplantation 
[17]. We previously reported ex vivo transduction of islets with adenoviral vector 
encoding human interleukin-1 receptor antagonist (IL-1Ra) to prevent IL-1β induced 
apoptotic cell death of islets [3]. We also demonstrated that the inhibition of caspase-3 
pathway helped to protect human islets from apoptosis caused by inflammatory cytokines 
in vitro [6]. However, the apoptosis of islets usually involved multiple inflammatory 
cytokines and a network of signal transduction pathways (Figure 3-1). The therapeutic 
effect gained from the inhibition in a single factor or pathway was limited and not 
capable to reverse the apoptosis of islets in a whole picture. For example, IL-1Ra 
expression was not able to address the apoptosis of islets caused by hypoxia and ROS. A 
target gene with more ubiquitous anti-apoptotic effect was needed.  
 
In this study, we identified XIAP as a target gene. XIAP is a well characterized 
inhibitor of apoptosis by inhibiting three types of caspase at the same time (Figure 3-1). 
The BIR2 domain of XIAP inhibits caspase 3 and caspase 7, while BIR3 domain inhibits 
caspase 9 [83-85]. Besides, XIAP is also capable of address the apoptosis from death 
receptor pathway and mitochondria pathway. Therefore, XIAP holds great potential to 
inhibit the apoptosis of human islets caused by hypoxic environment, ROS and 
inflammatory cytokines together.  
 
XIAP overexpression minimizes the injury in pancreatic β-cells caused by 
hypoxia and reperfusion [86]. Hui and colleagues demonstrated the reversal of the 
negative effects of immunosuppressive drugs by XIAP overexpression on human islets 
[87]. XIAP has also been proven to improve the murine islet viability after isolation [88]. 
However, the mechanism underlying the protective effect of XIAP was also not 
thoroughly understood and promising long term data normoglycemic control in animal 
experiments is still needed. Therefore, in this study, we transduced INS-1E cells and 
human islets with replication deficient adenovirus encoding XIAP to determine whether 
XIAP overexpression protects β cells and islets from cytokine induced cell death.  
                                                 
 
 Reprinted with permission from American Chemical Society. Wu, H, Panakanti, R, Li, 
F, and Mahato, RI (2010). XIAP gene expression protects beta-cells and human islets 
from apoptotic cell death. Molecular Pharmaceutics 7: 1655-1666. 
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Figure 3-1. Schematic diagram showing the role of XIAP in the apoptotic 
pathway of human islets  
XIAP inhibits caspase 3, caspase 7 and caspase 9 simultaneously. XIAP also inhibits the 
apoptosis caused by the mitochondria pathway (hypoxia, reactive oxygen species (ROS), 
and ultraviolet radiation) and death receptor pathway (inflammatory cytokines) at the 
same time. Therefore, we hypothesized that the anti-apoptotic effect of XIAP 
overexpression should be better than the gene silencing of caspase 3 or iNOS and the 
blocking of IL-1R. 
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Materials and Methods 
 
 
Materials 
 
The replication deficient (ΔE1/ΔE3) adenoviral vector encoding human XIAP 
(Adv-hXIAP) was purchased from Vector Biolabs (Philadelphia, PA). RPMI 1640 
medium was purchased from Invitrogen (Carlsbad, CA). CMRL-1066 medium was 
purchased from Sigma Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was purchased 
from MediaTech Cellgros (Herndon, VA). Phosphate buffer solution (PBS) was 
purchased from GIBCO-BRL (Gaithersburg, MD). Human XIAP enzyme-linked 
immunosorbent assay (ELISA) kits and cytokines such as IL-1β, TNF-α, and interferon 
(IFN)-γ were purchased from R&D Systems (Minneapolis, MN). Human Insulin ELISA 
kits were purchased from Alpco Diagnostics (Windham, NH). RNA extraction kit and 
Caspase-Glo 3/7 assay kit, DeadEnd Colorimetric terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) system, and APO-DIRECT TUNEL system were 
purchased from Promega (Madison, WI). SYBR Green real-time PCR master mix and 
reverse transcription reagents were purchases from Applied Biosystems (Foster city, CA). 
 
 
Virus amplification and titer determination 
 
Adv-hXIAP was transduced into 293 cells. At 48h post transduction, almost 90% 
of the cells were detached from the flask. Then, the cells were collected, centrifuged and 
freezed and thaw three times to release Adv-hXIAP viral particles. Then, the viral 
solution was used to determine the viral titer using an Adeno-X rapid titer kit from 
Clontech (Mountain View, CA). Briefly, different dilutions of Adv-hXIAP was taken and 
transduced to 293 cells, using untransduced cells as a control. After 48h post-
transduction, 293 cells were fixed and incubated with Anti-Hexon antibody, followed by 
a secondary horse radish peroxidase (HRP)-conjugated antibody. Then the cells were 
stained with 3, 3’ diaminobenzidine tetrahydrochloride (DAB) substrate and positively 
stained cells were counted under a microscope, and the titer was determined.  
 
 
Cell and islet culture and transduction  
 
INS-1E cells, a gift from Professor Claes B. Wolheim (University Medical 
Center, Geneva, Switzerland) were seeded at a density of 106 cells per 24-well plate. 
After 24h, INS-1E cells were transduced with Adv-hXIAP of indicated MOI for 3h 
followed by washing and further culturing for 2 days. Human islets were received from 
one of the several Islet Cell Resource (ICR) Centers through ICR services for Basic 
Science Applications, in culture media at 4°C. On receiving, the islets were cultured in 
CMRL-1066 medium containing 10 % FBS and 1 % Penicillin Streptomycin. INS-1E 
cells and human islets were transduced with Adv-hXIAP, while nontransduced human 
islets as well as the islets transduced with Adv-LacZ were used as controls. To determine 
the optimal MOI of Adv vectors in terms of plaque forming units (pfu) per IE, 1000 IE 
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were incubated with diluted Adv-hXIAP in 300μl media in a 96 well plate for 12 h, 
followed by washing and further culturing in 1ml of media in 24-well plates for 2 days.  
 
 
Quantitative real-time PCR  
 
INS-1E cells were collected to determine XIAP mRNA level by quantitative 
Real-time PCR post-transduction. Briefly, INS-1E cells were collected and total RNA 
was isolated using RNAeasy mini isolation kit from Promega (Madison, WI) 3 days post-
transduction. RNA concentration was measured by UV spectrophotometer. Then 170 ng 
of extracted RNA was converted into cDNA using MultiScirbe reverse transcriptase and 
random hexamers (Applied Biosystems, Inc., Foster City, CA) by incubation at 25°C for 
10 min, followed by reverse transcription at 48°C for 30 min and enzyme inactivation at 
95°C for 5 min. Then 2 μl cDNA was used as a template and analyzed by SYBR Green-I 
dye universal PCR master mix on a LightCycler 480 Instrument. Caspase 3 mRNA 
expression was also determined by the same method. β-actin was used as an internal 
control. All samples were run in triplicates. The primer sequences were as follows: 
human XIAP (forward) 5’-TGT TTC AGC ATC AAC ACT GGC ACG-3’, (reverse) 5’-
TGC ATG ACA ACT AAA GCA CCG GAC-3’; rat caspase 3 (forward) 5’-CAT GAC 
CCG TCC CTT GAA-3’, (reverse) 5’-CCG ACT TCC TGT ATG CTT ACT CTA-3’; rat 
β actin (forward) 5’-AGT CAT GTA CGT AGC CAT-3’, (reverse) 5’-CTC TCA GCT 
GTG GTG GTG-3’.  
 
 
ELISA and western blot  
 
At the indicated time post-transduction, INS-1E cells or human islets were 
collected to determine XIAP protein level by ELISA or Western Blot. Total protein was 
extracted by lysing INS-1E cells or human islets with RIPA buffer (Sigma) and stored in 
-80 oC for ELISA and Western Blot study. For ELISA, XIAP levels were measured as 
per the manufacturer’s protocol (R&D Systems, Minneapolis, MN). For Western Blot 
analysis, the samples were mixed with 6 × Laemmli sodium dodecyl sulfate (SDS) buffer 
(Boston BioProducts) and then boiled for 5 min to denature the protein. Then groups of 
samples were loaded to 4%-15% Tris-HCl Precast Polyacrylamide Gel (Bio-Rad, 
Hercules, CA) for electrophoresis and subsequently transferred to Immobilon 
Polyvinylidene Fluoride (PVDF) membrane (Millipore). After blocking with 3% bovine 
serum albumin in 1× PBST (PBS containing 0.05% Tween-20) for 1 h at room 
temperature, the membranes were further incubated with goat polyclonal IgG to XIAP 
and actin (Santa Cruz) primary antibodies (1:500) overnight at 4 °C. Membrane was then 
incubated with HRP-conjugated rabbit polyclonal antibody to goat (1:10000) (Abcam) 
for 1 h at room temperature. Target proteins were detected by enhanced 
chemiluminescence (ECL) detection kit (GE Healthcare Life Sciences, Pittsburgh, PA). 
Total protein concentration of INS-1E cells and islet extracts was also determined using 
the bicinchoninic acid (BCA) protein assay kit to normalize the results. Actin was used as 
an internal control for Western Blot. 
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Caspase detection 
 
Caspase-Glo 3/7, 8 and 9 assay kits were used to analyze caspase 3/7, 8 and 9 
activities, respectively, as per the manufacturer’s protocol (Promega). This assay kit 
provides a proilluminescent caspase substrate, DEVD, when cleaved by caspases, will 
release luciferin to quantitatively determine caspase concentration. Briefly, 48h following 
transduction and cytokine cocktail treatment for additional 3h, 100 μl Caspase-Glo 
reagent was added to 100 μl of culture supernatants in 96-well plates and incubated at 
room temperature for 1h. The contents were then transferred into culture tubes and 
luminescence was determined using a luminometer (Berthold, Germany). 
 
 
Cell viability 
 
Cell viability was determined using MTT assay. Briefly, following transduction 
with adenoviral vectors at MOI=2, INS-1E cells were further incubated with cytokine 
cocktail, including 5ng/ml IL-1β, 25ng/ml TNFα, and 25ng/ml IFNγ, for indicated time. 
At the end of the cytokine treatment, INS-1E cells were further cultured with medium 
containing 0.5mg/ml 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT, Sigma) for 2h in 37oC. Then the medium was removed and 200ul DMSO was 
added into each well to dissolve the formazan crystals. The absorbance was measured in 
550 nm using a microplate reader (Bio-Rad, Hercules, CA). The relative cell viability (%) 
was calculated. 
 
 
TUNEL assay 
 
To determine the apoptotic cell death, following transduction for 3h, INS-1E cells 
were incubated with cytokine cocktail for 48h. Apoptotic cells were dark stained using 
DeadEnd Fluorometric TUNEL System from Promega (Madison, WI) as per the manual. 
To quantitatively determine the effect of XIAP expression on cytokine induced INS-1E 
cell apoptosis, APO-DIRECT kit (Promega, Madison, WI) was used to detect apoptotic 
cells. Briefly, following transduction for 3h and incubation with the cytokine cocktail for 
additional 48h, INS-1E cells were made to single cell suspension by trypsin digestion as 
described above. The cells were fixed in 1% paraformaldehyde in PBS (pH 7.4) and then 
treated with ice-cold 70% ethanol and stained with FITC-dUTP and propidium iodide. 
Fluorescent intensity was measured by flow cytometry and analyzed using CELLQUEST 
software (BD Bioscience). Nontransduced cells without cytokine treatment were served 
as a negative control. Three sets of independent transduction experiments were carried 
out for each assay.  
 
 
Static insulin release  
 
In vitro function of INS-1E cells and human islets after transduction with Adv-
hXIAP was determined by the static incubation method. Briefly, after transduction media 
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was carefully removed with pipette, INS-1E cells and human islets were sequentially 
incubated in the media containing 2.5mM (basal) and 22mM glucose (stimulated) at 37ºC 
for 1h. Supernatants were collected and analyzed for insulin release by Insulin 
Ultrasensitive EIA kit (Alpco Diagnostics, Salem, NH). Insulin secretion was expressed 
as µU/ml and the ratio of insulin levels at 22mM to 2.5mM glucose was used to calculate 
the stimulation index.  
 
 
Islet transplantation studies 
 
Animal experiments were performed as per the NIH 
(http://grants1.nih.gov/grants/olaw/references/phspol.htm) and institutional animal care 
and use guidelines using the approved protocol. To induce diabetic animal model, STZ 
(40 mg/kg) was administered to NOD-SCID mice by intraperitoneal injection for 5 
consecutive days. Animals were considered to be diabetic after two consecutive 
measurements of blood glucose ≥ 300 mg/dl using a One Touch Ultra Glucometer 
(LifeScan, Inc.). Before transplantation, human islets were grouped in four and 
transduced with blank vehicle, Adv-hXIAP, Adv-LacZ, and Adv-hXIAP with 50 ng/ml 
embelin at the dose of 1,000 MOI for 12 h and washed with PBS. About 1,000 
transduced or non-treated islets were transplanted under the left kidney capsules of 
diabetic mice. The nonfasted glucose levels were measured from the snipped tail of each 
animal up to 42 days post-transplantation. Then the mice were anesthetized to collect 
blood to measure serum c-peptide level by ELISA; Alpco Diagnostics (Windham, NH), 
and the graft-bearing kidneys were removed from some animals to confirm the function 
of islet grafts by the return of blood glucose levels to ≥ 300 mg/dL for two consecutive 
days. Since most mice developed high blood glucose level ≥ 600mg/dL after STZ 
treatment and long time after transplantation, all mice were subjected to daily 
intraperitoneal administration of 10U/kg insulin to maintain mice survival. To minimize 
the interference to blood glucose measurement by insulin injection, all the measurement 
were done at least 5h after insulin injection.  
 
To determine the effect of ex vivo Adv-hXIAP transduction prior to 
transplantation on insulin production of human islets post transplantation, transplanted 
mice were sacrificed at day 43 and kidneys bearing islets were isolated, washed with 
PBS, fixed in 4% paraformaldehyde overnight, and embedded in paraffin as described 
before[12]. Sections of 5–7 μm thickness were cut and immune-stained with rabbit anti-
insulin first antibody (Abcam) 1:500 overnight. Then immune-reactivity was detected 
using goat anti-rabbit IgG, H& L chain specific peroxidase conjugate (Abcam) and 
subsequent incubated with DAB substrate. Sildes were further counter-stained 
Haematoxylin (Sigma).  
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Results 
 
 
XIAP gene expression in INS-1E cells and human islets 
 
As shown in Figure 3-2, real-time PCR results showed increase in XIAP mRNA 
level of INS-1E cells by 3000 folds and 100,000 folds after transduction of INS-1E cells 
with Adv-hXIAP at MOI of 1 and 10, respectively. Similarly, XIAP protein 
concentration increased by 13 folds (from 0.54 ng/μg to 6.94 ng/μg) and 28 folds (from 
0.54 ng/μg to 12.59 ng/μg) for INS-1E cells after transduction with Adv-hXIAP at MOI 
of 1 and 10. In human islets, dose-dependent XIAP gene expression was also observed 
after Adv-hXIAP transduction. XIAP protein level increased from the basal level of 
16.17 ng/μg to 28.87, 75.58, and 95.55 ng/μg when 1000 IEs were transduced with Adv-
hXIAP at MOI of 200, 1000, and 2000, respectively. These results were in good 
agreement with our Western Blot analysis, where XIAP band density increased with 
increasing MOI, suggesting increase in XIAP protein expression after transduction. 
 
 
XIAP improves INS-1E cells viability and function against inflammatory cytokines 
 
Following transduction, INS-1E cells were further incubated with inflammatory 
cytokine cocktail for 48h. INS-1E cell viability decreased after cytokine treatment, as 
determined by the MTT assay (Figure 3-3). However, transduction of INS-1E cells with 
Adv-hXIAP showed only 14% decrease in cell viability, compared with untransduced 
INS-1E cells (37%) and INS-1E cells transduced with Adv-LacZ (55%), suggesting the 
protective effect of XIAP. INS-1E cell function was determined by insulin stimulation 
test. Following transduction and cytokine treatment for 12h, INS-1E cells were 
sequentially incubated with 2.5 nM and 22.5 nM glucose medium and secreted insulin 
was determined by ELISA. The results showed that under cytokine treatment, Adv-
hXIAP transduced INS-1E cells did produce more insulin than untransduced INS-1E 
cells and Adv-LacZ transduced INS-1E cells, suggesting the protective effect of XIAP on 
INS-1E cell function. 
 
 
XIAP inhibits INS-1E cell apoptosis against inflammatory cytokines 
 
One crucial step in apoptosis is DNA fragmentation, resulting from the activation 
of endonucleases during the apoptotic process [89]. Therefore, the analysis of DNA 
fragmentation with TUNEL assay is a useful approach to gain information regarding cell 
apoptosis (Figure 3-4). After 48h of incubation with cytokine cocktail post-transduction, 
Adv-hXIAP transduced INS-1E cells showed significant decrease in the number of 
apoptotic cells, which were stained dark brown, compared with untransduced INS-1E 
cells, and Adv-LacZ transduced INS-1E cells. In a parallel experiment, all cells were 
fixed, stained with FITC, and run through flow cytometry to count the relative ratio of 
apoptotic cells. Adv-hXIAP transduced INS-1E cells showed an average of 5.7% of 
apoptosis, significantly lower than 27.9% and 32.8% of untransduced INS-1E cells and  
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Figure 3-2. Adenovirus mediated overexpression of XIAP in INS-1E cells and 
human islets  
Overexpression of XIAP in 106 INS-1E cells and 1000 IEs at 2 days after Adv-hXIAP 
transduction at indicated MOI as determined by Realtime PCR, ELISA and western blot. 
Realtime PCR was not done for human islets because of the difficulty of isolating mRNA 
from islet clusters. MOI describes the number of adenoviral particles capable to transduce 
each INS-1E cells or each islet cluster. *p<0.05 under one way ANOVA compared with 
untransduced group. Data are presented as the mean + SD. n = 3.  
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Figure 3-3. Beneficial effect of XIAP overexpression on INS-1E cell viability and 
function 
A. Higher viability of Adv-hXIAP transduced 106 INS-1E cells was observed in the 
presence of inflammatory cytokine cocktail, compared with untransduced cells and Adv-
LacZ transduced cells. B. More insulin production by INS-1E cells transduced with Adv-
hXIAP was observed under cytokine treatment. n = 3. Data are presented as the 
mean±SD. *p<0.05 under t test compared with Adv-XIAP group.  
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Figure 3-4. Anti-apoptotic effect of XIAP overexpression on INS-1E cells 
Left panel, dark stain of apoptotic INS-1E cells under cytokine treatment, as determined 
by DeadEnd Fluorometric TUNEL System. Right panel, apoptotic cell number counted 
by flow cytometry following fluorescent labeling by APO-DIRECT. The values indicate 
the percentage of apoptotic cells. A.D. Untransduced INS-1E cells. B.E. Adv-LacZ 
transduced INS-1E cells. C.F. Adv-hXIAP transduced INS-1E cells. Data are presented 
as the mean + SD of n = 3. *p<0.05 under one way ANOVA compared with 
untransduced group.   
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Adv-LacZ transduced INS-1E cells, respectively. 
 
 
XIAP inhibits caspase activity in INS-1E cells and human islets 
 
XIAP binds to caspase 3 and caspase 7 with its BIR2 domain and caspase 9 with 
its BIR3 domain [90], and is known to inhibit their activities [91]. Since caspase 3/7 was 
the converging point of apoptotic pathways, we determined the effect of XIAP gene 
expression on caspase 3/7 activity. XIAP overexpression led to dose dependent caspase 
inhibition under cytokine treatment (5ng/ml IL-1β, 25ng/ml TNFα, and 25ng/ml IFNγ for 
3h) (Figure 3-5). Caspase 3/7 activity decreased up to 40% post transduction of both 
INS-1E cells and human islets with Adv-hXIAP. Similarly, XIAP expression also 
inhibited caspase 8 and caspase 9 activities in human islets, resulting in a total inhibition 
of 45% and 40%, respectively. 
 
 
Prolonged normoglycemic control of diabetic mice by Adv-hXIAP transduced 
human islets 
 
The effect of XIAP gene expression on the islet survival and function post-
transplantation was determined in terms of blood glucose, animal weight gain, and insulin 
production, by comparing mice transplanted with Adv-hXIAP transduced human islets 
and mice transplanted with untransduced human islets, Adv-LacZ transduced human 
islets, and Adv-hXIAP with embelin co-transduced human islets. Following 
transplantation, blood glucose level decreased to around 200 mg/dL for all transplanted 
mice (Figure 3-6), suggesting the immediate reversal of diabetic hyperglycemia by islet 
transplantation. However, the blood glucose level of the mice transplanted with un-
transduced islets, Adv-LacZ transduced islets, and Adv-hXIAP plus embelin co-
transduced islets gradually increased after the first week post transplantation, and was 
maintained to the diabetic level (~600 mg/dL) since 2 weeks post transplantation (Figure 
3-6), suggesting the impaired normoglycemic control caused by the impaired islet 
viability and function. This result is also consistent with previous reports [4, 8, 92]. In 
contrast, the mice transplanted with Adv-hXIAP showed prolonged normoglycemic 
control till 6 weeks post transplantation, probably due to the improvement in transplanted 
islet viability and function by XIAP overexpression. It should be noted that since most 
mice became highly diabetic after STZ treatment and the experiment last for more than 6 
weeks, all mice were subjected to daily intraperitoneal administration of 10U/kg insulin 
from the second week post transplantation. To minimize the interference of insulin 
injections to blood glucose measurement, all the measurement were made 5h after insulin 
injection. 
 
As listed in Table 3-1, the mice transplanted with Adv-hXIAP transduced human 
islets showed significant increase in average body weight six weeks after transplantation, 
probably due to the prolonged normoglycemic control by XIAP overexpression. To 
further monitor the long-term islet function following transplantation, the kidney bearing 
Adv-LacZ transduced islets and Adv-hXIAP transduced islets were isolated at the end of  
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Figure 3-5. XIAP overexpression inhibits caspase activities of INS-1E cells and 
human islets after cytokine treatment 
XIAP expression significantly inhibited activities of caspase 3/7, 8, and 9 in a dose 
dependent manner as determined by Caspase Glo Kit. A. Caspase 3/7 activity in INS-1E 
cells. B. Caspase 3/7 activity in human islets. C. Caspase 8 and caspase 9 activities in 
human islets *p<0.05 under one way ANOVA compared with untransduced group. Data 
are presented as the Mean + SD. n = 3.  
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Figure 3-6. Effect of Adv-hXIAP transduction on the outcome of islet transplantation 
Blood glucose level of STZ-induced diabetic NOD-SCID mice transplanted with 1000 Adv-hXIAP transduced IEs under the kidney 
capsule The mice transplanted with Adv-LacZ transduced and nontransduced IE were used as controls. Embelin was also used as 
negative control since it can reverse the effect of XIAP overexpression. The nonfasting glucose levels were measured in each animal 
up to 42 days post-transplantation. At day 43 after transplantation, the islet graft-bearing kidney was removed and mice were 
sacrificed. Data are presented as the Mean±SD. n = 5. 
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Table 3-1. Mouse weight measurements after human islet transplantation 
 
Weight Day 0 Day 7 Day 28 Day 42 
Control 18.06±1.01 17.90±2.43 18.90±1.99 19.21±2.05 
Adv-LacZ 17.93±1.33 17.20±2.35 18.87±2.28 18.93±2.40 
Adv-hXIAP 18.39±0.69 17.83±1.85 20.49±2.36* 22.33±2.43* 
Adv-hXIAP+Embelin 18.18±0.93 18.07±2.70 18.76±2.07 19.13±3.07 
 
*p<0.05 under one way ANOVA test. Data are presented as the Mean±SD. n = 5. 
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experiment and subjected to immunohistochemical analysis. The right kidneys without 
islet transplantation were also isolated and used as the negative control (Figure 3-7). The 
positive staining of insulin was more evident in kidney section bearing Adv-hXIAP 
transduced islets, while only rare insulin staining was observed in the kidney section 
bearing Adv-LacZ transduced islets (Figure 3-7), suggesting the maintenance of insulin 
secretion. The serum of mice was also collected to measure serum c-peptide level by 
ELISA. Result showed that c-peptide level in the mice transplanted with Adv-hXIAP 
transduced islets was significantly higher than the other group, indicating improved islet 
function in Adv-hXIAP transduced human islets post transplantation (Figure 3-7). 
 
 
Protective effect of Adv-hXIAP transduction will be reversed by XIAP inhibitor 
embelin 
 
As shown in Figure 3-8, embelin cytotoxicity was first determined ex vivo by 
MTT. Embelin does not show significant toxicity on INS-1E cells in 24 h treatment when 
concentration is below 200 nM, and 50 nM was selected as a proper concentration of 
embelin to inhibit XIAP expression. XIAP expression in human islets was greatly 
inhibited after embelin treatment, even lower than the basal XIAP expression in normal 
islets, which was consistent with the literature [93, 94]. The cytoprotective effect of 
XIAP overexpression was impaired by XIAP inhibitor embelin. Adv-hXIAP transduced 
INS-1E cell viability was decreased to 44% after incubation with cytokine cocktail and 
50nM embelin for 24h, compared with 88% viability with just cytokine cocktail. Caspase 
3/7 activity was restored to the untransduced level after embelin treatment, suggesting the 
inhibitory effect of XIAP gene expression on caspase activity can be reversed by 
embelin. The prolonged normoglycemic control of diabetic mice by Adv-hXIAP 
transduced human islets can also be impaired by additional embelin incubation before 
transplantation, in which the duration of normoglycemia was significantly decreased 
from 6 weeks to 2 weeks (Figure 3-6), suggesting the loss of islet viability and function 
by XIAP inhibition.  
 
 
Discussion 
 
Human islet transplantation has great potential to provide type 1 diabetic patients 
with sustained and improved normoglycemic control and a period of insulin 
independence. However, most islet grafts get destroyed in the early days post-
transplantation due to inflammatory cytokines, ROS and failure to revascularize induced 
by immune rejection, let alone the islet loss in islet isolation, transportation and 
transplantation processes [95, 96]. Although the use of immunosuppressant to the 
transplant recipient can partially relieve graft rejection by the host immune system, these 
drugs have significant toxicity including nephrotoxicity, ulcers, hyperglycemia, 
osteoporosis, and increased risk of infection and neoplasms [97-100]. Therefore, islets 
from two to four donors are generally necessary for successful islet transplantation [101]. 
Since the limited islet supply nowadays cannot meet the increasing islet need for 
transplantation, improving islet graft viability and function post transplantation is one of  
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Figure 3-7. Immunohistochemical staining of kidney sections at 42 days after 
transplantation  
A. Kidney section bearing no islet graft. B. Kidney section bearing Adv-hXIAP 
transduced islet grafts. C. Kidney section bearing Adv-LacZ transduced islet grafts. 
Insulin was stained in brown color. Nuclear was stained in purple by haematoxylin. D. 
Increasing C-peptide level in Adv-hXIAP group was observed in the serum collected at 
42 days after transplantation. *p<0.05 under one way ANOVA compared with 
untransduced group. Data are presented as the Mean±SD. n = 5.  
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Figure 3-8. Beneficial effect of XIAP overexpression on INS-1E cells can be 
reversed by XIAP inhibitor embelin 
A. Cytotoxicity study of embelin on 106 INS-1E cells/well for 24 h. B-C. Embelin can 
inhibit XIAP expression as illustrated by ELISA and western blot. D. Embelin reversed 
the cytoprotective effect of XIAP overexpression on 106 INS-1E cells against cytokine 
treatment. E. Embelin reversed the caspase inhibition effect of XIAP overexpression on 
INS-1E cells. *p<0.05 under one way ANOVA compared with zero embelin 
concentration. Data are presented as the Mean±SD. n = 3.  
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the major barriers to overcome for successful islet transplantation.  
 
As we mentioned before, the first two weeks post islet transplantation is crucial 
for graft survival. This makes adenoviral vector a good candidate for ex vivo gene 
therapy because of its high transduction efficacy and stable expression ability up to eight 
weeks [102, 103]. In our group, we have been working on the adenovirus mediated gene 
therapy method to improve the islet viability and function against graft rejection post 
transplantation for years. Briefly, besides the growth factor gene delivery to reduce 
apoptotic β-cell death and promote β-cell proliferation post transplantation, we also 
demonstrated that proapoptotic gene silencing such as iNOS silencing and caspase 3 
silencing by siRNA and shRNA respectively, could reduce the apoptotic β-cell death 
caused by inflammatory cytokines [5, 6, 8, 17].  
 
Compared with other gene therapy methods, XIAP gene delivery holds its own 
merits. The major problem with growth factor gene therapy was that growth factors were 
secreted protein, whose effects were determined by microenvironment concentration. 
Therefore, in Adv-transduced human islet clusters, growth factor concentration in 
extracellular microenvironment could not be uniformly distributed and finely regulated. 
Accumulation of microenvironmental VEGF in the outer layer of human islets may 
finally lead to aberrant angiogenesis and islet loss [10, 104].  
 
XIAP is strictly localized in the cytoplasm in a granular supranuclear pattern 
[105]. Therefore, after Adv-hXIAP transduction, the outer layer of human islets which 
will be more exposed to the inflammatory cytokines and hypoxic environment, will 
express higher level of XIAP and achieve an optimal defense mechanism against 
cytokine and hypoxia challenge in the early stage of graft survival. Transduction of INS-
1E cells and human islets with Adv-hXIAP resulted in significant increased XIAP 
expression (Figure 3-2). With adenovirus mediated XIAP overexpression method, we 
can easily reach the caspase inhibition effect in human islets without inducing acute 
immune response by ex vivo transduction. Adv-hXIAP ex vivo transduction also led to 
~40% inhibition of caspase 3/7, caspase 8, and caspase 9 activities in both INS-1E cells 
and human islets (Figure 3-5). The protective effect of Adv-hXIAP transduction on 
human islets was lasted for more than six weeks after transplantation. Another advantage 
of XIAP expression, though not discussed in this paper, is its ability to reverse the islet 
loss caused by hypoxia [16, 106], which made it a good candidate for ex vivo 
transduction of islets prior to transplantation.  
 
As a result of caspases inhibition, we also observed the protective effect of XIAP 
expression on INS-1E cells against cytokine cocktail treatment. Compared with 
untransduced INS-1E cells, Adv-XIAP transduced INS-1E cells showed significant 
improved cell viability, decreased apoptotic cells and increased insulin production under 
cytokines treatment. One interesting point we observed in this experiment is that Adv-
LacZ transduced INS-1E cells showed decreased cell viability and decreased insulin 
production under cytokines treatment, despite the fact that Adv-LacZ at such low MOI 
(MOI=2) has no significant effect on INS-1E cell viability (data not shown), suggesting 
the cytotoxic or proapoptotic effect of inflammatory cytokines could be possibly 
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exaggerated by viral transduction. But since XIAP expression effectively blocked the 
caspases activation, it reversed the cytotoxic or proapoptotic effect of cytokines. 
 
Our in vivo data showed the prolonged normoglycemia control of highly diabetic 
NOD-SCID mice and increasing insulin production after transplantation with Adv-
hXIAP transduced human islets for six weeks, which was much longer than the previous 
reports [8, 17, 86], probably due to the protective effect of XIAP in the first two weeks 
after transplantation. However, when transplanted with human islets in which XIAP 
expression was almost silenced by co-culturing with its inhibitor embelin, the blood 
glucose level of the diabetic NOD-SCID mice was decreased (Figure 3-6). This result 
suggested XIAP level played a crucial role in determining islet viability after 
transplantation in highly diabetic patients. However, it should also be addressed that all 
mice were subjected to daily intraperitoneal administration of 10U/kg insulin from the 
second week post transplantation because it was necessary to keep the mice survival in all 
the other three groups except the one transplanted with Adv-hXIAP transduced human 
islets or these mice might not have survived for six weeks with such high blood glucose 
levels. To minimize the interference of insulin injection to blood glucose measurement to 
the lowest extent, all the measurement were made at least 5h after insulin injection. 
 
Adv-hXIAP transduced INS-1E cells and human islets, when exposed to small 
molecular XIAP inhibitor embelin, had greatly decreased XIAP activity and therefore 
decreased cell viability and insulin production under inflammatory cytokines. Our data 
suggest that embelin inhibited XIAP activity by blocking protein synthesis, which is in 
good agreement with the previous report that embelin regulated apoptotic related gene 
expression [107], not by structure based protein-protein interaction as described before 
[93]. Embelin could inhibit XIAP expression to an extremely low level which was even 
lower than the basal XIAP level in normal INS-1E cells and human islets, and hence 
reversed the protective effect of XIAP in INS-1E cells and human islets against cytokine, 
suggesting the important role of XIAP expression in graft viability and function post 
transplantation. 
 
The therapeutic range of Adv-hXIAP transduction is very hard to determine. The 
MOI of Adv vector used for transduction must be carefully selected to achieve optimal 
transduction efficacy, with little toxicity. Our data showed that Adv-hXIAP could elevate 
XIAP expression in human islets in a dose dependent manner (Figure 3-2) without 
significant toxicity, and this result was in good agreement with previous reports [4, 6, 8, 
16, 17].  
 
Taken together, these data confirm that XIAP overexpression in human islets 
enhances islet viability and function against inflammatory cytokines and in doing so 
helped to achieve prolonged normoglycemic control in diabetic mice, suggesting that 
clinical application of this protocol could immediately and greatly enhance the 
availability and long-term outcome of islet transplantation for type I diabetes.  
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CHAPTER 4.    RGD MODIFIED ADENOVIRUS ENCODING XIAP AND HGF 
TO SIMULTANEOUSLY PREVENT EARLY GRAFT APOPTOSIS AND 
PROMOTE REVASCULARIZATION TO IMPROVE THE OUTCOME OF 
HUMAN ISLET TRANSPLANTATION 
 
 
Introduction 
 
In the previous study, we get a proof of concept that anti-apoptotic gene delivery 
effectively prevented the early graft apoptosis of human islet transplantation. However, 
several issues were unsolved.  
 
First, the transduction efficiency of traditional adenovirus to human islet is low 
therefore a high MOI is needed to achieve sufficient transgene expression. In the previous 
study, to achieve optimal XIAP expression, human islet was transduced with Adv-XIAP 
at MOI 2000. A high MOI could lead to two unwanted outcomes, difficulties in washing 
off the free viral particles and the coexpression of a significant portion of viral proteins, 
which raised safety concerns of adenovirus-based gene therapy and increased the 
immunogenicity of human islets, respectively. The low transduction efficiency and high 
MOI of traditional adenovirus called for the construction of more efficiency vectors. 
 
Second, anti-apoptotic gene transfer is incapable to assist the revascularization of 
human islets. Insulin producing β cells in human islet need anti-apoptotic gene expression 
to overcome the challenges after transplantation. They also need supplies of oxygen and 
nutrition as well as the channels to export the insulin. Failure to revascularization led to 
hypoxia and starvation in human islets and subsequently caused a significantly portion of 
islet loss after transplantation. Previous studies demonstrated that a functional 
revascularization in the first two weeks after human islet transplantation is critical to the 
survival and engraftment of transplanted islets [17]. Therefore, co-expression of anti-
apoptotic proteins with angiogenesis factors could be a reasonable strategy to address this 
issue. 
 
Last but not the least, the diabetic animal model we used for human islet 
transplantation needed immediate improvements because most mice became over-
diabetic with current protocol of streptozotocin injection. Insulin must be injected to 
maintain the euglycemia besides the human islet transplantation which significantly 
clouded the outcome of transplantation surgery and the results of functional analysis of 
transplanted islets. A better protocol to induce diabetes in NOD-SCID mice was needed 
to generate moderate level of diabetes, which is similar to clinical cases and reversible by 
the islet transplantation only. By doing this, we will have an important standard to 
                                                 
 
 Reprinted with permission from John Wiley & Sons. Wu, H, Yoon, AR, Li, F, Yun, 
CO, and Mahato, RI (2011). RGD peptide-modified adenovirus expressing hepatocyte 
growth factor and X-linked inhibitor of apoptosis improves islet transplantation. The 
Journal of Gene Medicine 13: 658-669. 
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determine whether islet transplantation is successful or not by rendering the diabetic 
animals insulin-independent, an important clinical criterion of human islet transplantation. 
 
Therefore, in this study we tried to improve the traditional gene therapy on human 
islet transplantation from three aspects. First, we inserted an Arg-Gly-Asp (RGD) peptide 
expression cassette into the adenoviral genome encoding HI fiber knob so that an RGD 
modified fiber knob can be expressed on the surface of viral particles. We hypothesized 
this RGD modified adenovirus would have high transduction efficiency against human 
islets because RGD was known to bind with high affinity to several types of integrins 
present on the surface of mammalian cells. Second, instead of using adenovirus with one 
transgene insertion within E1 deletion, we used adenovirus with two inserts (XIAP and 
HGF) within E1 and E3 deletions. We hypothesized co-expression of anti-apoptotic gene 
and angiogenic factor would have significant advantage in the outcome of human islet 
transplantation to the previous studies in which one gene was expressed at a time. Third, 
we revaluated the methodology to generate diabetic mice and found out that the manner 
of STZ injection had great impact on the extent of diabetes. Because the optimal blood 
glucose level was within 300~500mg/dL for human islet transplantation, we developed a 
new manner of STZ injection so that >80% of mice will develop an optimal level 
diabetes which can be reversed to insulin-independence by the islet transplantation only. 
 
 
Materials and Methods 
 
 
Culturing islets 
 
Human islet preparations were received from the Integrated Islet Distribution 
Program funded by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) and with support from the Juvenile Diabetes Research Foundation International 
(JDRFI). Upon arrival, islet preparations were subjected to quality control assessment for 
viability by using calcein AM/propidium iodide staining and for purity by using dithizone 
staining. Dithizone binds zinc ions present in the beta cells of islets, and therefore stains 
the islets red. Other exocrine tissue also present in the preparations does not bind 
dithizone, and is therefore not stained[108]. Islet preparations with purity and viability > 
90% were cultured in CMRL-1066 medium (Sigma Aldrich, St. Louis, MO) containing 
10% FBS (Gibco, Gaithersburg, MD) in a 37°C incubator.  
 
 
Construction of RGD-modified Adv 
 
RGD-Adv-GFP was a kind gift from Dr. Hiroyuki Mizuguchi, Osaka University, 
Japan. Adv-GFP was constructed and passaged in our lab. To generate RGD-modified 
Adv, the genome encoding the fiber in Ad5 (from 28592 to 30470) was cloned into the 
SacII-KpnI site of pBluescript II SK(+) (Stratagene, La Jolla, CA), creating pSK5543, 
and the genome encoding the fiber in Ad5 (from 32123 to 32836) was cloned into the 
EcoRI-HindIII site of pSP72 (Promega, Madison, WI), creating pSP72(713). For ease of 
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incorporating the RGD epitope between the HI-loop 
(LNVTQETGDTTPSAYSMSFSWD) of the fiber knob, immediately downstream of the 
following the 11th threonine, new BamHI and MroI sites were added by PCR-mediated 
site-directed mutagenesis. For PCR-mediated site-directed mutagenesis, the following 
primer set was used: 5’- GAA ACA GGA GAC ACA GGA TCC GCG TCC GGA ACT 
CCA AGT GCA TAC -3’ as the sense primer and 5’- GTA TGC ACT TGG AGT TCC 
GGA CGC GGA TCC TGT GTC TCC TGT TTC -3’ as the antisense primer. After PCR 
amplification, the resulting mutated PCR product, containing BamHI and MroI sites 
(underlined) to make pSP72 [713-BM], was verified using an ABI PRISM 337 automatic 
DNA sequencer (Applied Biosystems, Foster City, CA). To construct a vector encoding 
the RGD epitope between the HI-loop of the fiber knob, two complementary 
oligonucleotides were synthesized and annealed to form a DNA duplex. This DNA 
duplex was designed to contain a BamHI overhang 5’ end and an MroI overhang 3’ end, 
so that the fragment could be inserted into the BamHI and MroI sites of the pSP72[713-
BM] vector. The RGD epitope consisted of a nine-amino acid sequence, CDCRGDCFC. 
Sequences of the oligonucleotides were 5’- GA TCC TGT GAC TGC CGC GGA GAC 
TGT TTC TGC T -3’and 5’- CC GGA GCA GAA TCA GTC TCC GCG GCA GTA 
ACA G-3’. These oligonucleotides encoded the RGD epitope (boldface and italicized). 
The resulting plasmid was then digested with NcoI and MfeI and cloned into pSK5543 to 
generate an Adv fiber shuttle vector, pSK[5543-RGD]. To generate the RGD-modified 
Adv, the newly constructed Adv fiber shuttle vector pSK[5543+RGD] was digested with 
SacII and XmnI, and the viral vector dl324 was digested with SpeI for homologous DNA 
recombination in E. coli BJ5183. 
 
 
Generating RGD-Adv-hHGF-hXIAP 
 
To generate an Adv encoding HGF and XIAP at the E1 and E3 regions, 
respectively, we first constructed an E3 shuttle vector expressing XIAP. The XIAP gene 
was cloned from pSport6-XIAP by using 5’-CG GGATCC ATG ACT TTT AAC AGT 
TTT GAA GGA TCT AAA-3’ and 5’-CG GGATCC TTA AGA CAT AAA AAT TTT 
TTG CTT GAA AGT-3’ primers and subcloned into the Adv E3 shuttle vector, pSP72-
E3[109], generating a pSP72-XIAP. The newly constructed pSP72-XIAP shuttle vector 
was linearized with XmnI digestion and then co-transformed with a replication-
incompetent Adv, dl324-RGD, into E. coli BJ5183. It was then digested with SpeI for 
homologous recombination, yielding Adv-encoding plasmid, dl324-XIAP (E3)-RGD. 
Structures of the resulting recombinant vectors were then confirmed by restriction 
enzyme digestion and PCR analysis. 
 
In addition, to construct an Adv E1 shuttle vector expressing HGF, HGF gene was 
excised from pCDNA3.1-HGF by using BamHI and XbaI and subcloned into the 
replication-incompetent E1 shuttle vector, pCA14 (Microbix, Ontario, Canada). Then, the 
Adv E1 shuttle vector was linearized with XmnI digestion and co-transformed into E. coli 
BJ5183 with the BstBI-digested dl324-XIAP-RGD for homologous recombination, 
generating dl324-HGF-XIAP-RGD. Recombinant Adv encoding plasmid was digested 
with PacI and transfected into 293 cells to generate the replication-incompetent Adv, 
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RGD-Adv-hHGF-hXIAP (Figure 4-1). The propagation, purification, titration, and 
quality analysis of all Adv used were performed as previously described [110]. 
 
 
Transduction efficiency 
 
Human islets were first transduced with Adv-GFP and RGD-Adv-GFP at equal 
MOI to determine the effect of RGD modification on the transduction efficiency of Adv. 
To determine the optimal MOI for RGD-Adv-hHGF-hXIAP, 500 hand-picked human 
islets were transduced with serial dilutions of RGD-Adv-hHGF-hXIAP in 24-well plates 
for 12 h and incubated for additional 48 h. Medium were collected. Human islets were 
washed with PBS and dispersed into a single-cell suspension by incubation with 0.25% 
trypsin/EDTA (Gibco, Gaithersburg, MD) at 37°C for 5 min followed by passage through 
a narrow-gauge pipette. Total protein was extracted with RIPA buffer (Sigma Aldrich, St. 
Louis, MO) and stored at -80oC. HGF concentration in the cultured medium and XIAP 
concentration in the total protein extract of human islets was measured by ELISA (R&D 
Systems, Minneapolis, MN).  
 
 
Caspase detection 
 
Caspase-Glo 3 assay kits were used to analyze caspase 3 activities as described 
before [6]. Briefly, 48 h following transduction, a single-cell islet suspension was 
generated by 0.25% trypsin/EDTA digestion. Then, 100 μl Caspase-Glo were added to 
100 μl of the single-cell suspension of 104 cells in 96-well plates and incubated at room 
temperature for 1 h. The contents were then transferred to culture tubes, and 
luminescence was determined using a luminometer (Berthold, Germany). 
 
 
Western blot 
 
Five hundred human islets were transduced with RGD-Adv-hHGF-hXIAP at 500 
MOI in 24-well plates for 12 h and incubated for additional 48 h. A single-cell islet 
suspension was generated by 0.25% trypsin/EDTA digestion. The total protein samples 
were extracted with RIPA buffer supplemented with a protease inhibitor cocktail (Sigma 
Aldrich, St. Louis, MO), mixed with 6 × Laemmli sodium dodecyl sulfate (SDS) buffer 
(Boston BioProducts) and then boiled for 5 min to denature the protein. Then, a 20μg-
sample was loaded onto a 4%-15% Tris-HCl precast polyacrylamide gel (Bio-Rad, 
Hercules, CA) for electrophoresis and subsequently transferred to an immobilon 
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). After blocking 
with 3% BSA in 1× PBST (PBS containing 0.05% Tween-20) for 1 h at room 
temperature, the membranes were incubated with goat polyclonal IgG to XIAP, BAX, 
BCL-2, p-AKT, AKT and GADPH (Abcam, Cambridge, MA) primary antibodies (1:500) 
overnight at 4°C. The membrane was then incubated with HRP-conjugated rabbit 
polyclonal antibody to goat (1:10000) (Abcam, Cambridge, MA) for 1 h at room 
temperature. Target proteins were detected by enhanced chemiluminescence (ECL) 
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Figure 4-1. Construction of RGD modified Adv genome encoding HGF and XIAP 
in E1 and E3 deletion  
RGD epitope expressing cassette, hXIAP cDNA and hHGF cDNA were sequentially 
incorporated into the Ad5 genome by homologous DNA recombination. 
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detection kit (GE Healthcare Life Sciences, Pittsburgh, PA).  
 
 
Apoptosis study 
 
A cytokine cocktail of recombinant TNFα (5ng/ml) and IL-1β (5ng/ml) was used 
to mimic the in vivo challenge to the INS-1E cells and human islets by the inflammatory 
cytokines. INS-1E cells were transduced with Adv for 3 h, stimulated with cytokine 
cocktail for an additional 48 h and characterized by DeadEnd™ Colorimetric TUNEL 
system (Promega, Madison, WI), in which fragmented DNA from apoptotic cells was 
labeled with biotinylated nucleotide and detected using hydrogen peroxide and 
diaminobenzidine (DAB). Human islets were transduced with Adv for 12 h and incubated 
with cytokine cocktail for an additional 3 days. Then islet cells were digested with 0.25% 
trypsin/EDTA into a single-cell suspension, stained with Annexin V-FITC Apoptosis 
Detection Kit (Abcam, Cambridge, MA) and analyzed with flow cytometry. Annexin V 
binds to phosphatidylserine on the cell surface, which is a feature found in apoptotic 
cells. Fluorescent intensity was analyzed using CELLQUEST software (BD Bioscience, 
Franklin Lakes, NJ). Nontransduced cells without cytokine treatment served as a negative 
control. Three sets of independent transduction experiments were carried out for each 
assay.  
 
 
Dynamic insulin release 
 
We designed and constructed an islet perifusion set for dynamic analysis of the 
function of human islets (Figure 4-2). Compared with static insulin release method, this 
method gives a real-time monitoring of the islet function against difference stimuli. 
Briefly, after being stimulated with a cytokine cocktail of IL-1β (5 ng/ml) and TNF-α (5 
ng/ml) for 3 days, 50 islets from each group were handpicked and loaded onto a Swinnex 
13 chamber (Millipore, Burlington, MA) and perifused with Krebs Ringer-bicarbonate 
(KRB) buffer containing basal glucose (2.5 mM). The flow rate was maintained at 2 
ml/min with a peristaltic pump (Themo Fisher, Waltham, MA) and the temperature was 
maintained at 37 °C with a solution heater (Warner Instruments, Hamden, CT). Islets 
were first perifused with basal glucose (2.5 mM) for 45 min and stimulated with glucose 
(22.5 mM) for 15 min and at last perifused with basal glucose (2.5 mM) until insulin 
release reversed to basal level. Samples were collected through a fraction collector 
(Waters, Milford, MA) and analyzed for insulin content by ELISA (Calbiotech, Spring 
Valley, CA). 
 
 
Generate moderate diabetic nod-scid mice 
 
To find out the best protocol to induce diabetes in NOD-SCID mice with 
moderate extent of blood glucose levels for human islet transplantation, several manners 
and doses of STZ injection were tested. In the first protocol, two shots of STZ were 
injected intraperitoneally into NOD-SCID mice at a dose 70mg/kg for two consecutive 
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Figure 4-2. Islet perifusion set for dynamic analysis of function of human islets 
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weeks. If the mice developed moderate level of diabetes (blood glucose 300~500 mg/dL) 
in the first week, the second shot can be skipped. In the second protocol, one shot of STZ 
was injected intraperitoneally into NOD-SCID mice at a fixed dose 150mg/kg. In the 
third protocol, STZ was injected intraperitoneally into NOD-SCID mice at a dose of 40 
mg/kg for 5 consecutive days. The levels of blood glucose of all mice were determined 
by a glucometer at 3 weeks after last STZ injection. A boxplot of the minimum, the 10 
percentile, the median, the 90 percentile, and the maximum was draw for each protocol. 
Since the measurable glucose concentration of our glucometer is 50~600mg/dL, if a 
measurement gives a reading HI (high) or LOW, it would be recorded as 600mg/dL and 
50mg/dL respectively. 
 
 
Islet transplantation  
 
Animal experiments were performed by approved protocol following NIH and 
institutional animal care and use Institutional Animal Care and Use Committee guidelines 
using an approved protocol. To induce diabetes, STZ (70 mg/kg) was administered to 
NOD-SCID mice by intraperitoneal injection for 2 consecutive days. Animals were 
classified as diabetic after two consecutive measurements of blood glucose ≥ 400 mg/dl 
with a glucometer. Upon receiving human islets from the Integrated Islet Distribution 
Program (IIDP) distribution centers, they were immediately transduced with RGD-Adv-
hHGF-hXIAP at 500 MOI for 12 h. Then islets were washed three times to remove free 
virus. Then 500 islets were carefully hand-picked and transplanted under the kidney 
capsule of each STZ-induced diabetic NOD-SCID mouse. Three shots of insulin (5U/kg) 
were given to each mouse on the first 3 days after transplantation to relieve the 
hyperglycemic stress to the newly transplanted islets and no insulin was given afterwards. 
The nonfasted glucose levels of all the mice were measured from the snipped tail of each 
animal at 2 p.m. during the first week after surgery and then weekly. At the end of study, 
the mice were anesthetized to collect blood to measure serum insulin and c-peptide levels 
by ELISA. The graft-bearing kidneys were then removed from some animals to confirm 
the function of islet grafts by the return of blood glucose levels to ≥ 400 mg/dL.  
 
 
Intraperitoneal glucose tolerance test 
 
Thirty days after islet transplantation, glucose tolerance was determined in 
overnight-fasted mice as described by Garcia-Ocana et al. [9]. Briefly, the mice were 
subjected to intraperitoneal injection of glucose at 2 g/kg of body weight. Blood samples 
were obtained from the snipped tail at 15, 30, 60, 90 and 120 min after injection and 
analyzed for glucose levels with a glucometer. 
 
 
Immunofluorescence staining 
 
In an independent study, 500 hundred handpicked islets were transplanted under 
the kidney capsule of STZ-induced diabetic NOD-SCID mice. Six mice from each group 
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(mice receiving untransduced human islets and mice receiving RGD-Adv-hHGF-hXIAP 
transduced human islets at 500 MOI) were sacrificed 30 days after transplantation. 
Another six from each group was sacrificed at 200 days after islet transplantation. The 
kidneys bearing islets were isolated, washed with PBS, fixed in 4% paraformaldehyde 
overnight, and embedded in optimal cutting temperature compound. Frozen sections of 
10 μm thickness were cut. To detect insulin-positive human islets, the slides were stained 
with guinea pig anti-insulin primary antibody (1:200) at 4°C overnight and Alexa Fluor 
568-conjugated goat anti-guinea pig secondary antibody (1:500) at room temperature for 
1 h. To detect revascularization, the slides were stained with rabbit anti-von-Willebrand 
factor (vWF) primary antibody (1:500) at 4°C overnight and Dylight 488-conjugated goat 
anti-rabbit secondary antibody (1:500) at room temperature for 1 h. Slides were counter-
stained with DAPI.  
 
 
Results 
 
 
Construction of RGD-Adv-hHGF-hXIAP 
 
To improve the transduction efficiency of Adv on human islets, we chose to 
introduce an RGD peptide, which is known to bind with high affinity to several types of 
integrins present on the surface of mammalian cells, into the HI loop of the fiber knob. 
An RGD-modified Adv was generated by sequentially incorporating and RGD epitope-
expressing cassette, hXIAP cDNA and hHGF cDNA, into the genome of adenovirus 
serotype 5 through homologous DNA recombination (Figure 4-1). Structures of the 
resultant recombinant vectors were then confirmed by restriction enzyme digestion and 
PCR analysis. A proper amount of recombinant plasmid was digested with PacI and 
transfected into 293 cells, thereby generating the replication-incompetent Adv, RGD-
Adv-hHGF-hXIAP.  
 
 
Transduction efficiency of RGD-Adv-hHGF-hXIAP on human islets 
 
The transduction efficiency of traditional Adv-GFP and RGD-Adv-GFP was compared. 
Results showed that the RGD modification increased the expression of GFP in human 
islets, suggesting improved transduction efficiency (Figure 4-3). Optimal MOI of RGD-
Adv-hHGF-hXIAP was determined by transducing human islets with serial dilutions of 
RGD-Adv-hHGF-hXIAP. Results showed that HGF and XIAP expression were 
upregulated in a dose-dependent manner. At 500 MOI, RGD-Adv-hHGF-hXIAP could 
upregulate HGF and XIAP to the extent usually requiring MOI >2000 for traditional Adv 
[8, 111]. The gene expression profile of RGD-Adv-hHGF-hXIAP-transduced human 
islets over 2 weeks indicated the transient manner of Adv-mediated gene expression. The 
amount of HGF and XIAP produced by RGD-Adv-hHGF-hXIAP transduced human 
islets peaked 2 days after transduction and decreased gradually in the following 14 days. 
However, the levels of HGF and XIAP were still much higher compared with the 
endogenous expression of these two therapeutic genes. 
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Figure 4-3. Transduction efficiency of RGD-Adv-hHGF-hXIAP into human islets 
A. GFP expression in human islets transduced with Adv-GFP and RGD-Adv-GFP. B. 
Dose dependent expression of HGF and XIAP in RGD-Adv-hHGF-hXIAP and Adv-
hHGF-hXIAP transduced human islets.  C. Time dependent expression of HGF and 
XIAP in RGD-Adv-hHGF-hXIAP transduced human islets at 500 MOI. 
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Pro-apoptotic gene inhibited and anti-apoptotic gene elevated 
 
Both HGF and XIAP hold antiapoptotic effect. HGF inhibited the apoptotic 
pathway via activating AKT kinase while XIAP was well known for its inhibition of 
caspase activities [112, 113]. Results showed that the activity of caspase 3 was  
significantly decreased in RGD-Adv-hHGF-hXIAP-transduced human islets over 14 days 
after transduction (Figure 4-4). Western blot results showed the upregulation of p-AKT 
at 2 days after Adv transduction.  These results suggested anti-apoptotic effect of RGD-
Adv-hHGF-hXIAP on human islets. We also observed elevated anti-apoptotic protein 
BCL-2 and suppressed pro-apoptotic protein BAX, which might be a result of XIAP 
overexpression and degradation as suggested by the reports from Deveraux et al. and 
Bratton et al. [114, 115]. 
 
 
Protection of RGD-Adv-hHGF-hXIAP on human islets 
 
TUNEL assay was used to determine the apoptotic cell death under cytokine 
treatment. We first test the anti-apoptotic effect of RGD-Adv-hHGF-hXIAP on insulin-
producing INS-1E cells because it is relatively easier to stain and detect the dead cell in 
monolayer. Numerous apoptotic cells were observed in untransduced INS-1E cells after 
cytokine treatment, while much fewer apoptotic cells were observed in RGD-Adv-hHGF-
hXIAP-transduced INS-1E cells (Figure 4-5). Similarly, the ratio of apoptotic cells was 
significantly reduced in RGD-Adv-hHGF-hXIAP-transduced islets compared with 
untransduced islets (Figure 4-5). However, it should be addressed that since flow 
cytometry did not differentiate insulin-producing β cells from other cell types in human 
islets, these results only suggested that the whole islet can be protected from cytokine 
induced cell death. Another glucose perifusion experiment is needed to determine the 
viability and function of insulin-producing β cells of human islets. 
 
Human islets were first transduced with RGD-Adv-hHGF-hXIAP and then 
stimulated with a cytokine cocktail of IL-1β and TNF-α. Results showed that insulin 
secretion by human islets was significantly impaired after treated with the cytokine 
cocktail (Figure 4-6). However, the insulin secretion of RGD-Adv-hHGF-hXIAP 
transduced human islets was not significantly impaired under cytokine treatment (Figure 
4-6), suggesting improved viability and function of the insulin-producing β cells of RGD-
Adv-hHGF-hXIAP transduced human islet. 
 
Generation of diabetic NOD-SCID mice for human islet transplantation 
 
Fifteen NOD-SCID mice were used for each protocol. STZ was injected at 40 
mg/kg for 5 shots, 150mg/kg for 1 shot, and 70mg/kg for 2 shots. The blood glucose level 
was determined by a glucometer at 3 weeks after last STZ injection. A boxplot of the 
minimum, the 10 percentile, the median, the 90 percentile, and the maximum as draw for 
each protocol as shown in Figure 4-7. The box area between the 10 percentile and 90 
percentile indicated the expected glucose levels for 80% of mice. The blood glucose level 
of 600mg/dL was the maximum for all three protocols because it is the maximum 
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Figure 4-4. HGF and XIAP expression led to inhibition of pro-apoptotic gene and 
elevation of anti-apoptotic gene  
A. Caspase 3 activity in RGD-Adv-hHGF-hXIAP transduced human islets was measured 
up to 14 days after transduction by Caspase 3 Glo kit. B. Expressions of proapoptotic 
marker BAX and antiapoptotic markers BCL-2, p-Akt were determined by western blot. 
MOI: 0, 5, 10, 50, 100, 500, left to right. 
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Figure 4-5. Transgene expression of HGF and XIAP protected INS-1E cells and 
human islets from inflammatory cytokine induced apoptotic cell death  
After transduction with RGD-Adv-hHGF-hXIAP, INS-1E cells and human islets were 
incubated with a cytokine cocktail of IL-β (5 ng/mL) and TNF-α (5 ng/mL) for 48 h and 
3 days, respectively. A. Apoptotic INS-1E cells were stained dark brown using 
DeadEnd™ Colorimetric TUNEL System. B. Islet was dispersed with trypsin into single 
cell suspension. Apoptotic cells were stained with annexin V-FITC and counted by flow 
cytometry. P3 indicated the percentage of apoptotic cells. All experiments were 
performed in triplicate and at least twice with similar results. Results are presented as 
mean ± SD. *, P < 0.05 as determined by Student t test.  
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Figure 4-6. Effect of HGF and XIAP gene expression on islet function  
Briefly, after transduction with RGD-Adv-hHGF-hXIAP and further stimulation with a 
cytokine cocktail of IL-β (5 ng/mL) and TNF-α (5 ng/mL) for 3 days, 50 islets from each 
group were sequentially perifused with basal glucose (2.5mM) for 45 min and stimulated 
with glucose (22.5mM) for 15 min and at last perifused with basal glucose (2.5mM) till 
insulin release reverse to basal level. The flow rate was maintained at 2ml/min. Samples 
were collected through a fraction collector and analyzed for insulin content by ELISA. 
All experiments were performed in triplicate. Results are presented as Mean±SD. n=3. 
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Figure 4-7. The manner and dose of STZ injection has great impact on the 
diabetic level of NOD-SCID mice 
In the first protocol, two shots of STZ were injected intraperitoneally into NOD-SCID 
mice at a dose 70mg/kg for two consecutive weeks. If the mice developed moderate level 
of diabetes (blood glucose 300~500 mg/dL) in the first week, the second shot can be 
skipped. In the second protocol, one shot of STZ was injected intraperitoneally into 
NOD-SCID mice at a fixed dose 150mg/kg. In the third protocol, STZ was injected 
intraperitoneally into NOD-SCID mice at a dose of 40 mg/kg for 5 consecutive days. The 
levels of blood glucose of all mice were determined by a glucometer at 3 weeks after last 
STZ injection. A boxplot of the minimum, the 10 percentile, the median, the 90 
percentile, and the maximum was draw for each protocol. 
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measurement level for the glucometer. The NOD-SCID mice receiving two shots of STZ 
at 70mg/kg developed a moderate level of diabetes with 80% of them at 300~500mg/dL 
and a median of 400mg/dL. The NOD-SCID mice receiving one shot of STZ at 
150mg/kg were slightly more diabetic with 80% of them at 300~550mg/dL. But the 
median glucose was increased to 500mg/dL. Most NOD-SCID mice receiving 5 shots of 
STZ at 40mg/kg were over diabetic, which was consistent with our previous study that 
constant insulin injection was needed for glucose control besides islet transplantation.  
 
We gathered a lot of useful information from this study. First, mice responded in a 
drastically different manner to STZ injection. For example, half of the mice developed 
moderate level of diabetes after the first shot of STZ at 70mg/kg. But the other half were 
not diabetic (<200mg/dL) before the second shot. Therefore, we developed a flexible 
protocol in which the blood glucose of all mice could be measured in the middle of STZ 
injection and the non-diabetic mice would receive a second shot. Secondly, some mice 
developed a pre-diabetes symptom with blood glucose at 180~250m/dL after the first 
shot of STZ. These mice had a chance back to normoglycemia without any treatment. But 
the mice with blood glucose higher than 300mg/dL hardly reversed normoglycemia. 
Therefore a blood glucose level of 300mg/dL was used to determine whether the mouse 
was “truly” diabetic and ready for the following islet transplantation. 
 
 
RGD-Adv-hHGF-hXIAP transduction prolonged islet survival after transplantation 
 
Islet transplantation reversed diabetes in every subject (Figure 4-8). However, the 
mice transplanted with RGD-Adv-hHGF-hXIAP-transduced islets showed clearly better 
transplantation outcome in terms of average blood glucose level, duration of 
normoglycemia, and insulin independent ratio (Figure 4-8). These results demonstrated 
the improved viability and function of human islets genetically modified with RGD-Adv-
hHGF-hXIAP.  
 
Intraperitoneal glucose tolerance test was performed 30 days after islet 
transplantation to determine whether ex vivo transduction of islets with RGD-Adv-
hHGF-hXIAP helped islet grafts engraft and respond to elevated blood glucose in real 
time. Prior to glucose injection, all mice displayed similar baseline blood glucose levels 
following overnight fasting. Blood glucose levels increased immediately following 
glucose (2 g/kg) injection, peaked at 15 min in all groups, and decreased over time 
(Figure 4-9). Results showed faster and better response to the glucose boost in those 
mice receiving RGD-Adv-hHGF-hXIAP-transduced human islets relative to the mice 
receiving untransduced islets (Figure 4-9). These results demonstrated that RGD-Adv-
hHGF-hXIAP-transduced human islets had a better engraftment outcome and led to 
superior glucose control and to tolerance as compared with untransduced islets. 
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Figure 4-8. Effect of RGD-Adv-hHGF-hXIAP transduction on the outcome of 
islet transplantation  
A-B. The blood glucose level of every single mouse after receiving 500 untransduced (A) 
or RGD-Adv-hHGF-hXIAP-transduced islets (B). C. The average blood glucose level of 
mice after islet transplantation. D. Reversed-diabetes ratio of the NOD-SCID mice after 
islet transplantation. Blood glucose≤200 mg/dL (dashed line in a, b) was identified as 
reversed-diabetes. Data are presented as the mean ± SD, n=10. *P < 0.05 as determined 
by Student t test.  
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Figure 4-9. Intraperitoneal glucose tolerance test of the mice at 30 days after islet 
transplantation 
Results from non-treated diabetic mice and non-diabetic mice were used as negative and 
positive controls, respectively. Data are presented as the mean ± SD, n=6. *P < 0.05 as 
determined by Student t test compared with mice receiving untransduced human islets. 
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RGD-Adv-hHGF-hXIAP transduction improved islet revascularization after 
transplantation 
 
As shown in Figure 4-10, immunofluorescence staining showed the successful 
engraftment of insulin-positive islets under the kidney capsule 30 days after islet 
transplantation. Untransduced islets and RGD-Adv-hHGF-hXIAP-transduced islets both 
showed proper engraftment and function at this time. At 200 days after transplantation, 
the clear insulin staining in the kidney bearing RGD-Adv-hHGF-hXIAP transduced islets 
indicated morphological integrity and appropriate function of transplanted islets (Figure 
4-11). In addition, the potent staining of vWF in proximity to these islets indicated the 
functional revascularization of islet grafts under the kidney capsule. However, in the 
kidney bearing untransduced islets, only scarce vWF staining was seen and weak insulin 
staining indicated poor morphology and function of transplanted islets. 
 
 
Discussion 
 
PNF is the major reason leading to islet loss after transplantation except immune 
rejection. PNF is mostly caused by the inflammatory cytokines and poor 
revascularization. Dinarello et al. summarized that IL-1 and TNF are the two most 
important effectors in autoimmune diseases [27]. Donath et al. concluded that anti-
inflammatory therapeutic approaches to block β-cell apoptosis could be an important 
strategy in treating type 1 and 2 diabetes [28]. We previously reported that IL-1Ra 
expression in human islets effectively blocked the IL-1β-mediated apoptotic islet death [8, 
29], but it did not stop the apoptosis caused by other inflammatory cytokines such as 
TNFα and IFNγ. We also reported that XIAP expression in human islets repressed 
apoptotic islet death by inhibiting caspase activation [30], but its effect is limited because 
of low transduction efficiency. In the current study, we genetically engineered Adv with 
an RGD peptide to improve transduction efficiency and co-expressed HGF and XIAP, 
both of which hold anti-apoptotic effect but through different pathways [21, 31]. Our 
results demonstrated that the levels of HGF and XIAP were significantly upregulated and 
gradually decreased 14 days after Adv transduction (Figure 4-3C), which accords with 
the transient property of Adv-mediated gene expression. Consequently, a high HGF level 
activated the PI3K-Akt pathway and a high XIAP level suppressed caspase 3 activity in 
the first 14 days after Adv transduction (Figure 4-4). In an inflammatory condition 
mimicked by a cytokine cocktail of IL-1β and TNFα, TUNEL assay and islet perifusion 
study indicated that overexpression of HGF and XIAP gene prior to cytokine treatment 
effectively protected islet viability and function from apoptotic cell death (Figures 4-5, 
4-6). The in vivo viability and function were further confirmed by immune fluorescence 
analysis (Figure 4-10). 
 
Revascularization is another crucial factor for successful islet transplantation. 
Islets are a cluster of heterogeneous cell types with extensive intra-islet vessels. These 
vessels get disrupted during islet isolation, leading to the collapse of vasculature, the 
accumulation of endothelial fragments, and the compromised perfusion in the core of the 
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Figure 4-10. Immunofluorescence staining of the kidney section bearing RGD-Adv-
hHGF-hXIAP-transduced human islets at 30 days after islet transplantation  
A. Untransduced human islets. B. RGD-Adv-hHGF-hXIAP-transduced human islets. 
Human insulin was stained in red. Slides were back-stained with DAPI. Scale bar 
represents 100 μm. 
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Figure 4-11. Immunofluorescence staining of the kidney section bearing RGD-
Adv-hHGF-hXIAP-transduced human islets at 200 days after islet transplantation  
Insulin was stained in red (first column) and vWF factor was stained in green (second 
column). A-B. Kidney section bearing untransduced human islets under 10x and 40x 
magnification. C-D. Kidney section bearing RGD-Adv-hHGF-hXIAP-transduced human 
islets human islets under 10x  and 40x magnification. 
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islets [32]. Therefore, extensive and functional revascularization is required to promote 
the survival of islet grafts posttransplantation [33]. VEGF is a popular angiogenic factor, 
but its effect is so potent that caution should be exercised to avoid aberrant angiogenesis 
[34]. Recently, HGF has been seen as a more favorable growth factor because it can 
prevent apoptotic islet death and can promote the proliferation of pancreatic β-cells [12]. 
In this study, we demonstrated that HGF expression of human islets can be upregulated 
over 14 days after Adv transduction (Figure 4-3) Consequently, extensive 
revascularization was observed in the mice transplanted with RGD-Adv-hHGF-hXIAP-
transduced human islets in the immune fluorescence study (Figure 4-11). 
 
Islet destruction following transplantation can be greatly reduced by gene therapy 
[35]. Since islet is a compact cluster of about 1000 non-dividing cells, it is difficult to 
transfect intact islets by the available non-viral approaches, such as cationic liposomes 
and polymer-based systems, which are also toxic at high doses [36]. In contrast, 
replication deficient (E1, or E3 deleted) Adv vectors are known to efficiently transduce 
islets. In addition, adenoviral vectors can be produced in high titers and there is no risk of 
insertional mutagenesis as they do not integrate into host genome. However, Adv 
transduction of human islets leads to increasing immune responses, because some viral 
genomes co-express with therapeutic genes and elicit increased immune response and 
allograft rejection [37, 38]. This problem may be exaggerated when a relatively higher 
MOI is required to achieve optimal transduction efficiency on solid organs like human 
islets [13, 14].  
 
We incorporated an RGD peptide sequence into the Adv fiber knob to interact 
with αvβ integrins to facilitate Adv transduction into human islets [39]. Our results 
indicated that the transduction efficiency on human islets could be significantly improved 
using RGD-modified Adv (Figure 4-1). Transduction efficiency could be further 
increased when MOI was increased to 1000 and 5000 (data not shown). However, we 
decided not to transduce islets with an MOI higher than 500 to avoid any toxic side 
effects. The insulin perifusion study demonstrated that there was no decrease in insulin 
production from RGD-Adv-hHGF-hXIAP-transduced islets (Figure 4-6). RGD 
modification of Adv may be of significant importance to the development of new viral 
vectors, which can be genetically redirected to specialized cells as gene delivery vehicles. 
A similar RGD sequence placed in the virus hexon coat protein increased gene transfer to 
cells that were normally refractory to Adv transduction [40]. Similarly, adding a cationic 
polylysine sequence (pK7) to the fiber knob COOH terminus, which facilitates viral 
binding to negatively charged cell surface molecules such as heparan sulfates, increased 
transduction to macrophages, endothelial cells, smooth muscle cells, fibroblasts, and T 
cells [41, 42]. In this study, we also evaluated a bipartite Adv vector for multiple gene 
delivery to human islets for promoting revascularization and inhibiting inflammatory 
cytokine-mediated destruction. Because transfection with the bipartite plasmid encoding 
hHGF and hXIAP (dI324-hHGF-hXIAP-RGD, Figure 4-1) produced very little hHGF or 
hXIAP (data not shown), viral vector seems to be the only choice for gene therapy on 
human islets. Bipartite Adv vectors are usually constructed with one therapeutic gene and 
another marker gene, especially GFP [43, 44]. Using a bipartite vector not only simplifies 
the amplification and purification process of Adv vectors but also decreases the use of 
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total Adv backbone, compared to the use of two single Adv vectors. This procedure is 
expected to minimize the immunogenicity and toxicity of Adv vectors. 
 
Islet isolation and preparation is another state-of-the-art in clinical islet 
transplantation. Unlike other species from which islets can be isolated with little 
contamination, human islet preparations are usually composed of a majority (50~60%) of 
β cells and many other cell types including duct cells, acinar cells, α cells, and lymph 
node cells [45, 46]. Regardless of their origin, all cells within an islet preparation may 
contribute to the immune response induced after transplantation. Therefore, purity and 
viability of islets used for transplantation have a significant impact on the outcome of 
islet transplantation. Dithizone staining is carried out to discriminate between endocrine 
and non-endocrine cells to increase the purity of the islet preparation to 70–95% [46, 47]. 
Using hand-picked islets helped to further improve islet purity by discarding other tissues 
such as acinar cells and lymph nodes [48]. However, further purification of the islet 
preparations remains a challenge because of a remarkable loss of insulin-producing cells.  
 
To summarize, our study demonstrated that RGD modification is a useful tool to 
improve the transduction efficiency of Adv. Ex vivo transduction of islets with RGD-
Adv-hHGF-hXIAP decreased apoptotic islet death and improved islet revascularization 
and eventually improved the outcome of human islet transplantation. 
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CHAPTER 5.    BMSC AS GENE DELIVERY VEHICLE TO EXPRESS HGF 
AND IL-1RA TO IMPROVE THE OUTCOME OF HUMAN ISLET 
TRANSPLANTATION 
 
 
Introduction 
 
Traditional gene therapy directly transfers genetic materials into human islet using 
viral or nonviral vectors to generate genetically modified human islets. This strategy is 
promising because the resistance of islet to a specific challenge can be selectively 
enhanced by overexpression of a specific gene but holds some weakness because 1) 
human islets will be subjected to gene transfer for at least 1 day before transplantation 
causing inevitable PNF in the transduction process and 2) the co-expression of transgenes 
with viral genes could increase the immunogenicity of transduced human islets and make 
them easily recognized and cleared by the host immune system. 
 
MSC are adult progenitor cells with differentiation potential and self-renewal 
capacity. MSCs have great promise in repairing injured tissues including pancreatic islets 
[42]. MSCs also hold hypoimmunogenic property [55], since they are in lack of major 
histocompatibility complex II (MHC-II) and co-stimulatory molecules, such as CD14, 
CD86, CD40L and CD95L. MSCs suppress inflammation, either by receptor-mediated 
signal-transduction, probably through MMP2/MMP9-CD25 signal pathway [60], or the 
secretion of immunosuppressive factors such as TGF-β1, interleukin 10 (IL-10) and 
PGE2. Therefore, MSCs are unlikely to cause inflammation at the transplant site. These 
characteristics make MSCs attractive vehicles for virus-based gene therapy.  
 
BMSC was selected for several reasons. First, BMSC can be readily isolated from 
bone marrow and many other tissues. Secondly, BMSC is an adult stem cell with limited 
expansion and differentiation potential. Therefore the tumorigenicity of BMSC was low. 
Thirdly, BMSC was accessible to a wide spectrum of genetic modifications, which were 
not reported to affect the stem-cell-like properties of BMSC. Fourthly, BMSC actively 
secreted multiple growth factors as a trophic mediator which can help the engraftment of 
human islets after transplantation. We hypothesized that BMSC genetically modified to 
express soluble factors can be a competent strategy to help human islet transplantation 
without direct transduction of human islets (Figure 5-1). However, it should be noted 
that BMSCs alone, through systemic administration or local transplantation, were less 
competent to prevent the islet loss immediately after transplantation, which accounts for 
more than 70% of islet loss in the first week after transplantation [95, 96]. This 
phenomenon probably explains the inadequate control of the blood glucose level in the 
early stage (< 3 weeks) after transplantation in most islet/MSC co-transplantation studies 
[54, 116].   
                                                 
 
 Reprinted with permission from Springer. Wu, H, Lu, W, and Mahato, RI (2011). 
Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation. 
Pharmaceutical Research 28: 2098-2109. 
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Figure 5-1. A schematic demonstration of Adv-hHGF-hIL-1Ra-transduced 
BMSCs co-transplantation with human islets  
A. BMSCs were transduced with Adv-hHGF-hIL-1Ra prior to islet transplantation. B. 
After co-transplantation with human islets under the kidney capsule of diabetic NOD-
SCID mice, BMSCs expressed HGF and IL-1Ra into the surrounding microenvironment 
to support islet viability and function. 
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Because traditional gene transfer into human islets is less efficient and time 
consuming and BMSC mediated cell therapy is less competent to prevent the acute graft 
loss, we planned to utilize BMSC mediated gene therapy in this study. We hypothesized 
that adenovirus mediated gene therapy can prevent the acute graft loss while the BMSC 
can support the islet function for long term.  We selected genes encoding HGF and IL-
1Ra, both of which were soluble factors, as the therapeutic genes in this study. The anti-
apoptotic effect of IL-1Ra expression may not be able to compete with XIAP because IL-
Ra blocked the islet apoptosis caused by death receptor pathway but XIAP blocked the 
islet apoptosis in a more ubiquitous manner (Figure 3-1).  But we avoided the toxicity 
associated with direct transduction and the viral expression in human islets. Moreover the 
gene transfer efficiency on BMSC which can be seeded in a tissue culture flask is 
significantly higher than human islets. BMSC can also be transduced and expanded 
before we received islet preparations, therefore we can save one day of gene transfer into 
human islets and it may significantly prevent the loss of islet due to PNF. Other benefit of 
this study is that BMSC was known to maintain its stem cell properties after transduction. 
Therefore when the transgene expression mediated by adenovirus diminished in 2 weeks, 
the growth factors produced by BMSC, though in a lesser extent, may help islet survival 
for a long duration. We were trying to test these hypotheses in the following study.  
 
In this study, we evaluated the capability of primary BMSCs as gene delivery 
vehicles to protect the graft viability of human islets in a STZ induced NOD-SCID mice 
model. Adv-hHGF-hIL-1Ra-transduced BMSCs served as gene delivery vehicles to 
express HGF to promote islet revascularization, and IL-1Ra to reduce acute islet loss 
from inflammatory cytokines. We also determined the capability of BMSCs as nursing 
cells to prevent long-term islet graft rejection.  
 
 
Materials and Methods  
 
 
Materials 
 
The replication-deficient (ΔE1/ΔE3) Adv-hHGF-hIL-1Ra containing a CMV 
promoter, hHGF cDNA, and rabbit β-globin poly A in the E-1 region, and a CMV 
promoter, hIL-1Ra cDNA, and rabbit β-globin poly A in the E-3 region was constructed 
amplified and the titer measured in our lab as previously described (Figure 5-2) [8]. The 
control virus encoding green fluorescent protein (Adv-GFP) was constructed and kept in 
our lab. Primary BMSCs, HyClone Advanced Stem Cell Medium and Medium 
Supplement were purchased from Thermo Fisher Scientific (Waltham, MA), passaged, 
and frozen in our lab. Human islets were received from Integrated Islet Distribution 
Program (Duarte, CA). CMRL-1066 medium for islet culture and 6-diamidino-2-
phenylindole (DAPI) were purchased from Sigma Aldrich (St. Louis, MO). FBS was 
purchased from MediaTech Cellgro. (Herndon, VA). PBS was purchased from GIBCO-
BRL (Gaithersburg, MD). Human HGF ELISA kits, IL-1Ra ELISA kits, IL-10 ELISA 
kits, VEGF ELISA kits, Stem cell factor (SCF) ELISA kits and recombinant IL-1β were 
purchased from R&D Systems (Minneapolis, MN). Human insulin and c-peptide ELISA  
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Figure 5-2. Construction of bipartite Adv-hHGF-hIL-1Ra using AdenoQuick 
cloning system 
Shuttle plasmids pE 3.1 which contains IL-1Ra gene and pE 1.2 which contains HGF 
gene were cloned into AdenoQuick plasmid 13.1 to generate a cosmid containing genes 
of interest and the entire sequence of recombinant adenovirus by homologous 
recombination. After transfection into 293 cells, recombinant adenovirus Adv-hHGF–
hIL-1Ra was produced. 
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kits were purchased from Alpco Diagnostics (Windham, NH). The primary antibodies for 
hHGF, hIL-1Ra, insulin, vWF, and the Dylight 488-conjugated secondary antibody were 
purchased from Abcam (Cambridge, MA). The Alexa Fluor 568-conjugated secondary 
antibody and 0.25% trypsin was purchased from Invitrogen (Carlsbad, CA). 8-well Lab-
Tek Chamber Slides were purchased from Nalge Nunc. (Rochester, NY). Ultrasensitive 
One Touch glucose test strips and One Touch Ultra glucometer were purchased from 
LifeScan (Milpitas, CA). Tissue-Tek O.C.T. compounds were purchased from Sakura 
Finetek (Torrance, CA). 
 
 
Adv transduction of BMSCs  
 
Primary BMSCs were seeded at a density of 5 × 105 cells per well with 2 ml 
HyClone Advanced Stem Cell Medium in a 6-well plate and allowed 24 h for adherence. 
Prior to transduction, morphology of BMSCs was checked under a bright field 
microscope. To determine the optimal MOI for Adv transduction, primary BMSCs were 
transduced with Adv-GFP at 60 MOI and 120 MOI for 3 h followed by washing three 
times. The GFP expression was determined under a fluorescent microscope at 2 days 
after transduction. Primary BMSCs were then transduced with Adv-hHGF-hIL-1Ra at 
120 MOI for 3 h followed by washing three times. The expressions of HGF, IL-1Ra, IL-
10, VEGF, and SCF were measured by ELISA at 0, 2, 4, 6, 8, 10, 12, 14 days after 
transduction according to the manufacturer’s instructions. The protein concentration was 
normalized using the number of cells in each well. 
 
 
Islet viability study 
 
After transduction with Adv-hHGF-hIL-1Ra at 120 MOI for 3 h, 5 × 105 primary 
BMSCs were digested with 0.25% trypsin and co-culture with 500 IEs in a 10 cm dish of 
CMRL-1066 medium with 10% FBS for 2 days. Then, the islet/BMSC co-culture was 
stimulated with 5μg/ml IL-1β for 4 days and stained with 5 μg/ml calcein-AM and 2 
μg/ml propidium iodide for 30 min. Cell viability was monitored under a fluorescent 
microscope. Viability of human islets was also determined by staining with dithizone, a 
zinc chelating agent. Briefly, at 4 weeks after cultured alone or co-cultured with Adv-
hHGF-hIL-1Ra-transduced primary BMSCs, human islets were stained with dithizone as 
described previously [12]. The insulin production of human islets was quantified by the 
static insulin release method. Briefly, five hundred IEs were cultured alone or with 5 × 
105 untransduced primary BMSCs or with 5 × 105 Adv-hHGF-IL-1Ra-transduced 
primary BMSCs (120 MOI) in a 10-cm dish of CMRL-1066 medium with 10% FBS for 
10 days. At day 10, 5 μg/ml IL-1β was added to the medium and the islet/BMSC co-
culture was incubated with IL-1β for 4 days. Insulin release from islets was measured at 
day 0, 10 and 14 by sequentially stimulated islets with the media containing 2.5 mM 
(basal) and 22 mM glucose (stimulated) at 37ºC for 1 h. 
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Islet transplantation  
 
Animal experiments were performed following NIH 
(http://grants1.nih.gov/grants/olaw/references/phspol.htm) and institutional animal care 
and use guidelines using an approved protocol. To induce diabetes, STZ (70 mg/kg) was 
administered to NOD-SCID mice by intraperitoneal injection for 2 consecutive days. 
Animals were considered to be diabetic after two consecutive measurements of blood 
glucose ≥ 400 mg/dl using a glucometer. Primary BMSCs were transduced with Adv-
hHGF-hIL-1Ra at 120 MOI and labeled with Qdot 565 prior to transplantation according 
to the manufacturer’s instructions. Then islets were transplanted into the kidney capsule 
of diabetic NOD-SCID mice alone or with Adv-hHGF-hIL-1Ra-transduced primary 
BMSCs at constant ratio (islet: BMSC = 1:100). The nonfasted glucose levels and body 
weights of all the mice were measured from the snipped tail of each animal up to 15 
weeks after transplantation. Then the mice were anesthetized to collect blood to measure 
serum insulin and c-peptide levels by ELISA. The graft-bearing kidneys were then 
removed from some animals to confirm the function of islet grafts by the return of blood 
glucose levels to ≥ 400 mg/dL for 2 consecutive days.  
 
 
Intraperitoneal glucose tolerance test 
 
Two weeks after islet transplantation, glucose tolerance was analyzed in overnight 
fasted mice as described by Garcia-Ocana et al [9]. Briefly, the mice were subjected to 
intraperitoneal injection of glucose at 2 g/kg of body weight. Blood samples were 
obtained from the snipped tail at 15, 30, 60, 90, 120, and 180 min after injection and 
analyzed for glucose levels using a glucometer. 
 
 
Immunofluorescence staining 
 
For Adv-hHGF-hIL-1Ra-transduced BMSCs, primary BMSCs were seeded at the 
density of 5×104 each well into an 8-well chamber slide. After 24 h, these cells were 
transduced with Adv-hHGF-hIL-1Ra at 120 MOI for 3 h followed by washing three 
times and culturing an additional 48 h. The slides were then detached from the media 
chamber and fixed with ice-cold methanol. To detect HGF expression, the slides were 
stained with rabbit anti-HGF primary antibody (1:200) at 4 °C overnight and Alexa Fluor 
568-conjugated goat anti-rabbit secondary antibody (1:500) at room temperature for 1 h. 
To detect IL-1Ra expression, slides were stained with rabbit anti-IL-1Ra primary 
antibody (1:200) at 4 °C overnight and Dylight 488-conjugated goat anti-rabbit secondary 
antibody (1:500) at room temperature for 1 h. Slides were counter-stained with DAPI. 
 
For the kidney section, 1000 IEs were mixed with Adv-hHGF-hIL-1Ra-
transduced BMSCs and co-transplanted under the kidney capsule of STZ-induced 
diabetic NOD-SCID mice. Mice receiving islets alone and islets co-transplanted with 
primary BMSCs were sacrificed 4 weeks after islet transplantation. Mice receiving islets 
co-transplanted with Adv-hHGF-hIL-1ra transduced BMSCs were sacrificed at 4 weeks 
 72 
and 15 weeks after islet transplantation. Kidneys bearing islets were isolated, washed, 
fixed in 4% paraformaldehyde overnight, and embedded in optimal cutting temperature 
compound. Frozen sections of 5 μm thickness were cut. To detect insulin-positive human 
islets, the slides were stained with guinea pig anti-insulin primary antibody (1:200) at 4 
°C overnight and Alexa Fluor 568 conjugated goat anti-guinea-pig secondary antibody 
(1:500) at room temperature for 1 h. To detect revascularization, the slides were stained 
with rabbit anti-vWF primary antibody (1:500) at 4 °C overnight and Dylight 488-
conjugated goat anti-rabbit secondary antibody (1:500) at room temperature for 1 h. 
Slides were counter-stained with DAPI. Images were analyzed using the Measure RGB 
function of ImageJ to quantify the relative intensity of protein expression. 
 
 
Statistical analysis 
 
Statistical significance of the difference between the two groups was determined 
by unpaired t-test and between several groups by one-way ANOVA. 
 
 
Results 
 
 
Characterization of Adv-hHGF-hIL-Ra-transduced BMSCs 
 
As shown in Figure 5-3, primary BMSCs exhibit a spindle-shaped fibroblastic 
morphology after ex vivo expansion. The optimal MOI was determined by transduction 
of BMSCs with Adv-GFP at 60 MOI and 120 MOI. Results showed that the Adv 
transduction efficiency into primary BMSCs is >30% at 60 MOI and >80% at 120 MOI. 
Then 120 MOI was selected for optimal transduction of Adv-hHGF-hIL-1Ra. Results 
showed that primary BMSCs transduced with Adv-hHGF-hIL-Ra at 120 MOI produced 
significantly elevated levels of hHGF and hIL-1Ra since two days after transduction. The 
expressions of HGF and IL-1Ra by Adv-hHGF-hIL-1Ra transduced primary BMSCs 
decreased with time but were still significantly higher than the expressions by 
untransduced BMSCs at 14 days after transduction. The exogenous expressions of HGF 
and IL-1Ra by Adv-hHGF-hIL-1Ra transduced primary BMSCs were validated by 
immunofluorescence staining. Primary BMSCs produced IL-10 in picogram level and 
VEGF in nanogram level and the native expressions of IL-10 and VEGF were not 
changed by Adv transduction (data not shown). As in previous reports [117, 118], we did 
not detect expression of SCF from primary BMSCs (data not shown). In summary, these 
results indicated that primary BMSCs simultaneously expresses the target exogenous 
gene after transduction by Adv-hHGF-hIL-1Ra without losing their native characteristics.  
 
 
Protection of human islets by Adv-hHGF-hIL-Ra-transduced BMSCs  
 
Primary BMSCs participated extensively in organ repair [119]. HGF and IL-1Ra 
were widely reported to hold anti-apoptotic ability [120, 121]. We tested the protection of  
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Figure 5-3. Transduction efficiency of Adv-hHGF-hIL-1Ra into BMSCs 
A. Primary BMSCs exhibit a spindle-shaped fibroblastic morphology after ex vivo 
expansion. B. GFP expression in primary BMSCs after the transduction of Adv-GFP at 
60 MOI. C. GFP expression in primary BMSCs after the transduction of Adv-GFP at 120 
MOI. D. Time profile of HGF gene expression in primary BMSCs after the transduction 
of Adv-hHGF-hIL-1Ra at 120 MOI as determined by ELISA. E. Time profile of IL-1Ra 
gene expression in primary BMSCs after the transduction of Adv-hHGF-hIL-1Ra at 120 
MOI as determined by ELISA. F-G. Expression of HGF and IL-1Ra in BMSCs after the 
transduction of Adv-hHGF-hIL-1Ra at 120 MOI as determined by immunofluorescence 
staining. Data are represented as the mean ± SD. n = 3. *P < 0.05 under t test. 
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human islets against inflammatory cytokine from Adv-hHGF-hIL-1Ra transduced 
primary BMSCs in an ex vivo co-culturing study. Results showed that after stimulated 
with 5 ng/ml recombinant human IL-1β for 4 days, the cluster-like structures of islets 
were destroyed and viability of islets decreased (Figure 5-4). However, the viability 
andmorphological integrity were better preserved in the islets co-cultured with Adv-
hHGF-hIL-1Ra transduced primary BMSCs. The protection on cultured human islets 
from Adv-hHGF-hIL-1Ra transduced primary BMSCs even lasted to 4 weeks. To 
determine whether this protection effect was a result of the Adv-hHGF-hIL-1Ra 
transduction on BMSCs or the organ repairing function of primary BMSCs, the insulin 
release profiles over time from islets cultured alone, islets cultured with untransduced 
primary BMSCs and islets cultured with Adv-hHGF-hIL-1Ra transduced primary 
BMSCs were monitored (Figure 5-4). Results showed that the insulin releases from islets 
cultured with primary BMSCs were significantly higher than the islets cultured alone at 
day 10 of culture, indicating that BMSCs did help to protect islets viability. However, 
untransduced BMSCs did not provide sufficient protection against the apoptotic islet 
death caused by IL-1β. Results showed that insulin releases from islets cultured with 
untransduced primary BMSCs decreased dramatically (75.1 ± 9.7%) in 4 days after 
stimulating with 5 ng/ml recombinant human IL-1β. However, insulin releases from islets 
cultured with Adv-hHGF-hIL-1Ra-transduced BMSCs decreased only slightly (23.4 ± 
5.6%).  
 
In summary, these results demonstrated that primary BMSCs supported islet 
viability and function, but primary BMSCs alone failed provide islets with sufficient 
protection against inflammatory cytokines in the physiology condition. Adv-hHGF-hIL-
1Ra-transduced primary BMSCs effectively prevented the apoptotic islet death caused by 
inflammatory cytokines. 
 
 
Co-transplantation of islets with Adv-hHGF-hIL-Ra-transduced BMSCs improved 
outcome of islet transplantation 
 
Transplantation of islets under the kidney capsule of diabetic NOD-SCID mice 
reversed diabetes in every subject. As shown in Figure 5-5, the mice transplanted with 
1000 IEs all reverted to diabetes after only 4 weeks. However, the diabetic mice receiving 
1000 IEs and Adv-hHGF-hIL-Ra-transduced BMSCs maintained the blood glucose level 
≤250 mg/dL for 15 weeks, suggesting prolonged protection of islets by Adv-hHGF-hIL-
Ra-transduced primary BMSCs. Results also showed that increasing islet mass from 1000 
IEs to 2000 IEs effectively improved the outcome of islet transplantation (Figure 5-5), 
although rapid increase in blood glucose level was still observed when no additional 
BMSCs were co-transplanted. We considered mice with blood glucose ≤250 mg/dL as 
the reversed-diabetes mice to determine the cumulative outcome of islet transplantation. 
Co-transplantation of islets with Adv-hHGF-hIL-1Ra-transduced BMSCs significantly 
increased the reversed-diabetes ratio, suggesting the positive role of Adv-hHGF-hIL-Ra-
transduced primary BMSCs after islet transplantation. To determine the islet function at 
15 weeks after islet transplantation, the mice were anesthetized to collect blood to 
measure serum insulin and c-peptide level by ELISA. Results showed that the levels of 
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Figure 5-4. Adv-hHGF-hIL-1Ra-transduced BMSCs helped to preserve islet 
viability against IL-1β stimulation 
A. Viability of naked islets after IL-1β stimulation for 4 days, as determined by calcein-
AM/PI double staining. B. Viability of islets co-cultured with Adv-hHGF-hIL-1Ra-
transduced BMSCs after IL-1β stimulation for 4 days, as determined by calcein-AM/PI 
double staining. C. Glucose-stimulated insulin release from islets alone, islets co-cultured 
with primary BMSCs and islets IEs co-cultured with Adv-hHGF-hIL-1Ra-transduced 
BMSCs at day 0, day 10, and day 14 after co-culturing, as determined by ELISA. 5μg/ml 
IL-1β was added at day 10 (arrow) and incubated with islets for 4 days. Data are 
presented as the mean ± SD, n = 3. *P < 0.05 under one-way ANOVA test. D-F. Viability 
of human islets cultured for 4 weeks alone (bottom left) or with Adv-hHGF-hIL-1Ra 
transduced primary BMSCs (bottom right) as determined by dithizone staining. Fresh 
islets were used as positive control (bottom center). 
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Figure 5-5. Outcome of islet transplantation after being cotransplanted with Adv-
hHGF-hIL-1Ra-transduced BMSCs  
A-D. The blood glucose level of every single mouse after receiving 1000 IEs (A), 1000 
IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (B), 2000 IEs (C) and 
2000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (D). Blood 
glucose ≤ 250 mg/dL was identified as reversed-diabetes (dashed line). E. Reversed-
diabetes ratio of the NOD-SCID mice after islet transplantation. White triangles = mice 
receiving 1000 IEs, white squares = mice receiving 1000 IEs co-transplanted with Adv-
hHGF-hIL-1Ra-transduced BMSCs, black triangles = mice receiving 2000 IEs, black 
squares = mice receiving 2000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced 
BMSCs. F. Average serum insulin level of the mice receiving 1000 IEs and 1000 IEs co-
transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs 15 weeks after islet 
transplantation, as determined by ELISA. G. Average serum c-peptide level of the mice 
receiving 1000 IEs and 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced 
BMSCs 15 weeks after islet transplantation, as determined by ELISA. Data are presented 
as the mean ± SD, n = 7. *P < 0.05 under t test. 
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insulin and c-peptide of the mice transplanted with 1000 IEs co-transplanted with Adv-
hHGF-hIL-1Ra-transduced primary BMSCs were significantly higher than those of the 
mice transplanted with islets alone. The body weight was also measured to validate the 
blood glucose measurement (Figure 5-6). The increases in body weight were 
significantly slower in mice receiving islets alone since their blood glucose reverted to 
diabetes sooner after transplantation. However, this phenomenon was not observed in 
mice receiving islets and Adv-hHGF-hIL-1Ra-transduced primary BMSCs.  
 
Intraperitoneal glucose tolerance test was used to determine islet engraftment and 
function 2 weeks after transplantation. Results showed faster and better response to the 
glucose boost in mice receiving 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-
transduced primary BMSCs compared with mice receiving islets alone (Figure 5-7). 
These results demonstrated the improvement in islet engraftment and function after co-
transplantation of islets with Adv-hHGF-hIL-1Ra-transduced primary BMSCs and agreed 
with recently published results [60].  
 
 
Adv-hHGF-hIL-Ra-transduced BMSCs promoted islet engraftment and 
revascularization  
 
As shown in Figure 5-8, immunofluorescence staining showed the engraftments 
of insulin-positive islets under the kidney capsule. Qdot labeled BMSCs were detected in 
proximity of human islets, suggesting a protective role. As shown in Figure 5-9, the 
staining of vWF was undetectable in the kidney sections bearing islets alone and sparse in 
the kidney sections bearing islets and untransduced primary BMSCs. However, evident 
vWF staining in the kidney sections bearing islets co-transplanted with Adv-hHGF-hIL-
1Ra-transduced primary BMSCs was detected at both 4 weeks and 15 weeks after islet 
transplantation. After analyzed the relative vWF intensity from three independent regions 
using ImageJ, these results suggested increased revascularization by Adv-hHGF-hIL-
1Ra-transduced primary BMSCs. 
 
 
Discussion 
 
The purpose of this study was to combine MSC based cell therapy with 
adenovirus based gene therapy to improve the outcome of islet transplantation. We have 
been working on Adv based gene therapy for years. Replication-deficient Adv vectors are 
extensively reported to be effective in blocking the inflammatory cytokine pathway and 
increasing the islet resistance to post-transplantation challenges [4]. HGF is known to 
induce angiogenesis, promote β-cell proliferation and protect islets from apoptosis and 
eventually helps to improve the transplantation outcome in STZ-induced diabetic mice [9, 
122].  IL-1Ra binds to the cell surface interleukin-1 receptor and prevents IL-1 from 
sending a signal to that cell. Ex vivo transduction of human islets with Adv-hIL-1Ra has 
been reported to prevent IL-1β cell induced apoptotic cell death in islets [3]. We 
previously reported the improved islet transplantation using Adv-hHGF-hIL-1Ra 
transduced human islets [8]. However, most Adv vector failed to support the long-term  
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Figure 5-6. Body weight and blood glucose after human islet transplantation  
A-B. The average blood glucose level (A) and average body weight (B) of mice receiving 
1000 IEs and 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (B). 
C-D. The average blood glucose level (C) and average body weight (D) of mice receiving 
2000 IEs and 2000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (D). 
Decreasing average weight gain was observed in the mice receiving islets alone sooner 
after the average blood glucose reversed back to diabetic level (arrow). However, this 
phenomenon was not observed in mice receiving islets and Adv-hHGF-hIL-1Ra-
transduced BMSCs.  
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Figure 5-7. Intraperitoneal glucose tolerance test of the mice receiving 1000 IEs 
and 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs at 2 
weeks after islet transplantation  
Data are presented as the mean ± SD, n = 7. *P < 0.05 under t test. 
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Figure 5-8. Immunofluorescence staining of the kidney section bearing islets and 
Adv-hHGF-hIL-1Ra-transduced BMSCs  
A.B. Images under 20x magnification from bright field (A) and fluorescent microscope 
(B). C.D. Images under 100x magnification from bright field (C) and fluorescent 
microscope (D). Insulin was stained in red to indicate the functional human islets. Qdot 
565 labeled BMSCs were green “blinking” dots in close proximity of transplanted islets 
(white arrows). 
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Figure 5-9. Adv-hHGF-hIL-1Ra-transduced BMSCs promoted revascularization 
of the transplanted islets 
A-D. Representative staining of vWF factor (green) in the kidney bearing islets alone at 4 
weeks after transplantation (A), the kidney bearing islets co-transplanted with 
untransduced primary BMSCs at 4 weeks after transplantation (B), the kidney bearing 
islets co-transplanted with Adv-hHGF-hIL-1Ra-transduced primary BMSCs at 4 weeks 
after transplantation (C) and the kidney bearing islets co-transplanted with Adv-hHGF-
hIL-1Ra-transduced primary BMSCs at 15 weeks after transplantation (D). E. vWF 
fluorescent intensity was quantified using ImageJ from three independent regions. Data 
are presented as the mean ± SD, n = 3, *P < 0.05 under t test.   
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survival of islet grafts, probably due to the short expression profile of Adv. For example, 
the expression of HGF and IL-1Ra drastically decreased at 14 days after Adv 
transduction (Figure 5-3). Lentivrus could be an alternative solution for long term gene 
therapy. But since lentivirus integrates into the host genome and has the potential for 
generation of replication competent lentivirus and oncogenesis [123], great caution 
should be used before starting in this area. 
 
Another problem with Adv based gene therapy is the viral genome, more or less, 
co-expressed with target genes may trigger an increasing immune response to the 
transplanted organs. Some reports suggested that Adv transduction led to immune 
reaction to the Adv-bearing organs and made them more susceptible to attack from the 
recipient’s immune system with potentially dangerous consequences [124, 125]. 
Therefore, how to find the perfect vehicles to provide prolonged protection to islet grafts 
with less immunogenicity is a critical question to be answered by traditional gene 
therapy. 
 
BMSCs seem to be one of these perfect vehicles for gene delivery. BMSCs are 
pluripotent adult stem cells with the property of self-renewal and the potential to 
differentiate into many types of cells [40]. They are open to genetic manipulation and 
capable of secreting endogenous growth factors to promote engraftment of human islets 
[58, 126]. They are also hypoimmunogenic, probably by releasing anti-inflammatory 
cytokines and inhibiting T cell proliferation and activation [127, 128].  All these 
characteristics make BMSCs good nursing cells to advance current clinical studies of islet 
transplantation by combining gene therapy with cell therapy. 
 
However, probably because of the lack of standard operating protocols for 
isolating, preserving, and culturing BMSCs, the supporting role of BMSCs is still under 
discussion. The secretion of growth factors such as HGF, VEGF, and stem cell factor by 
BMSCs is controversial. We did not detect SCF expression by primary BMSCs, and the 
basal expression of HGF and VEGF from primary BMSCs was too low to support an 
optimal revascularization for islet graft survival (Figure 5-8) as noted in previous reports 
[129]. We demonstrated that exogenous expression of HGF by Adv-hHGF-hIL-1Ra-
transduced primary BMSCs could be maintained for at least 2 weeks and may eventually 
lead to the notable increasing revascularization of islet grafts after transplantation 
(Figure 5-3).  
 
Despite many reports on hypoimmunogenic nature of BMSCs, its mechanism is 
unclear. There are two hypotheses: 1) through the secretion of immunosuppressive 
cytokines, such as IL-10 and TGFβ [130]; and 2) through cell surface molecules of 
BMSCs to inhibit T cell activity and proliferation [71]. Previous reports showed that the 
co-transplantation of islets with primary BMSCs prevented the allogeneic rejection and 
helped engraftment of islets, but one common feature in all these studies was that the 
BMSCs were incompetent to reverse the blood glucose levels of recipients in the acute 
stage (<3 weeks) after transplantation, suggesting the slow engraftment of transplanted 
islets [43, 54, 116]. To make the situation even worse, the hyperglycemia caused by slow 
engraftment in turn accelerated the apoptotic islet cell death [95]. We hypothesized that 
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this phenomenon was probably due to the incapability of primary BMSCs to protect islets 
against the inflammatory-cytokine induced apoptotic cell death. In consistence with 
previous report [131], we demonstrated that the native secretion of IL-10 by BMSCs was 
insufficient to support islet survival against the inflammatory cytokine (Figure 5-4). We 
also demonstrated that Adv-hHGF-hIL-1Ra transduced primary BMSCs has clear 
advantaged in preventing inflammatory-cytokine induced islet death compared with 
untransduced primary BMSCs (Figure 5-4).  
 
BMSCs are hypoimmunogenic cells in lack of the major histocompatibility 
complex class II (MHC II) [56], making them capable of escaping the recognition by 
Natural Killer cells and alloreactive T cells. This is an important feature for the gene 
therapy to improve islet transplantation because 1) adding primary BMSCs into islets will 
not significantly raise allogeneic rejection, and 2) BMSCs could serve as gene delivery 
vehicles to avoid the notable immunogenicity of Adv vectors. Primary BMSCs were also 
capable of repairing injured tissues in long term [132]. We demonstrated that when islets 
were co-transplanted with Adv-hHGF-hIL-Ra transduced primary BMSCs, the blood 
glucose levels of diabetic NOD-SCID mice were maintained ≤ 250 mg/dL for more than 
15 weeks (Figure 5-5), significantly longer than most reported islet transplantations 
using genetic modified islets [4, 16, 133]. These results indicated the advantage of 
primary BMSCs as gene delivery vehicles to improve the outcome of islet 
transplantation. Although an immunocompetent animal model should be used to further 
validate the benefit of hypoimmunogenic primary BMSCs as gene delivery vehicles, our 
work provided useful information for further research. 
 
The differentiation capability of BMSCs is another interesting feature worthy of 
mentioning. The capacity of BMSCs to differentiate into a variety of cells including 
osteoblasts, adipocytes and chondrocytes and so on is one of most important mechanisms 
underlying its capability of tissue repair [132]. Moreover, viral transduced BMSCs still 
retained their differentiation capacity [134, 135]. This tissue repairing capacity of 
primary BMSCs, as supported by majority of reports, may eventually lead to the long 
term protection on human islets and was further supported by the fact that BMSCs were 
in close proximity to the islet grafts (Figure 5-8). Other reports showed that BMSCs have 
the potential to differentiate into vascular endothelial cells [136]. This is also possible 
because revascularization was observed mostly around islet grafts where most BMSCs 
settled (Figure 5-9). However, whether the neoforming blood vessels in the kidney 
bearing islet grafts is from BMSCs alone or other cell types remains to be clarified. 
 
In agreement with other reports on islets/BMSCs co-transplantation [67, 137], our 
results indicated that the co-transplantation of islets with Adv-hHGF-hIL-1Ra-transduced 
primary BMSCs into diabetic NOD-SCID mice promoted local revascularization, 
improved islet viability and reversed diabetes in long term. We are the first group to 
report the combination strategy of Adv-based gene therapy and BMSC-based cell therapy 
to improve the outcome of islet transplantation. Our data indicated that BMSCs were 
efficient gene delivery vehicles to improve the outcome of islet transplantation, as they 
did to treat other diseases [138, 139]. Adv-hHGF-hIL-1Ra-transduced primary BMSCs 
secreted elevated levels of HGF and IL-1Ra and retained their protective capability for 
 84 
the long-term survival of islet grafts. Since current gene therapy approaches still focus on 
the expression of endogenous growth factors in human islets, our report provides a novel 
direction for future exploration of other factors and cells for co-transplantation. Our 
studies in rodents also provide useful information on the future studies on the 
immunocompetent animal model. However, several issues still need clarification before 
this approach can be clinically applicable, including the immunogenicity and in vivo fate 
of Adv-transduced BMSCs, mechanism underlying the long-term protection of BMSCs, 
and the optimal ratio between islet and BMSC numbers. 
 
In our previous and present studies [6, 8], most transplanted human islets survived 
only up to 4~6 weeks in diabetic NOD-SCID mice without any treatment. We can also 
find out similar length of islet survival in other reports [140, 141]. We are aware of 
several reports of islet survival beyond 60 days post-transplantation. This discrepancy is 
due to the fact that islet survival and function post-transplantation depends on multiple 
factors, including donor condition, islet purity, immunocytes, hyperglycemia, hypoxia 
and inflammation after transplantation. The degree of diabetes and variability in mice 
used for transplantation also greatly affect the length of islet survival and function. The 
other reason may be the pre-transplantation treatment after islet isolation. When hand-
picked islets were used for transplantation, the length of islet survival was significantly 
improved, possibly due to discarding of lymph nodes in the hand-picking process as the 
existence of lymph nodes is detrimental to the survival of islets after transplantation. 
However, we are not personally in charge of the isolation process and we do not prefer to 
use hand-picked islets for transplantation. 
 
In summary, co-transplantation of islets and BMSCs promoted revascularization, 
protected islet viability, and significantly reduced the islet mass required for reverse 
diabetes. The production of HGF and IL-1Ra by Adv-hHGF-hIL-1Ra-transduced primary 
BMSCs and the protective capability of BMSCs synergistically helped to improve the 
islet survival in the early stage and graft function in the long term run after 
transplantation. 
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CHAPTER 6.    BMSC PREVENTS ALLOGRAFT REJECTION OF HUMAN 
ISLET TRANSPLANTATION IN HUMANIZED MOUSE MODEL 
 
 
Introduction 
 
We marched a long trip to find the best ways to induce diabetes, to purify human 
islets and to transplant human islet under the kidney capsule of diabetic mice. However, 
the absence of human immunity in all the animal experiments has rendered all the 
previous efforts far from clinical human islet transplantation. In fact, human islets can 
only settled in immunodeficient animals for longer time (>4 weeks) and the absence of 
human immunity is a common weakness of all studies involving human islet 
transplantation in diabetic animals. These studies were actually focused on the PNF, 
which is the loss of human islets caused by non-immune challenges including 
inflammatory cytokines, hypoxia, ROS and poor revascularization, instead of immune 
rejection. 
 
To introduce immune rejection into preclinical studies regarding human islet 
transplantation, some groups have been using immunocompetent rodents [60, 142]. 
However, the immune responses from mice and human are drastically different and the 
results from these studies must be interpreted with caution. Recently, the development of 
humanized mouse marked a huge advance in the animal models used for human islet 
transplantation [79]. First, it is a perfect model to study the development of type 1 
diabetes, which is an autoimmune disease. Second, the interaction between transplanted 
islets and the adoptively transferred human immunity provide useful information about 
immune rejection after human islet transplantation. The human immunity can be 
established in several specialized mouse strains by injection of human immunocytes 
validated by the presence of human IgG in the blood steam and CD3+ T cells in the 
mouse spleen [79]. The adoptively transferred human immunity posed a challenge, which 
is similar to the clinical immune rejection, to the transplanted human islets.  
 
Compared with previous studies using immunodeficient animals [52, 54], the 
duration of insulin independence in humanized mice was significantly reduced [79], 
suggesting the existence of immune rejection. However, the introduction of human 
immunity also led to GvHD, a fetal disease characterized by the attack to the recipient’s 
major organs by the infused xenogeneic immunocytes. The risk of GvHD can be 
controlled by reducing the amount of the infused immunocytes and even eradicated by 
generating humanized mice using hematopoietic stem cells [79]. 
 
The potential of BMSC as a novel personalized medicine has inspired us to 
explore its potential as an immune modulator. Although the recent improvements in the 
                                                 
 
 Reprinted with permission from Nature Publishing Group. Wu, H, Wen, D, and Mahato, 
RI (2013). Third-Party Mesenchymal Stem Cells Improved Human Islet Transplantation 
in a Humanized Diabetic Mouse Model. Molecular Therapy, (in press). 
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regimen of immunosuppressive drugs such as tacrolimus, sirolimus and MPA have 
greatly reduced their side effects, these drugs are still toxic to the viability and function of 
transplanted islets. BMSC on the other hand, which can be easily isolated from a diabetic 
patient and expanded in vitro, does not cause such concerns.  
 
Unlike Gene therapy, which is incapable to prevent the immune rejection, stem 
cell therapy has recently met great success as a novel regenerative medicine to support 
solid organ transplantation including human islet transplantation [52, 143]. Among all 
types of stem cells, BMSCs are given special interest for their self-renewal potential, 
multi-lineage capacities, paracrine effects (trophic mediator) and immune modulatory 
effects [40, 55], making it a great candidate for improving human islet transplantation.   
 
MSC-based therapy has been used to improve human islet transplantation from 
several aspects. Ding et al. reported the immunosuppressive effects of MSCs by secreting 
soluble factors [60]. Korbutt et al. reported that co-culture with MSCs improved islet 
viability and function against inflammatory cytokines [144]. Ito et al. and other 
researchers reported that MSCs were capable of promoting the revascularization of islets 
in vivo [52, 54]. However, the translation to a real clinical breakthrough is slow and the 
data from limited clinical trials seems vague and controversial, probably due to the lack 
of the human immunity in most of the previous studies. Hereby we evaluated the 
effectiveness of BMSCs from a third party donor to improve the outcome of human islet 
transplantation in a diabetic humanized NSG mouse model. We plan to answer two 
questions by this study: 1) the interaction of BMSCs with adoptively-transferred human 
immunity to protect islets in vivo; 2) the tropic effect of BMSCs to support islet function. 
 
 
Materials and Methods 
 
 
Materials 
 
NSG and NOD-SCID mice were purchased from Jackson Laboratory and housed 
in pathogen-free microisolator cages.  Human PBMCs were isolated from fresh buffy 
coats (Lifeblood South, Memphis, TN) by gradient centrifugation using Ficoll-Paque (GE 
Healthcare, Little Chalfont, UK). Before use, the preparations of PBMCs were 
characterized by FlowCellect™ Human Lymphocyte ZAP-70 Characterization Kit 
(Millipore, Billerica, MA). To establish human immunity, PBMCs were injected 
intraperitoneally into NSG mice (5x106/mouse) as described before [145]. The settlement 
of T cells in the spleen was assessed two weeks after injection by immunofluorescence 
staining. The function of B cells was assessed by measuring human IgG concentration in 
the mouse blood. Human islets were received from Integrated Islet Distribution Program 
(Duarte, CA). Primary BMSCs were purchased from Thermo Fisher Scientific (Waltham, 
MA), passaged, and frozen in our lab. Before use, BMSCs were characterized of the 
surface markers including human leukocyte antigens (HLA)-DR, HLA class I, CD14, 
CD80, CD86 and Fas Ligand (FasL or CD95L) (Abcam, Cambridge, MA).  
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Mixed lymphocyte reaction (MLR) 
  
The proliferation of PBMCs was determined using CFSE proliferation assay. 
CFSE passively diffuses into cells, retained by the cells throughout division and can be 
used to differentiate the successive generations from the parental generations. Briefly, 
CFSE-labeled PBMCs (1x106) were stimulated with phytohaemagglutinin (PHA, 
1μg/mL) for 24h and co-cultured with BMSCs (5x104) in the same well or in a transwell 
system for indicated time. In the transwell system, the BMSCs were adherent to the 
bottom of the cell culture plate while the PBMCs were cultured in a 0.4µm transwell cell 
culture inserts (Corning, Tewksbury, MA). The media was carefully monitored to rule 
out the penetration of the PBMCs from the inserts. The division history of PBMCs was 
analyzed by flow cytometry. The percentage of proliferated cells was calculated by 
dividing the number of cells undergoing divisions with the number of total cells in the 
cultures. The total number of PBMCs was measured using T4 Automatic Cell Counter 
(Nexcelom, Lawrence, MA). The extent of T cell activation was determined by 
measuring the level of IL-2, IL-2sRa and IFN-γ in the medium using ELISA. IL-10 level 
in the medium was also determined by ELISA. Total T cells, CD4+ T cells, CD19+ B 
cells and CD14+ monocytes were isolated or depleted from PBMCs using specific 
Dynabeads for each population, respectively (Invitrogen, Carlsbad, CA). The mRNA 
levels of IL-10 in each subpopulation were determined by Realtime PCR and normalized 
by the levels of β-actin. The percentage of CD4+CD25+FoxP3+ Tregs was determined 
by Human Regulatory T cells 3-color kit (RnD System, Minneapolis, MN) using flow 
cytometry. To study whether a direct contact between BMSCs and PBMCs was required 
for the immunosuppression of BMSCs, a transwell system was set up.  
 
 
Islet viability study  
 
Primary BMSCs (5×105) were co-cultured with 500 islets in a 10 cm dish of 
CMRL-1066 medium with 10% FBS for 2 days. Then, the islet/BMSC co-culture was 
stimulated with cytokine cocktail of TNFα (50 ng/mL), IL-1β (5ng/mL) and IFN-γ (50 
ng/mL) for 4 days and the insulin secretion from human islets was quantified using a 
dynamic islet perifusion assay. Briefly, 50 islets from each group were handpicked and 
loaded onto a Swinnex 13 chamber (Millipore, Burlington, MA, USA) and perifused with 
Krebs-Ringer bicarbonate HEPES buffer of the following composition (in mM): 129 
NaCl, 5 NaHCO3, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, and 10 HEPES at pH 
7.4. The flow rate was maintained at 1 ml/min with a peristaltic pump (Themo Fisher, 
Waltham, MA) and the temperature was maintained at 37°C with a solution heater 
(Warner Instruments, Hamden, CT). Islets were first perifused with basal glucose 
(1.67mM) for 60 min and stimulated with glucose (16.7mM) for 30 min and finally 
perifused with basal glucose (1.67mM) until insulin release reversed to the basal level. 
Samples were collected once per two minutes through an automatic fraction collector 
(Waters, Milford, MA) and analyzed for insulin content by ELISA. 
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Islet transplantation  
 
A long-term low-dose STZ injection was used to induce diabetes in NSG mice. 
Briefly, STZ (70 mg/kg) was injected intraperitoneally to NSG mice in the first day the 
first and third week. Animals were mostly diabetic after three weeks as indicated by two 
consecutive measurements of blood glucose ≥ 400 mg/dl using a glucometer. Then 500 
handpicked human islets (150~300μm in diameter) were co-transplanted with primary 
BMSCs at serial ratios (islet: BMSC = 1:0, 1:50, 1:100 and 1:200) under the kidney 
capsule of diabetic NSG mice. The nonfasted glucose levels and body weights of all the 
mice were measured from the pricked tail of each animal up to 15 weeks after 
transplantation. PBMCs (5x106/mouse) were infused intraperitoneally into these mice at 
4 weeks after islet transplantation. At the end of study (17 weeks after islet 
transplantation), the graft-bearing kidneys were removed from some mice to confirm the 
function of islet grafts by the return of blood glucose levels to ≥ 400 mg/dL for 2 
consecutive days and all mice were subjected to euthanasia. Serum was collected serum 
to measure the level of human insulin and c-peptide by ELISA. Whole blood was 
collected and human CD4+ T cells were isolated using Dynabeads. The percentage of 
CD4+CD25+FoxP3+ Tregs was determined by flow cytometry. 
 
 
Intraperitoneal glucose tolerance test 
 
Two weeks after islet transplantation, glucose tolerance was analyzed in overnight 
fasted mice as described by Garcia-Ocana et al. [9]. Briefly, the mice were subjected to 
intraperitoneal injection of glucose at 2 g/kg of body weight. Blood samples were 
obtained from the snipped tail at 15, 30, 60, 90, 120, and 180 min after injection and 
analyzed for glucose levels using a glucometer. 
 
 
Immunofluorescence staining 
 
Mice receiving islets alone and islets co-transplanted with primary BMSCs were 
sacrificed 4 weeks after transplantation. The kidneys bearing islets were isolated, washed 
with PBS, fixed in 4% paraformaldehyde overnight, and embedded in optimal cutting 
temperature compound. Frozen sections of 5 μm thickness were cut. To detect insulin-
positive human islets, the slides were stained with guinea pig anti-insulin primary 
antibody (1:200) at 4 °C overnight and Alexa Fluor 568 conjugated goat anti-guinea pig 
secondary antibody (1:500) at room temperature for 1 h. To detect CD3+ T cells, the 
slides were stained with rabbit anti-CD3 primary antibody (1:500) at 4 °C overnight and 
Dylight 488-conjugated goat anti-rabbit secondary antibody (1:500) at room temperature 
for 1 h. Slides were counter-stained with DAPI. Three independent images were analyzed 
using ImageJ to quantify the fluorescence intensity. 
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Statistical analysis 
 
Statistical significance of the difference between the two groups was determined 
by unpaired t-test and between several groups by one-way ANOVA. 
 
Results 
 
 
Generation and characterization of humanized NSG mice 
 
Human PBMCs were isolated from human buffy coat using Ficoll Paque and 
gradient centrifugation. Typically 1x109 of PBMCs can be isolate from 60 mL of buffy 
coat. A detailed isolation protocol is listed in the appendix. PBMCs isolated from 
concentrated human buffy coat was composed of T lymphocytes (~55%) and B 
lymphocytes (~40%) (Figure 6-1A). To further isolate a subpopulation of PBMCs, 
specific dynabeads for each population can be used. Potent human IgG in the mouse 
blood stream and evident human CD3+ T cells in the spleen sections were detected at 
around two weeks after the intraperitoneal injection of PBMCs (5x106/mouse), 
suggesting the successful establishment of human immunity (Figure 6-1B-C). In 
contrast, human IgG and CD3+ T cells were not detected in NOD-SCID mice because 
NOD-SCID mice expelled the xenogeneic immunocytes constantly [79].  
 
 
BMSCs are fibroblast like adult stem cells 
 
Primary BMSCs exhibit a spindle-shaped fibroblastic morphology after ex vivo 
expansion. To understand the immunomodulatory effects of BMSCs, we decided to 
characterize the surface markers of BMSCs. HLA Class I and HLA-DR (class II) were 
tested because BMSCs might act as antigen presenting cells. We also tested CD14, CD80 
and CD86 which are important co-stimulatory factors. Besides, FasL was also tested 
because they might participate in the apoptosis of T cells [146]. The BMSCs maintained 
in our lab were positive for HLA class I and negative for HLA-DR, FasL, CD14, CD80 
and CD86 (Figure 6-2). However, the lack of co-stimulatory molecules such as CD80 
and CD86 suggested that the antigen presentation through BMSCs led to the reversal of T 
cell maturation and subsequent immune tolerance as suggested by previous literatures 
[147].  
 
 
BMSCs suppressed the activation and proliferation of PBMCs 
 
PBMCs were isolated from human buffy coats. We first tested the 
immunomodulatory effect of BMSCs on PBMCs in a MLR. Carboxyfluorescein diacetate 
succinimidyl ester (CFSE), a fluorescent dye retained within cells for a long period, was 
used to stain PBMCs before co-culturing with BMSCs. The PBMC/BMSC co-culture 
was stimulated with phytohaemagglutinin (PHA) (5μg/mL) and allowed to proliferate for 
2 days. The daughter cells were determined by the progressive halving of CFSE 
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Figure 6-1. Establish human immunity in NSG mice using human PBMCs  
A. Isolation and characterization of PBMCs from fresh buffy coat. B-C. The serum 
human IgG concentration (B) and the staining of human CD3+ T cells in the spleen 
sections (C) of NSG mice and NOD-SCID mice at 2 weeks after the injection of PBMCs 
(5x106/mouse). 
 
 
 
 
 
 
 
Figure 6-2. Characterization of human BMSCs 
A. BMSCs are spindle-shaped adult stem cells under bright field. B. BMSCs are positive 
for HLA class I and negative for HLA-DR, FasL, CD14, CD80 and CD86. Open circle 
represents the isotype control.  
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fluorescence following each division. The co-incubation with BMSCs strongly inhibited 
the proliferation of PBMCs as indicated by the area of successive generations at 24h after 
co-incubation (Figure 6-3A). The total number of PBMCs in the co-culture was also 
significantly less than the PBMCs cultured alone (Figure 6-3B). Moreover, less IFN-γ, 
IL-2 and IL-2sRα (a soluble subunit of IL-2 receptor) were detected in the co-culture, 
suggesting less T cell activation (Figure 6-3C). We then determined whether the 
inhibition required direct contact between PBMCs and BMSCs. Surprisingly, BMSCs 
were equally potent to inhibit the proliferation of PBMCs and the expression of IFN-γ, 
IL-2 and IL-2sRα in a transwell system, suggesting a predominant paracrine model. Or in 
other words, BMSCs inhibited PBMCs by secreting soluble factors. 
 
IL-10 is a well-documented immunosuppressive factor by suppressing T cell 
activation, preventing antigen presenting process and inhibiting inflammatory cytokines. 
We previously reported marginal IL-10 expression (~20pg/mL) in the medium of primary 
BMSCs [52]. However, IL-10 expression was significantly boosted (300~400pg/mL) in 
the PBMC/BMSC co-culture, despite the existence of PHA-stimulation (Figure 6-4A). 
The inhibition of IL-10 pathway partially restored the production of IFN-γ, IL-2 and IL-
2sRα by the stimulated T cells in the presence of BMSCs (Figure 6-4B), indicating the 
crucial role of IL-10 in the immunomodulatory effects of BMSCs. We next determined 
which subpopulation of PBMCs produced IL-10. Neither T cells nor B cells have been 
reported to produce potent IL-10. We found that CD14+ monocytes were required for IL-
10 expression in the PBMC/BMSC co-culture since CD14+ monocyte depleted PBMCs 
produced significantly less IL-10 (Figure 6-4C). Realtime PCR also demonstrated that 
IL-10 transcription was activated in CD14+ monocytes instead of T cells or B cells, 
suggesting that the signal transduction between BMSCs and monocytes might be the first 
step toward the production of IL-10 and subsequent immune suppression. 
 
Other literatures showed positive expression of FasL on the surface of BMSCs 
and hypothesized that BMSCs promoted the apoptosis of T cells and subsequent immune 
tolerance [58, 146]. However, we did not detect FasL expression on the surface of 
BMSCs maintained in our lab (Figure 6-1). Annexin V staining demonstrated that 
BMSCs had no effect on the apoptosis of T cells in the co-culture (data not shown). Our 
results was supported by the results from Ryan et al [55]. 
 
 
BMSCs improved islet function  
 
Bedsides immune rejection, islets also suffers from the PNF which is the loss of 
islet function by non-immune reactions. Although still in debate, inflammatory cytokines 
seem to play important roles in the PNF of human islets because raised inflammatory 
cytokines was accompanied with most post-transplantation challenges including hypoxia 
in the core of islet grafts, inflammation in the transplantation site and the disruption of 
vasculature [17]. In this study, we used a cocktail of inflammatory cytokines (TNFα 50 
μg/mL, IL-1β 5μg/mL and IFN-γ 50 μg/mL) to mimic the PNF related challenges to 
human islets. Without inflammatory cytokines, the presence of BMSCs in the co-culture 
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Figure 6-3. Human BMSCs prevent the proliferation and activation of PBMCs  
A. The percentage of successive generations of PBMCs when stimulated with 
phytohaemagglutinin (PHA, 1μg/mL) for 1 day and allowed to proliferate for 2 more 
days. PBMCs were labeled with CFSE and subjected to analysis using flow cytometry. 
Left, PBMCs alone; right, PBMCs with BMSCs. B. The total amount of PBMCs as 
determined by an automatic cell counter. C. The levels of IL-2, IL-2sRα and IFN-γ in the 
medium as determined by ELISA. D-F. Repeat of the previous experiments (a-c) using a 
transwell system. n=3. 
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Figure 6-4. CD14+ monocytes and IL-10 were required for the 
immunomodulatory effect of BMSCs  
PBMCs were stimulated with phytohaemagglutinin (PHA, 1μg/mL) for 1 day and co-
cultured with BMSCs for 2 more days. A. IL-10 was highly expressed by the 
PBMC/BMSC co-culture but not by PBMCs alone. B. The inhibition of PBMCs 
mediated by BMSCs can be reversed by adding IL-10sR. C. Monocyte depleted PBMCs 
(PBMCsΔMono) failed to produce high level of IL-10 in the PBMC/BMSC co-culture. D. 
IL-10 mRNA was highly expressed in CD14+ monocytes but not B cells and T cells in 
the PBMC/BMSC co-culture. n=3.  
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did not affect insulin release from human islets when exposed to stimulatory glucose. 
Inflammatory cytokines significantly impaired the first-phase (the first peak appears 
immediately after stimulatory glucose) and the total insulin release of human islets after 4 
days (Figure 6-5A). However, the presence of BMSCs in the co-culture significantly 
ameliorated the impairment caused by inflammatory cytokines (Figure 6-5B), suggesting 
a protective effect of BMSCs.   
 
 
BMSCs improved islet transplantation in humanized NSG mice 
 
The co-administration of STZ and PBMCs usually led to strong T cell 
alloreactivity and subsequent GvHD and death. In this study, we first used a long term 
injection of low doses of STZ to induce diabetes. Mice were mostly diabetic after three 
weeks. Then, 500 handpicked human islets were transplanted under the kidney capsule of 
each diabetic NSG mouse with BMSCs at serial ratios (islet: BMSC = 1:0, 1:50, 1:100 
and 1:200). At 4 weeks after successful islet transplantation, PBMCs (5x106/mouse) were 
injected intraperitoneally to establish the human immunity. This strategy helped us to 
identify the settlement of human immunity by comparing blood glucose before and after 
PBMC injection and to avoid STZ-stimulated GvHD. Glucose measurement showed that 
all mice restored normoglycemia during the first 4 weeks after islet transplantation, 
indicating successful islet engraftment and function (Figure 6-6A). However, the blood 
glucose of some mice reversed to hyperglycemia after PBMC infusion, probably due to 
the destruction of islet grafts by the established human immunity. Briefly, 11/11 mice 
receiving islets only were back to diabetes in the first two weeks after PBMC infusion. In 
contrast, 10/11, 6/12 and 2/10 mice were back to diabetes when the islets were 
transplanted with BMSCs (islets: BMSCs=1:50, 1:100, 1:200), respectively (Figure 
6-6B). Dose dependent improvement of the outcome of human islet transplantation was 
observed by increasing the ratio of BMSCs, suggesting the protective role of BMSCs 
against the adoptively transferred human immunity.  
 
Intraperitoneal glucose tolerance test was performed 2 weeks after the PBMC 
injection to determine the function of islets in real time. Despite the difference in the non-
fasted blood glucose level between different groups, all mice displayed similar baseline 
blood glucose levels following overnight fasting. Blood glucose levels increased 
immediately following glucose (2 g/kg) injection, peaked at 15 min in all groups, and 
decreased over time (Figure 6-6C). The mice receiving islet/BMSC co-transplantation 
showed faster and better response to the stimulatory glucose compared to the mice 
receiving islets alone (Figure 6-6C), suggesting a better glucose control. At the end of 
study, the mice were anesthetized to collect blood to measure serum insulin and c-peptide 
level by ELISA. The levels of insulin and c-peptide of the mice receiving islet/BMSC co-
transplantation were significantly higher than those of the mice transplanted with islets 
alone (Figure 6-6D). 
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Figure 6-5. Human BMSCs protected the function of human islets against the 
inflammatory cytokines  
A. The dynamic insulin release from human islets. Briefly, 50 islets from each group 
were perifused with basal glucose (1.67mM) for 60 min, stimulatory glucose (16.7mM) 
for 30 min and finally basal glucose until the insulin release reversed to the basal level. 
The flow rate was maintained at 1 ml/min and the temperature was maintained at 37°C. 
Samples were collected once per two minutes and analyzed for insulin concentration. For 
the cytokine treatment groups, islets, alone or with BMSCs, were stimulated with a 
cytokine cocktail (TNFα 50 μg/mL, IL-1β 5μg/mL and IFN-γ 50 μg/mL) for 4 days prior 
to perifusion. B. Cumulative insulin release calculated from dynamic insulin release 
profile on the left. n=3.  
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Figure 6-6. The outcome of human islet transplantation with BMSCs in diabetic 
humanized NSG mice  
A. The blood glucose levels of all mice after successful islet transplantation. For each 
mouse, 500 handpicked islets ((150~300μm in diameter) were transplanted alone or with 
BMSCs at serial ratios (islet: BMSC =1:50, 1:100 and 1:200) under the kidney capsule of 
STZ induced diabetic NSG mice. The blood glucose level of each mouse was monitored 
using a glucometer weekly. An intraperitoneal injection of PBMCs (5x106/mouse) was 
given 4 weeks after islet transplantation. At 17 weeks after islet transplantation, the graft-
bearing kidneys were then removed from some mice to validate the function of islet 
grafts by the return of blood glucose levels to ≥ 400 mg/dL. B. The Kaplan–Meier plot 
for the percentage of insulin-independent mice of each group after PBMC injection. The 
mouse with blood glucose level < 200mg/dL for two consecutive measurements was 
identified as insulin-independent. P value was calculated as compared to the islet-alone 
group using R version 2.15.2. C. Intraperitoneal glucose tolerance test was done with the 
mice receiving islet alone and islet/BMSC cotransplantation (islet: BMSC =1:200) to 
determine the islet function at 2 weeks after the injection of PBMCs. D. The serum 
insulin and c-peptide of the mice receiving islet alone and islet/BMSC cotransplantation 
(islet: BMSC =1:200) at the end of study. Data are presented as Mean±SD, n=9. 
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BMSCs prevented T cell infiltration and increased Tregs 
 
The kidney bearing islets was isolated at the end of study and subjected to 
immunofluorescence staining. The location and function of islet grafts were identified by 
staining for insulin. Insulin signal in the kidney capsule bearing islet/BMSC was 
significantly higher than those bearing islets only (Figure 6-7A). However, CD3+ T cells 
were significantly less in the kidney capsules bearing islet/BMSC than those bearing 
islets only. Taken together, these data suggested that BMSCs prevented T cell infiltration 
into the transplantation site and prevented the destruction of islets in vivo.  
 
The expansion of Tregs might play an important role in the immune tolerance of 
transplanted organs in vivo [148]. Moreover, BMSCs were recently reported to increase 
the proportion of Tregs [149, 150]. To further explore whether such mechanism can 
explain the reduced infiltration and destruction by alloreactive T cells into the 
transplantation site, we isolated all CD3+ T cells and detected the percentage of Tregs 
from the blood stream of NSG mice. Despite the low cell recovery, significantly higher 
percentage of CD3+CD25+Foxp3+Tregs was detected in the blood stream (Figure 
6-7B), which was consistent with the BMSC/T cells co-culture study in vitro (Figure 
6-7C). Taken together, these results suggested that BMSC mediated increase in the 
proportion of Tregs might contribute to the immune tolerance of islet transplantation.    
 
 
Discussion 
 
Edmonton protocol for human islet transplantation, which was developed more 
than 20 year ago, failed to maintain insulin independence in the long term in most 
patients. Despite the development of new immunosuppressive regimens and new 
combination therapy, graft rejection remains a major challenge for human islet 
transplantation. Other challenges are summarized as PNF caused by the hypoxic 
environment, secretion of inflammatory cytokines and apoptosis of islet cells during 
isolation, transportation and storage process. 
 
MSC-based cell therapy has attracted wide attention in regenerative medicine and 
tissue engineering. There are two major strategies of using MSCs for islet transplantation: 
1) direct the differentiation of MSCs to replenish the lost islets; 2) use MSCs to nourish 
islet grafts and mitigate immune response. For the first strategy, several groups have 
reported the generation of islet-producing cells and islet-like clusters by the in vitro 
transdifferentiation of MSCs [76, 77]. However, this strategy usually required long-term 
in vitro induction and failed to generate enough islets for clinical study and the risk of 
tumorigenicity was somehow overlooked. For the second strategy, MSCs constitutively 
secreted multiple factors, which are capable of regulating insulin production, 
revascularization, immune rejection and apoptosis of human islets. This strategy does not 
require in vitro transdifferentiation and huge amount of MSCs. Most importantly, MSCs 
can be isolated from and infused back into the same patient to exert the therapeutic 
potential as indicated by several clinical studies [39]. Therefore, in this study, we selected 
the second strategy for improving human islet transplantation.  
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Figure 6-7. Human BMSCs prevent the T cell infiltration into the transplantation 
site  
A. The immune fluorescence staining of the kidney section bearing human islets alone 
(left) or with BMSCs (right). Briefly, three mice in each group were sacrificed at 2 weeks 
after the injection of PBMCs (5x106/mice), or 6 weeks after islet transplantation. Insulin 
was stained in red to identify the transplanted human islets, while CD3+ T cells were 
stained in green. All experiments were done in triplicates and an representative picture 
was shown. B. The percentage of CD4+CD25+FoxP3+ regulatory T cells (Tregs) 
recovered from the blood stream of NSG mice at 2 weeks after the injection of PBMCs. 
Briefly, the total CD4+ T cells was isolated and purified from the total blood of NSG 
mice using Dynalbeads at the end of study. The percentage of CD25+FoxP3+ Tregs 
among the total CD4+ T cells was determined by flow cytometry. Q2 represents the 
Tregs. C. The percentage of Tregs of the total CD3+ T cells when co-culture with 
BMSCs in vitro.  
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The pattern of the surface markers has great impact on the function of BMSCs 
and provided useful information to the following studies. Our BMSCs were positive for 
HLA class I and negative for CD14 (Figure 6-2), which concurred with previous report 
and suggested BMSCs can be recognized and destroyed by the cytotoxic T cells [55]. 
BMSCs were also negative for costimulatory factors such as CD80 and CD86, which 
might explain why BMSCs were unable to stimulate the multiplication of helper T (Th) 
cells and the subsequent antibody production. Generally, the lack of co-stimulatory 
factors (CD80 and CD86) led to an immature antigen presenting to the Th cells and 
subsequent immune tolerance [151]. Despite that some groups showed that BMSCs 
expressed FasL and promoted the apoptosis of T cells through direct contact [146, 152], 
our BMSCs were negative for FasL (Figure 6-2), which was supported by the results 
from other groups [55, 153] and confirmed by the MLR that BMSCs did not promote the 
apoptosis of T cells (data not shown). The expression of HLA class II on the surface of 
BMSCs is still unclear. While some groups demonstrated that BMSCs were positive for 
HLA class II [151], the studies from our and other groups suggested that BMSCs were 
negative for HLA class II which explained the hypoimmunogenicity of MSCs (Figure 
6-2) [55].  This discrepancy is probably due to the difference in culture conditions and the 
sources of BMSCs and can only be solved if a standard operating protocol is developed 
and maintained among all research groups. 
 
T cells are the most important cells mediating the recognition and destruction of 
human islets. T cells can be activated by PHA and the activation of T cells is 
characterized by the production of IL-2, IL-2R and IFNγ. In the MLR, BMSCs prevented 
PHA-induced proliferation and activation of PBMCs by secreting the soluble factors, 
among which IL-10 may play an important role (Figures 6-3, 6-4). However, despite 
potent IL-10 expression in the PBMC/BMSC co-culture, significantly less IL-10 was 
expressed by BMSCs or PBMCs when they were cultured alone [52], suggesting that the 
communications between BMSCs and a subpopulation of PBMCs were required for the 
production of immunosuppressive IL-10 [63, 65]. We identified CD14+ monocytes as the 
prerequisite of the BMSC-mediated immune suppression (Figure 6-4), which is 
consistent with previous reports that monocytes or monocyte-derived dendritic cells were 
deeply involved in the BMSC-mediated T cell inhibition [154, 155]. First, BMSCs 
secreted soluble factor(s) and activated CD14+ monocytes to express IL-10. Then IL-10 
suppressed the subsequent proliferation and activation of T cells. Such two-step 
immunosuppression could be an important feature for the co-transplantation of human 
islets and BMSCs as the BMSCs only exert a local effect to protect human islets without 
impairing the host immunity systemically. However, these results should be interpreted 
with caution because 1) the role of IL-10 in the BMSC-mediated immunosuppression is 
controversial as some groups observed IL-10 inhibition did not reverse and even further 
suppressed T cell proliferation [63, 154] and 2) the soluble factors secreted by BMSCs in 
this process remained unknown. Besides IL-10, other immunosuppressive factors such as 
HGF, TGFβ and PGE2 may also play important roles in the BMSC-mediated 
immunosuppression [52, 55, 156]. It is highly possible that the immunomodulatory effect 
of BMSCs is mediated through a network of molecular pathways instead of a single 
pathway.    
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Next we evaluated the interactions of BMSCs with human islets and human 
immunity in vivo. In fact, several groups have previously shown the improvement of islet 
transplantation using MSCs, either through co-transplantation or intravenous infusion. 
For example, Ito et al. reported that MSCs improved the outcome of islet transplantation 
by promoting the revascularization of islet grafts [54]. Ding et al. reported MSCs 
prevented the rejection of allogeneic islets by matrix metalloproteinase-2 and -9 (MMP2 
and MMP9) [60]. Yeung et al. reported that MSCs protected human islets from 
inflammatory cytokines [144]. However, the lack of human immunity in most of these 
studies caused limited understanding regarding the immune mediated graft loss. Yet the 
mechanism of BMSC-mediated protection to human islets in the presence of human 
immunity has not been thoroughly understood. Although xenogeneic human islet 
transplantation in immunocompetent rodents has been reported [142], the distinct 
differences in the immune system between rodent and human hindered the translation 
into a real clinical advance. The humanized mouse developed by Dr. Lenny Schultz is a 
“state of the art” animal model for research related to human immunity [79]. First, it is a 
perfect model to study the development of type 1 diabetes, which is an autoimmune 
disease. Second, the interaction between transplanted islets and the adoptively transferred 
human immunity provide useful information about immune rejection after human islet 
transplantation. The human immunity was established in NSG mice by injection of 
human PBMCs and validated by the presence of human IgG in the blood steam and 
CD3+ T cells in the mouse spleen (Figure 6-1). The adoptively transferred human 
immunity posed a challenge, which is similar to the clinical immune rejection, to the 
transplanted human islets. Compared with previous studies using immunodeficient 
animals [52, 54], the duration of insulin independence was significantly reduced in 
humanized NSG mice, as evidenced by the rapid loss of islet and T cell infiltration 
(Figures 6-6A, 6-7A). Co-transplantation with BMSCs significantly prolonged the 
duration of insulin independence in the presence of human immunity (Figure 6-6A). The 
intraperitoneal glucose tolerance test and the serum levels of human insulin and c-peptide 
further validate the improved islet function in the islet/BMSC co-transplantation group 
(Figures 6-6C-D). The interactions between BMSCs and T cells may of critical 
importance to the protection to human islets. We previously demonstrated that BMSCs 
“switched on” the production of immunosuppressive IL-10 by CD14+ monocytes to 
prevent the proliferation and activation of T cells in co-culture (Figure 6-3). In vivo 
results showed that BMSCs prevented the infiltration of CD3+ T cells into the 
transplantation site, probably due to the reversal to T cell activation (Figure 6-7A). 
Besides, we also found increased immunosuppressive Tregs in the blood stream of 
humanized NSG mice receiving islet/BMSC co-transplantation, suggesting locally 
injected BMSCs still had the potential to exert a considerable systemic effect (Figure 
6-7B). Similar results were found in the MLR and supported by the results from Weng et 
al. (Figure 6-7C) [150]. However, further explorations are still required to unveil the 
underlying pathways to the proliferation of Treg.  
 
Besides the immune modulatory effect, BMSCs improved insulin production of 
human islets against inflammatory cytokines in an islet perifusion assay (Figure 6-5), 
suggesting the role of BMSC as a trophic mediator to prevent the PNF of human islets. 
BMSCs also produce multiple growth factors including HGF and VEGF to promote the 
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revascularization, which has been explored in depth in immune deficient animal model 
by us and other groups [52, 54].   
  
Based on our results, we hereby propose three possible mechanisms for BMSC-
mediated islet tolerance (Figure 6-8): 1) BMSCs inhibit alloreactive T cells by the 
immature antigen presenting and/or activating CD14+ monocytes to produce IL-10; 2) 
BMSCs promote the proliferation of Tregs through soluble factors; 3) BMSCs prevent 
the PNF of islets. The protection of human islets by BMSCs in the presence of human 
immunity may be a result of the synergistic combination of all three mechanisms. 
 
Despite the evidences that BMSCs significantly improved islet transplantation in 
humanized NSG mice, the data should be interpreted with caution as several issues 
needed to be resolved. First, we did not characterize the interactions of BMSCs with B 
cells and natural killer cells. Such characterization may uncover the new aspects of 
BMSCs mediated immune tolerance and is necessary in future. The second issue is the 
GvHD caused by the infused mature immunocytes. Most humanized NSG mice or even 
NRG-Akita mice, which simultaneously develop diabetes without STZ injection, will 
develop GvHD in 5~7 weeks after the infusion of PBMCs [79], providing us a limited 
window to evaluate the efficacy of BMSC cotransplantation. The amount of infused 
PBMCs has great effect on the onset of GvHD. The dose of 5x106 PBMCs was reported 
to be relatively safe to induce significant GvHD and adopted for this study [79]. Due to 
the presence of BMSCs which hold strong immunomodulatory effects we did not detect 
significant GvHD-like symptoms including weight loss, hunched posture, ruffled fur, 
reduced mobility and tachypnea in the mice receiving islet/BMSC cotransplantation. 
However, we did observe GvHD in the mice receiving islets alone from 5 weeks after the 
infusion of PBMCs. Humanized mice generated from hematopoietic stem cells may 
resolve the issue of GvHD [80]. The third issue is the route of the administration of 
BMSCs. Many reports have shown that the systemic administration of BMSCs prevented 
the onset of type 1 diabetes. However, the systemic injection of BMSCs may be 
sequestered in the lung and other sites. In this study, we chose islet/BMSC co-
transplantation to exert a local effect, which might have more impact on the future 
clinical application because the immunity of the patients receiving islet transplantation 
will not be compromised. Previous studies from us and other groups also ruled out the 
possibility of BMSC migration and demonstrated that BMSC co-transplantation stayed in 
the proximity of islet grafts and helped the engraftment and revascularization of islet 
grafts [52, 54]. Last but not the least, despite our demonstration that BMSCs from the 
third party is equally potent to protect human islets from adoptively transferred human 
immunity (Figure 6-7A). The mismatch in HLA typing remains a concern for future 
clinical application. To better fit the scope of personalized medicine, BMSCs and PBMCs 
isolated from the same subject would be preferred. That requires further collaboration of 
institutions with hospitals.   
 
In summary, our studies demonstrated that co-transplantation with BMSCs can be 
a promising strategy to improve the current status of human islet transplantation. The 
BMSC served as a major role of immune modulator to protect islets from immune 
destruction while also as a trophic mediator to prevent the PNF of islet transplantation. 
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Figure 6-8. Schematic illustration of why BMSCs improved human islet 
transplantation 
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CHAPTER 7.    A NOVEL COMPOUND DRUG FOR HUMAN ISLET 
TRANSPLANTATION IN HUMANIZED MOUSE MODEL 
 
 
Introduction 
In the study described in Chapter 6, we used BMSCs to prevent the immune 
rejection of human islet transplantation (Figures 6-6, 6-7). BMSCs also prevented the 
PNF of islet transplantation caused by inflammatory cytokines (Figure 6-5). Compared 
with gene therapy, stem cell therapy is a more biocompatible strategy for human islet 
transplantation. However, the unlimited proliferative capacity and transdifferentiation 
potential of stem cells especially genetically modified stem cells (Chapter 5) pose risks of 
tumorigenicity and immunogenicity, though in a lesser extent to islet recipient.   
 
BMSCs infused intravenously will be sequestered in the lung.  Therefore BMSCs 
were mostly co-transplanted with human islets and unsuitable for repeatedly injection, 
making the transplantation outcome hard to predict and manage. The cost and time 
needed for the isolation, expansion and even genetic modification of enough amounts of 
BMSCs for clinical application is another of concern using BMSCs. Therefore, in this 
study, we proposed a novel compound drug, in which an antiapoptotic drug is conjugated 
with immunosuppressive compound, for human islet transplantation. We hypothesized 
that the compound drug could prevent the inflammatory cytokine induced PNF and the 
immune rejection at the same time. Most importantly, this compound is easy to 
synthesize and can be injected repeatedly into a diabetic patient. 
 
Zeng et al. synthesized a series of quinic acid (QA) derivatives and determined 
their anti-inflammatory activity in human A549 cells [157]. They demonstrated that 
among many QA derivatives, KZ41 had strongest inhibition of NK-kB activity against in 
A549 cells the stimulation of TNFα and can be used for as an anti-inflammation drug 
(Figure 7-1). We hypothesized that KZ41 was equally potent to suppress the 
inflammatory pathway in human islets and could prevent the PNF caused by 
inflammatory cytokines. MPA is an immunosuppressive drug frequently used in organ 
transplantation. MPA is commonly marketed under the trade names CellCept (Roche) and 
Myfortic (Novartis). MPA inhibits inosine monophosphate dehydrogenase, which 
controls the purine synthesis in T cells and B cells.  
 
Therefore, in this study, we synthesized JP-3-110 by conjugating quinic acid 
amide and MPA via ester bond. We first compared the antiapoptotic effect of the 
compound drug JP-3-110 with its antiapoptotic counterpart KZ41 on human islets against 
inflammatory cytokines. We then compared the immunosuppressive effect of JP-3-110 
with its immunosuppressive counterpart MPA against the activation and proliferation of T 
cells. Lastly, we evaluated the effectiveness of this new compound drug to improve the 
outcome of human islet transplantation in a diabetic humanized NSG mouse model. We 
hypothesized that the compound drug JP-3-110 can prevent the immune rejection and the 
PNF of human islet transplantation at the same time. 
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Figure 7-1. KZ41 and NF-kB inhibition  
A. The structure of KZ41. B. NF-kB activity was measured using A549 cells stably 
transfected with a secreted alkaline phosphatase (SEAP) reporter at 18 hours after 
addition of TNF-α (10 ng/mL) and either QA or QA derivatives (3–13; 1 μM). KZ41 was 
lane 3. Dexamethasone (Dex; 1 μM) was used as a positive control. Data are presented as 
percent (%) inhibition relative to control (ctl; TNF-α alone) and represent mean ± SD. n = 
3. Blank: media only. 
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Materials and Methods  
 
 
Materials 
 
Human islets were received from Integrated Islet Distribution Program (Duarte, 
CA). CMRL-1066 medium for islet culture and DAPI were purchased from Sigma 
Aldrich (St. Louis, MO). FBS was purchased from MediaTech Cellgro. (Herndon, VA). 
PBS was purchased from GIBCO-BRL (Gaithersburg, MD). NF-kB SEAPorterTM Assay 
Kit was purchased from IMGENEX (San Diego, CA). Human IL-2, IL-2sRa, IL-10 
ELISA, TNFα and IFN-γ ELISA kits were purchased from R&D Systems (Minneapolis, 
MN). The primary antibodies for CD3, CD4, insulin and the Dylight 488-conjugated 
secondary antibody were purchased from Abcam (Cambridge, MA). The Alexa Fluor 
568-conjugated secondary antibody and 0.25% trypsin were purchased from Invitrogen 
(Carlsbad, CA). Ultrasensitive One Touch glucose test strips and One Touch Ultra 
glucometer were purchased from LifeScan (Milpitas, CA). Tissue-Tek O.C.T. compounds 
were purchased from Sakura Finetek (Torrance, CA). 
 
 
Synthesis and characterization of antiapoptotic immunosuppressive drug 
 
All reagents for the synthesis were purchased from commercial sources and were 
used without further purification. Moisture-sensitive reactions were carried out under an 
argon atmosphere. Routine TLC was performed on aluminum backed Uniplates 
(Analtech, Newark, DE). NMR spectra were obtained on a Bruker ARX-400 MHz 
(Billerica, MA) or a Varian Inova-500 MHz spectrometer (Varian NMR Inc., Palo Alto, 
CA). Chemical shifts are reported as parts per million (ppm) relative to TMS (0 ppm) in 
CDCl3. Temperature was regulated with a general accuracy of ±0.1°C. Mass spectral data 
were collected on a Bruker ESQUIRE-LC/MS system equipped with an ESI source. The 
synthesis of ester 4 used in the pancreatic islets protection studies was synthesized as 
illustrated in Figure 7-2.  The starting compound 5,7-dihydroxy-2,2-dimethyl-N-propyl-
hexahydrobenzo[d][1,3]dioxole-5-carboxamide (amide 1), which has been described 
before[158], was coupled with acetylated MPA 2 to obtain quinic acid ester 3 and further 
deprotection of acetanoid group using 1N HCl in tetrahydrofuran (THF) to give 
compound 4. 
  
Synthesis of Compound 2. Acetic anhydride (0.2 mL, 1.9 mmol) was slowly 
added to a pyridine (5 mL) solution of MPA (0.2 g, 0.62 mmol) and 4-
Dimethylaminopyridine (DMAP, 0.03 g, 0.25 mmol) at 0 °C. The reaction mixture was 
stirred for 2 h and then poured onto crushed ice. The aqueous phase was acidified with 2 
M aq. HCl (pH ~ 2) and extracted with EtOAc (3 x 400 mL). The combined organic 
extracts were dried over Na2SO4, filtered, and the solvent was removed under reduced 
pressure to afford acetylated MPA 2 (0.18 g, 83%) as a white powder mp 155-157 oC. 
 
1H NMR (500MHz, CDCl3): δ 5.18-5.5 (m, 3H), 3.79 (s, 3H), 3.28 (d, J = 6.9 Hz, 
2 H), 2.43-2.38 (m, 5H), 2.33-2.28 (m, 2H), 2.21 (s, 3H), 1.79 (s, 3H). Mass:  385.2  
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Figure 7-2. Synthesis and characterization of JP-3-110  
A. The synthetic scheme of JP-3-110. i) DIC, DMAP, DCM, 73%; ii) IN HCl/THF, 12h, 
21%. B. The 1H NMR spectrum of JP-3-110. 
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(M+Na). 
 
Synthesis of Compound 3. A solution of amide 1 (0.32 g, 0.88 mmol), acetylated 
MPA 2 (0.24 g, 0.88 mmol), N,N-dimethyl amino pyridine (0.16 g, 1.32 mmol) and 
diisopropyl carbodiimide (0.21 mL, 1.32 mmol) in CH2Cl2 (10 mL) was stirred at room 
temperature under Ar atmosphere overnight. The reaction mixture was diluted with 
CHCl3 (20 mL) and then washed with 1 N HCl (10 mL), water (10 mL), aqueous 
saturated NaHCO3 solution (10 mL), and brine (10 mL). The organic layer was dried 
(Na2SO4) and evaporated, and the residue was purified by column chromatography 
(silica gel, 30% acetone in petroleum ether) to afford (E)-6-hydroxy-2,2-dimethyl-6-
(propylcarbamoyl)-hexahydrobenzo[d][1,3]dioxol-4-yl-6-(4-acetoxy-6-methoxy-7-
methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (compound 3, 0.4 g, 
73%) as a white solid mp 71-73oC. 
 
1H NMR (400MHz, CDCl3): δ 7.08 (t, 1 H), 5.32-5.23 (m, 1H), 5.17 (s, 1H), 
5.15-5.08 (m, 1H), 5.32-5.24 (m, 1H), 4.54-.48 (m, 1H), 4.14-4.08 ( m, 1H), 3.84 (s, 1H), 
3.78 (s, 3H), 3.5 (d, J = 6.9 Hz, 2 H), 3.24-3.15 (m, 2H), 2.45- 2.36 (m, 5H), 2.33-2.28 
(m, 2H), 2.23 (s, 3H), 2.03-1.90(m, 2H), 1.76 (s, 3H), 1.58 (s, 3H), 1.55-1.48 (m, 2H), 
1.36 (s, 3H). 0.93 (t, 3H). Mass:  640.3 (M+Na). 
 
Synthesis of Compound 4. Compound 3 (0.4 g, 0.64 mmol) was dissolved in THF 
(3 mL), then aqueous 1N HCl (5 mL) was added at room temperature and the reaction 
mixture was stirred for 12h and monitored by ESI-MS. After completion of reaction, 
solution was saturated with solid NaCl and aqueous phase was extracted with ethyl 
acetate (3x 100 mL). The organic layer was dried (Na2SO4) and evaporated, and the 
residue was purified by column chromatography (silica gel, 90% ethyl acetate in 
petroleum ether) to afford compound 4 (0.08 g, 21%) as a white solid mp 74-76 oC. 
 
1H NMR (400MHz, CDCl3): δ 7.08 (t, 1 H), 5.22-5.16 (m, 3H), 5.11-5.05 (m, 
1H), 4.84 (s, 1H), 4.29-4.24 (m, 1H), 3.80 (s, 3H), 3.68-3.61 (m, 1H), 3.38 (d, J = 6.9 Hz, 
2 H), 3.32-3.30 (M, 1H), 3.25-3.16 (m, 3H), 2.45- 2.36 (m, 5H), 2.33-2.28 (m, 2H), 2.23 
(s, 3H), 2.15-2.0 (m, 4H), 1.8 (s, 3H), 1.51-1.50 (m, 2H), 0.9 (t, 3H). Mass:  578.3 
(M+H). 
 
 
NF-kB activity 
 
INS-1E cells which were stably transfected with the SEAP gene containing the 
response-element for NF-kB were used to screen for anti-inflammatory activity.  Briefly, 
106 cells/well were seeded overnight followed by treatment with 10 ng/mL human 
recombinant TNFα and either KZ41 or hybrid drug JP-3-110 (1μM). SEAP activity was 
measured 18h later in supernatant samples (50 lL) using the NF-kB SEAPorterTM Assay 
Kit (IMGENEX) and a microplate luminometer. SEAP activity was normalized to the 
total protein content. Inhibitory potency (IC50) was determined from dose-response 
curves (n = 3 separate experiments). 
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Caspase assay 
 
Caspase-Glo 3 assay kits were used to analyze caspase 3 as per the manufacturer’s 
protocol (Promega). This assay kit provides a proilluminescent caspase substrate, DEVD, 
that, when cleaved by caspases, will release luciferin to quantitatively determine caspase 
concentration. Briefly, following sequential treatment by JP-3-110 for 48h and a cytokine 
cocktail of recombinant TNFα (5 ng/ml) and IL-1β (5 ng/ml) for additional 48h, 100 μL 
of Caspase-Glo reagent was added to 100 μL of culture supernatants in 96-well plates and 
incubated at room temperature for 1 h. The contents were then transferred into culture 
tubes, and luminescence was determined using a luminometer (Berthold, Germany). 
 
 
Griess assay 
 
Nitric oxide (NO) production and accumulation is a vital step in the apoptotic 
pathway. Nitrite concentration was determined using the Griess assay (Promega, 
Madison, MI). Fifty microliters of cell culture supernatant was added to a 96 well-plate 
and mixed with 50 μL of 1% sulfanilamide in 5% phosphoric acid solution and incubated 
for 5 min at room temperature in the dark. Then, 50 μL of 0.1% N-1-
naphthylethylenediamine dihydrochloride (NED) aqueous solution was added to each 
well. The plate was incubated for an additional 10 min, and absorbance was measured at 
560 nm using a microplate reader. To determine the nitrite concentration in each sample, 
a standard curve was prepared using nitrite standard solution and blank culture. 
 
 
Apoptosis studies  
 
A cytokine cocktail was used to mimic the in vivo challenge to the INS-1E cells 
and human islets by the inflammatory cytokines. Briefly, following JP-3-110 treatment 
for 48h and cytokine cocktail treatment for additional 48h, INS-1E cells were 
characterized by the DeadEnd™ Colorimetric TUNEL system (Promega, Madison, WI, 
USA), in which fragmented DNA from apoptotic cells was labeled with biotinylated 
nucleotide and detected using hydrogen peroxide and diaminobenzidine. Following 
treatment with JP-3-110 and cytokines, human islets were digested with 
0.25%trypsin/EDTA into a single-cell suspension, stained with the Annexin V-FITC 
Apoptosis Detection Kit (Abcam) and analyzed with flow cytometry. Annexin V binds to 
phosphatidylserine on the cell surface, which is a feature found in apoptotic cells. 
Fluorescent intensity was analyzed using CellQuest software (BD Bioscience, Franklin 
Lakes, NJ, USA). Three sets of independent transduction experiments were carried out 
for each assay.  
 
 
Islet perifusion study  
 
The insulin secretion from human islets was quantified using a dynamic islet 
perifusion assay. Briefly, 50 islets from each group were handpicked and loaded onto a 
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Swinnex 13 chamber (Millipore, Burlington, MA, USA) and perifused with Krebs-Ringer 
bicarbonate HEPES buffer of the following composition (in mM): 129 NaCl, 5 NaHCO3, 
4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, and 10 HEPES at pH 7.4. The flow rate 
was maintained at 1 ml/min with a peristaltic pump (Themo Fisher, Waltham, MA) and 
the temperature was maintained at 37°C with a solution heater (Warner Instruments, 
Hamden, CT). Islets were first perifused with basal glucose (1.67mM) for 60 min and 
stimulated with glucose (16.7mM) for 30 min and finally perifused with basal glucose 
(1.67mM) until insulin release reversed to the basal level. Samples were collected once 
per two minutes through an automatic fraction collector (Waters, Milford, MA) and 
analyzed for insulin content by ELISA. 
 
 
Mixed lymphocyte reaction (MLR) 
  
PBMCs were isolated using Ficoll Paque as described in Chapter 6. T cells were 
isolated from PBMCs using Dynabeads for. T cells were stimulated with PHA (1μg/ml) 
for 24h and then cultured in the presence of KZ41 (5μM) or JP-3-110 (5μM) or additional 
4 days. The total number of PBMCs was measured using T4 Automatic Cell Counter 
(Nexcelom, Lawrence, MA). The extent of T cell activation was determined by 
measuring the level of IL-2, IL-2sRa, TNFα and IFN-γ in the medium using ELISA at 
indicated time.  
 
 
Rebuild human immunity  
 
Human PBMCs were isolated from buffy coats by gradient centrifugation using 
Ficoll Paque. The T cells and B cells of PBMCs were stained with FITC conjugated CD3 
antibody and APC conjugated CD19 antibody, respectively, and characterized using flow 
cytometry. The PBMCs were infused into diabetic NSG mice at the concentration of 
5x106/mouse to establish human immunity. The settlement of T cells in the spleen was 
assessed by immunofluorescence staining. Briefly, spleen were isolated, washed with 
PBS, fixed in 4% paraformaldehyde overnight, and embedded in optimal cutting 
temperature compound. Frozen sections of 5 μm thickness were cut. The slides were 
stained with rabbit anti-human CD3 primary antibody (1:200) at 4 °C overnight and 
Alexa Fluor 568 conjugated goat anti-rabbit secondary antibody (1:500) at room 
temperature for 1 h. The function of B cells was assessed by measuring human IgG 
concentration in the mouse blood. 
 
 
Statistical analysis 
 
Statistical significance of the difference between the two groups was determined 
by unpaired t-test and between several groups by one-way ANOVA. 
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Results  
 
 
Synthesis of JP-3-110 
 
Quinic acid amide analog KZ41 was synthesized as described before [157]. JP-3-
110 was synthesized by conjugating KZ41with MPA and the structure of JP-3-110 was 
confirmed by 1H NMR (Figure 7-2). The solubility of JP-3-110 was determined to be 
0.48±0.16mg/ml (0.80±0.27mM) by HPLC, which is practically insoluble according to 
USP solubility criteria (Figure 7-3).  
 
 
Apoptotic effect of JP-3-110 
 
Although the water solubility of JP-3-110 was extremely poor, we still tried to 
determine whether JP-3-110 can suppress the NF-kB activity as its counterpart KZ41 in  
insulin producing INS-1E cells. A cocktail of inflammatory cytokines (TNFα 10 ng/mL, 
IL-1β 5ng/mL and IFN-γ 10 ng/mL) was used to mimic the inflammation in vivo. Results 
indicated that JP-3-110 was equally potent as KZ-41 to suppress the NF-kB activity of 
INS-1E cells under the stimulation of inflammatory cytokines (Figure 7-4). We then 
determined the activities of caspase 3 which is a converging point of apoptotic pathway. 
Results showed that INS-1E cells pre-treated with KZ-41 and JP-3-110 showed 
significant decrease in caspase 3 activity (Figure 7-5A), suggesting the inhibition of 
apoptotic pathway by KZ41 and JP-3-110. As a result, the inflammatory-cytokine-
induced apoptotic cell death was significantly reduced in INS-1E cells in the presence of 
KZ41 or JP-3-110 (Figure 7-5B). 
 
We then determine the protective effect of KZ41 on human islets against 
inflammatory cytokines. We demonstrated that the percentage of apoptotic cells in human 
islets were significantly reduced in the presence of KZ41 at 2 days and  4 days after 
stimulation with cytokine cocktail, suggesting a protective role of KZ41 (Figure 7-6). 
Interestingly, we also demonstrated that the INS-1E cells and human islets conditioned 
with KZ41 and JP-3-110 acquired similar resistance to the challenges of inflammatory 
cytokines (data not shown), suggesting that KZ41 and JP-3-110 can be used as preventive 
medicine. 
 
 
Immunosuppressive effect of JP-3-110 
 
Besides the PNF of islet grafts caused by inflammatory cytokines, immune 
rejection is another key barrier for successful islet transplantation. We determined 
whether JP-3-110 retained the immunosuppressive effect as MPA. Typically, T cell 
activation is characterized by an early and transient expression of IL-2 and a long-lasting 
expression of TNFα and IFNγ (Figure 7-7). JP-3-110 showed minimal effect on the 
expression of IL-2 but it strongly inhibited the expressions of TNFα and IFNγ in long 
term. Further study illustrated that JP-3-110 significantly suppressed T cell proliferation  
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Figure 7-3. Use HPLC to determine the solubility of JP-3-110  
A. Standard curve of JP-3-110. From top to bottom, 0.2, 2, 20, 200, 2000 mg/mL of JP-3-
110 in acetonitrile (ACN). B. Triplicates of JP-3-110 saturated water solution. C. HPLC 
conditions. Column: Inertsil ODS-3, 250 x 4.6mm, 5μm. 
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Figure 7-4. JP-3-110 and KZ41 suppressed NF-kB activity in INS-1E cells 
A. Schematic illustration of the mechanism of SEAP reported gene assay to determine 
NF-kB activity. Briefly, a plasmid construct containing NF-kB promoter and SEAP gene 
was transferred into INS-1E cells by lipofectamine. SEAP was then expressed and 
secreted into culture supernatant and allowed chemiluminescent detection using a 
substrate PNPP under 405 nm. B. NF-kB activity was measured 24 hours after addition of 
cytokine cocktail and either JP-3-110 (5μM) or KZ41 (5μM). CMV/SEAP construct 
constitutively expressed SEAP and served as positive control. 
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Figure 7-5. KZ41 and JP-3-110 pretreated INS-1E cells were resistant to cytokine 
induced apoptotic cell death  
A. Caspase 3 activities in INS-1E cells after treated with KZ41 (5μM) and JP-3-110 
(5μM). Dexamethasone (Dex, 1μM) was used as a positive control. B. INS-1E cells were 
stimulated with a cytokine cocktail alone or in the presence of KZ41 or JP-3-110 for 2 
day. Then all cells were subjected to TUNEL assay using DeadEnd Colorimetric TUNEL 
system. Apoptotic cells were stained in dark. *p<0.05 as determined by an unpaired 
Student’s t-test, n=6. 
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Figure 7-6. KZ41 inhibited the apoptotic cell death of human islets after 
stimulation with cytokine cocktail  
Briefly, after stimulated with cytokine cocktail in the presence or absence of KZ41 (5µM) 
for indicated time, islet was collected and dispersed with 0.25% Trypsin/EDTA into 
single cell suspension. Apoptotic cells were stained with FITC labeled annexin V and 
counted by flow cytometry. P3 indicated the percentage of apoptotic cells. All 
experiments were performed in triplicates. Results are presented as the mean ± SD. 
*p<0.05 as determined by an unpaired Student’s t-test, n=6. 
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Figure 7-7. JP-3-110 suppressed T cell proliferation but not T cell activation  
A-D. The levels of IL-2, IL-2 receptor, TNFα and IFNγ of T cells following PHA 
stimulation and the treatment JP-3-110 (5μM). The levels of IL-2 and IL-2 receptor were 
not affected by the treatment of JP-3-110 but the levels of TNFα and IFNγ were 
significantly reduced. E. The T cell proliferation after PHA stimulation is characterized 
by a quick drop in the early stage (24h) and a following fast-proliferation stage. The 
presence of JP-3-110 significantly reduced the T cell proliferation after PHA stimulation. 
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following activation therefore the results of less expressions of TNFα and IFNγ might be 
due to less number of total T cells  (Figure 7-7) which is consistence with previous 
reports [159, 160]. Taking together, the results indicated that JP-3-110 retained the 
immunosuppressive function similar to MPA. 
 
 
JP-3-110 inhibited the function of T cells and B cells in humanized NSG mice  
 
NSG mice were adoptively transferred human PBMCs to build human immunity 
as described in Chapter 6. The human IgG level in the serum and CD3+ T cell staining in 
the spleen indicated that NSG mice can be readily humanized by injecting 5x106 human 
PBMCs (Figure 7-8). No sign of GvHD was observed after humanization. To determine 
whether JP-3-110 can suppress immune reactivity in humanized NSG mice, we 
administered JP-3-110 intraperitoneally at 50mg/kg for consecutive 7 shots. Results 
indicated that the amount of human T cells in the spleen of humanized NSG mice were 
significantly reduced after JP-3-110 administration (Figure 7-8B). Serum human IgG 
level of the mice receiving JP-3-110 was also significantly reduced compared with the 
mice receiving equal amount of saline (Figure 7-8C), suggesting that JP-3-110 
suppressed the function of T cells and B cells in humanized NSG mice.  
 
 
Discussion 
 
The idea of synthesizing a compound drug to prevent immune rejection and PNF 
of human islet transplantation simultaneously emerged from the research in BMSC 
mediated cell therapy. BMSC effective prevented the immune rejection and PNF as an 
immune modulator and trophic mediator, respectively. However, BMSC was unsuitable 
for intravenous injection therefore can only be co-transplanted with human islets. 
 
All these drawbacks of BMSCs encouraged us to find an alternative for BMSC 
based stem cell therapy. In our most recent work, we proposed to take advantage of 
immunosuppressive drug and anti-apoptotic drug to test whether we can synthesize a 
compound drug to prevent immune rejection and PNF of human islet transplantation 
simultaneously. 
   
Most immunosuppressive drugs have significant side effects. Therefore the dosing 
of these compounds in the patients is closely monitored and controlled. Among these 
immunosuppressive compounds, MPA is a commonly used for organ transplantation 
especially human islet transplantation. MPA inhibits the purine synthesis and thereby the 
proliferation of T cells and B cells [161]. However, MPA also impaired the viability and 
function of human islets in the coculture condition [87]. Hereby we reported a new 
compound JP-3-110, which combines the immunosuppressive drug MPA with a novel 
anti-apoptotic compound KZ41. We hypothesized that on one hand, the compound drug 
can used as a modified MPA so that the toxicity of MPA can be significantly reduced. 
One the other hand, the conjugated part, KZ41 had antiapoptotic potential to prevent the 
PNF of human islet transplantation. 
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Figure 7-8. JP-3-110 inhibited the function of T cells and B cells in humanized 
NSG mice  
A. A representative spleen section of humanized NSG mice after receiving 7 consecutive 
shots of JP-3-110 (50mg/kg, upper) and equal amount of saline (lower) each day. NSG 
mice were humanized by intraperitoneal injection of 5x106 human PBMCs and allowed 
to settle for two weeks. Sections were stained for CD3 positive T cells (red) and black 
stained with DAPI (blue). B. The T cell intensity in the spleen section of humanized NSG 
mice calculated from the immunofluorescence staining by ImageJ. C. The serum IgG 
level of humanized NSG mice. P<0.05 under student t test. N=3. 
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We demonstrated that the compound drug JP-3-110 had immunosuppressive effect 
as its counterpart MPA in the MLR.  Although JP-3-110 did not prevent the activation of 
T cells by PHA, it did prevent the proliferation of T cells after activation (Figure 7-7). To 
better fit the scope of clinical human islet transplantation, we employed a novel 
humanized mouse model to evaluate the effectiveness of the JP-3-110 to prevent the 
immune rejection caused by human immunity. The staining of CD3+ human cells in the 
spleen section and the level of human IgG in the serum of NSG mice both suggested that 
JP-3-110 suppressed the alloreactivity of T cells and B cells in vivo (Figure 7-8). This 
study may provide useful insight into the modification of traditional immunosuppressive 
drugs. 
 
 Previous studies indicated that KZ41 is a potent suppressor of NF-kB activity of 
human alveolar A579 cells and thus a potent anti-inflammatory compound [157]. We 
demonstrated that the anti-inflammatory effect of KZ41 can be transferred into insulin-
producing INS-1E cells and human islets against the stimulation of a cytokine cocktail 
(Figures 7-5, 7-6).  We also demonstrated that the conjugation of KZ41 with MPA did 
not affect the pharmacological activities of MPA as a single drug.  
 
Unfortunately, this work is not close to complete at this stage as we faced lots of 
challenges in the research of this small molecular compound. The major challenge is 
about the rationale of the project, how we are going to evaluate the compound drug JP-3-
110. As shown in Table 7-1, KZ41 inhibits the production of inflammatory cytokines 
through NF-kB inhibition while MPA inhibits the proliferation of T cells and B cells, 
suggesting a potential synergistic effect to prevent the immune rejection of human islets. 
However, KZ41 and MPA demonstrate opposite effects on the apoptosis of human islets. 
Without compelling evidences that the anti-apoptotic effect of KZ41 is significantly 
higher than the pro-apoptotic effect of MPA, the compound drug may not show a benefit 
to prevent the apoptosis of human islets. Further studies are needed to compare the anti-
apoptotic effect of KZ41 alone, KZ41 in the presence of MPA and JP-3-110. If KZ41 is 
not capable to mask the pro-apoptotic effect of MPA, JP-3-110 is just a less toxic 
immunosuppressant instead of a compound drug with two therapeutic potentials. 
 
Moreover, there are other challenges regarding this project. The first issue is the 
solubility of JP-3-110. KZ41 is still fairly water-soluble (~0.8 g/mL), but JP-3-110 is not 
even close to that range with water solubility of only 0.5 mg/mL. The difficulties of 
working with a compound of such solubility are 1) the poor solubility of JP-3-110 is 
unsuitable for injection into animals because a huge amount of water is needed to fully 
dissolve the compound and 2) a micellar or liposomal delivery system cannot be used to 
formulate JP-3-110 because the solubility of JP-3-110 is not that poor and JP-3-110 may 
leak out from the delivery system. To solve issue, we need to modify the molecular 
structure of JP-3-110 to drastically change the solubility toward either direction while 
keeping the pharmacological activities of JP-3-110. 
 
The second issue is the stability of the compound. The ester bond of JP-3-110 is 
susceptible to hydrolytic degradation, releasing KZ41 and MPA as two single drugs. 
More than 40% of JP-3-110 in the aqueous solution will be degraded when stored in 4oC  
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Table 7-1. The pharmacological activities of KZ41 and MPA 
 
Pharmacological activity KZ41 MPA 
Apoptosis impact Prevents apoptosis of 
human islets at 5μm 
Toxic to human islets at 
10μm 
Immune impact Inhibits the production of 
inflammatory cytokines 
Prevents the proliferation 
of T cells and B cells 
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for 1 week (Figure 7-9). Although this degradation has not caused us any problem in 
efficacy, it may pose potential problem in the formulation of this drug.  
 
The third issue is the difficulty in the synthesis process therefore limited amount 
of JP-3-110 had been synthesized for each batch. We have synthesized a total amount of 
80 mg of JP-3-110, which was just enough for the in vitro characterization but far from 
enough for human islet transplantation, which last for months.   
 
In summary, we demonstrated a proof of concept that a compound drug 
composing of a immunosuppressive part and an antiapoptotic part can be an effective 
strategy to prevent the immune rejection and PNF of human islet simultaneously. 
However, further effect is still needed to improve the solubility and stability of this 
compound and formulate it for in vivo test.    
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Figure 7-9. The hydrolysis of JP-3-110 in aqueous solution 
A. The characterization of JP-3-110 aqueous solution (0.4mg/mL) stored in 4oC for 1 
week. The peak at 2 minutes was denoted as MPA degraded from JP-3-110. KZ41 does 
not have a benzene ring therefore cannot be detected under UV detector. B. The HPLC of 
MPA under a same setting as a reference. C. The HPLC setting.  
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CHAPTER 8.    CONCLUSION 
 
 
What We Achieved in the Past 5 Years 
  
The limited supply of human islet, the inadequate means to prevent graft rejection 
and the PNF remains three important obstacles for successful human islet transplantation. 
In the past five years, we have developed several strategies for the PNF and immune 
rejection. For example, we identified XIAP as a potent anti-apoptotic gene to prevent the 
PNF caused by inflammatory cytokines. We generated RGD modified adenovirus to 
achieve efficient gene transfer while reducing the viral titer.  We also identified BMSC as 
a novel gene carrier to express therapeutic genes while avoiding the viral transduction on 
human islets. The establishment of humanized NSG mice has been a significant 
milestone in five years’ research. This novel animal model provided us a clinical relevant 
platform to evaluate the immune rejection of human islets. Using humanized NSG mice, 
we successful evaluated the efficacies of BMSCs and a novel compound JP-3-110 to 
prevent the immune rejection of humanized mice. 
 
In the past five years, our knowledge and skills about human islet transplantation 
has also been reshaped. For the strategies, we moved from gene therapy to stem cell 
therapy and stem cell based gene therapy. For the materials, we stopped using INS-1E 
cells but focused on the human islets. For the target genes, we are now targeting at least 
two genes simultaneously instead of one gene at a time. For the molecular cloning, we 
moved from buying commercially available vectors to constructing vectors and even 
surface-modified vectors. For in vitro islet studies, we designed and developed a new set 
of perifusion equipment for dynamic measurement of islet function. For the animal 
model, we started to use a more clinically-relevant humanized model to substitute the 
immunodeficient models we used before. For the transplantation techniques, we are 
generating a more reliable diabetic animal model and successful render a majority of 
diabetic mice insulin-independent after surgery.  
 
 
New Challenges and Future Directions  
 
Humanized animal model will be among the most popular animal models for the 
research in solid organ transplantation and immunology in the next decade. There are so 
many studies requiring the involvement of human immune system. Humanized model 
could be a perfect model for the proof of concept for these studies without the 
involvement of human subjects. However, the occurrence of GvHD remains a big 
challenge for our humanized mouse model. 
 
The GvHD is characterized by the recognition and destruction of the major organ 
of mouse by the infused mature human lymphocytes. Dr. Leonard Shultz, the pioneer of 
humanized mouse, has reviewed his previous work and concluded that the humanized 
mice generated from mature human lymphocytes will develop GvHD typically in 5-7 
weeks [79, 162]. The GvHD causes short life-span and a limited window to evaluate the 
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immune rejection. The only way to avoid GvHD seems is to introduce the progenitor 
cells of human immunocytes, which are hematopoietic stem cells into NSG mice at early 
age [163]. As long as the maturation of human lymphocytes happens inside the thymus or 
bone marrow immunodeficient mice, those mature human lymphocytes seem to be less 
likely to attack the mouse organs. 
 
Gene therapy, even in its best scenario, cannot prevent the immune rejection from 
the islet recipient. Stem cell therapy through immunomodulatory BMSCs will be a better 
strategy to prevent the immune rejection. However, three weakness of stem cell therapy 
cannot be overlooked. First, BMSCs are unsuitable for intravenous injection, making 
repeated dosing impossible. Secondly, BMSC produces minimal levels of HGF and 
VEGF, which are not enough to support a fast and functional revascularization of human 
islets. Thirdly, if BMSCs from a third party were used in large quantities, they may cause 
immunogenicity and tumorigenicity.  
 
To address these concerns, we raise three questions here: 1) can we expand Treg 
in vitro as a substitute for BMSC therapy, 2) can we modify stem cells in such a way that 
the therapeutic potential of stem cells can be increased and these cells can be selective 
cleared from body at a indicated time point and 3) can we substitute stem cells with a 
non-proliferation system which holds similar therapeutic potential. We believe that 
finding proper answers for these questions will expand our research in width and depth to 
further improve human islet transplantation.  
 
The size of BMSC is quite large, making them susceptible to be sequestered in the 
lung after intravenous injection. Tregs are relatively smaller cells which travel freely 
through the bloodstream. Our data suggested that BMSCs promoted the proliferation of 
Tregs which in turn may contribute to the immune tolerance in human islet 
transplantation (Figure 6-7). Therefore, if we isolate and expand Tregs in vitro and 
infused back into the diabetic patient, we can increase the immune tolerance of human 
islets to a similar extent. Two groups in University of Chicago and University of 
Maryland have independently reported their preliminary data in rodent model to support 
this hypothesis [164, 165]. 
 
We demonstrated that BMSCs supported the revascularization of human islets in 
immune deficient NOD-SCID mice (Figure 5-9). However, our results suggested that 
BMSCs produce marginal level of HGF and VEGF which are incapable to support a fast 
and functional revascularization. Therefore, one possible outcome might be that the islets 
which are not destructed by the immune rejection will be PNF due to poor 
revascularization. In fact, we are thinking about using genetically modified BMSCs to 
prevent the immune rejection and PNF in humanized mouse model. To proceed with this 
idea, we must prove that genetic modifications, either with adenoviruses or plasmids, do 
not change the stem-cell-like properties and the immunomodulatory effect of BMSCs. 
Since telomerase reverse transcriptase (TERT)-modified BMSCs have been reported to 
induce tumor in animal models [55], the tumorigenicity of genetically modified BMSCs 
should be evaluated as well.  
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For the last question whether a non-proliferative system with similar therapeutic 
effect can be used to substitute BMSC, we believe that the exosome secreted from BMSC 
can be good candidate. Exosomes are 40 to 100 nm vesicles secreted by a wide range 
of mammalian cell types, including BMSC. Exosomes also have a way to avoid the 
reticulo-endothelial system (RES) system [166]. These features make exosome good 
candidate for intravenous delivery. Exosomes typically contain proteins and RNA and 
therefore can be used for a wide range of purpose. For example, exosomes be used as a 
bridge connecting BMSC mediated stem cell therapy and adenovirus mediated gene 
therapy as shown in Figure 8-1. 
 
In this ideal application of exosomes for human islet transplantation, step 2 can be 
further improved if we can insert genes of interest and target-ligand expression cassette 
into one single adenoviral vector. Step 5 needs to be optimized experimentally as the 
necessary dose for an optimal transplantation outcome should be determined. Since our 
preliminary data suggested that the BMSCs suppressed the proliferation and activation of 
PBMCs through soluble factors (Figure 6-3). We expect that the exosomes secreted by 
BMSC had similar immunomodulatory effect. Moreover, since we can introduce any 
gene of interest which may increase the resistance of islets to PNF, we expected that the 
exosome therapy would provide additional benefit compared with BMSCs therapy alone. 
 
Exosomes mainly delivery secreted proteins and RNA. In our preliminary study 
we demonstrated that the adenoviral transduction significantly increased the total 
expression of HGF by BMSCs.  Among the total HGF production, a majority stayed in 
the exosomes instead of being directly released into the media. These results suggested 
two important facts that 1) the expression of HGF by BMSCs is mainly through 
exosomes and 2) exosomes from genetically modified BMSCs hold therapeutic 
advantage above exosomes from primary BMSCs.   
 
Future studies regarding exosomes generated from BMSCs can be approached 
from two directions. First, we will identify the immunosuppressive factor(s) produced by 
BMSCs and generate the exosomes to deliver the factor(s). If we failed to identify any of 
the immunosuppressive factors, we can hijack the cellular machinery of BMSCs with 
adenoviral vectors to produce exosomes containing well-known immunosuppressive 
factors such as IL-10 or TGFβ. The second direction is to modify the exosomes with 
targeting ligands for targeted delivery to the transplantation site. The glucagon-like 
peptide 1 receptor (GLP1R) is one well-known receptor of pancreatic β cells. Itoh et al. 
recently reported high expression of a type of G protein–coupled receptor GPR40 on the 
surface of pancreatic β cells [167].  These receptors can be potential candidate for the 
targeted delivery of exosomes to human islets in vivo. 
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Figure 8-1. An ideal application of targeting exosomes for islet transplantation in 
humanized NSG mice  
Step 1: Isolation and expansion of primary BMSCs. Step 2: Gene transfer into BMSCs. 
Adenoviral vectors encoding genes of interest and a plasmid encoding targeting ligand 
were transferred together into BMSCs. Step 3: Expression of targeting ligand and 
“cargo”. Targeting ligands (red) are typically expression on the membrane and released 
with exosomes. “Cargo” (blue) can be secreted proteins if an expression adenoviral 
vector is used or shRNA if a silencing adenoviral vector is used. Step 4: Harvest of the 
targeting exosomes. Step 5: Intravenous injection of exosomes into humanized NSG mice 
receiving islet transplantation. 
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